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Abstract.
The physiological mechanisms initiating labour at term are poorly
understood. In the fetal sheep activation of the fetal hypothalamo-pituitary-
adrenal (HPA) axis in late gestation is essential for the birth of a viable fetus.
Little is known of the ontogeny of the hypothalamic pathways controlling
adrenocorticotrophin (ACTH) secretion in the fetus, nor of the metabolic or
placental signals to which they are responding to initiate the surge in
pituitary adrenal activity in late gestation. Exogenous agonists at central N-
methyl-D-aspartate (NMDA) receptors stimulate ACTH secretion in the ovine
fetus and the ACTH response to NMDA increases with gestation. These
studies investigate the regulation of the HPA axis by endogenous amino
acid transmitters acting through the NMDA receptor in the late gestation fetal
sheep. The HPA axis responsiveness to neuropeptide Y (NPY), a
neurotransmitter implicated in metabolic feedback to the HPA axis, is also
investigated.
In the chronically cannulated late gestation sheep fetus CGP 37849, a
competitive NMDA receptor antagonist, significantly decreased the ACTH
and Cortisol response to insulin hypoglycaemia stress on day 130 (term=145
days), and also reduced basal plasma concentrations on day 138,
confirming that endogenous excitatory amino acid neurotransmitters acting
through the NMDA receptor regulate ACTH secretion in the late gestation
fetus. The coupling of the NMDA receptor to CRH and AVP secretion at the
median eminence was investigated by a microdialysis approach. Pre-
treatment with CGP 37849 attenuated the ACTH and Cortisol responses to
insulin hypoglycaemia, but not AVP secretion at the median eminence. It
was not possible to detect CRH in the dialysate from any of the fetuses, but
the failure of CGP 37849 to suppress AVP release suggests that NMDA
receptors regulate ACTH secretion through CRH neurons. The potential for
placental steroids to regulate the HPA axis response to NMDA was also
investigated. Infusion of estradiol from day 120 for 96 h did not alter basal
plasma ACTH or Cortisol concentrations, pituitary sensitivity to AVP and
vi
CRH, or ACTH or Cortisol responses to NMDA, despite there being a
significant suppression of plasma follicle stimulating hormone
concentrations and an increase in plasma prolactin concentrations.
The role of NPY pathways to stimulate the HPA axis was also
examined. In fetal sheep at day 125 gestation administration of 30 rig NPY
into the lateral cerebral ventricle stimulated a small but significant increase
in plasma concentrations of ACTH.
Overall, these studies suggest an important role for the NMDA
receptor acting through CRH neurons in the late gestation increase in fetal
HPA axis activity, however, the increase in HPA axis activity and sensitivity
to NMDA are not dependent upon estrogen. Activation of the HPA axis may
be due to metabolic signals since in late gestation NPY pathways can
stimulate the HPA axis. A model is proposed where increasing sensitivity to
NMDA reflects maturation of the hypothalamic pathways regulating ACTH
secretion, and once these pathways are sufficiently developed metabolic
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Maturation and function of the fetal
hypothalamic pituitary adrenal axis
1.1 Introduction
"Deform'd, unfinish'd, sent before my time
Into this breathing world, scarce half-made up,
And that so lamely and unfashionable
That dogs bark at me, as I halt by them;"
Richard III (Shakespeare)
The transition at birth to extra-uterine life places remarkable demands
upon the developing fetus. In an instant it must be able to breathe for itself,
and then in the longer term take in nourishment and maintain internal
homeostasis. The timing of birth at a point where fetal organs have matured
sufficiently to be able to support independent life is critically important. Nearly
60% of human infants born at 26 weeks will not survive their first few months,
and in those that do, the incidence of clinically apparent neurological deficit is
around 25% (Morrison and Rennie 1997). Survival and morbidity improve
steadily with increasing gestational age but even infants born at 35 weeks are
at risk of transient tachypnoea of the newborn and respiratory distress
syndrome due to lung immaturity (Morrison, Rennie et al. 1995). It is
estimated that about 0.5% of births occur before 28 weeks, and 5-10% before
37 completed weeks (Morrison and Rennie 1997). Conversely pregnancy
carried beyond term is associated with increased risk of stillbirth as the
spectres of oligohydramnios and diminishing placental reserve supervene
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(Grant 1994; Hilder, Costeloe et al. 1998). An understanding of why birth
occurs early in some pregnancies and late in others and how this is linked
with fetal maturation is of major clinical importance for the development of
effective strategies for the prevention of preterm birth, the promotion of fetal
maturity and the induction of labour.
It has been known for several decades that the fetal adrenal is
intimately linked with adaptation to extrauterine life: increased secretion of
corticosteroids by the fetal adrenal in late gestation promotes lung maturity in
preterm animals and human infants as well as maturing many other organ
systems (Liggins 1976; Fowden, Li et al. 1998). In species such as the sheep
it is clear also that products of the fetal adrenal initiate the endocrine cascade
that leads to labour, so ensuring the birth of an appropriately mature fetus.
Inevitably there are species differences in some of endocrine events of
parturition but there are also considerable similarities reflecting the common
evolution of the utero-cervical canal from a primitive genital pore (Ryan 1977).
Increasing fetal corticosteroid production turns out to be a conserved signal
used by all mammalian species to orchestrate the maturational changes
needed for extra uterine survival with birth (Liggins 1983; Fowden, Li et al.
1998), just as a change in the balance of progesterone to estrogen in the
maternal circulation regulates uterine activity and cervical compliance (Lye
1994).
Despite some three decades of research the processes which lead to
increasing secretion of steroids from the fetal adrenal cortex to initiate
parturition remain enigmatic. This thesis examines aspects of hypothalamic
regulation of the fetal adrenal cortex in late gestation in the sheep. The
following review chapter considers how the fetal sheep hypothalamo-pituitary-
adrenal axis initiates parturition and draws parallels with the primate fetus,
then describes the basic organisation of the hypothalamo-pituitary-adrenal
axis and the functional development of the axis in fetal life, the putative
peripheral signals which may drive increasing adrenal steroid secretion
through hypothalamic pathways, and lastly what little is known of the
hypothalamic pathways themselves. From this a series of hypotheses are
advanced about the role of excitatory amino acid neurotransmitters and
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Neuropeptide Y pathways in the regulation of the fetal adrenal The remainder
of the thesis details the experimental work involved in testing these
hypotheses.
1.2 The fetal hypothalamo-pituitary-adrenal axis and parturition
1.2.1 The ovine model
Perhaps the best insight into the mechanisms controlling fetal
maturation and birth come from the sheep. Serendipitous observation
revealed a major role of fetal adrenal steroids in initiating labour when it was
noted that sheep grazing on pokeweed (Veratrum californicum) early in
pregnancy gave birth to deformed fetuses which were carried well beyond
term (Binns, James et al. 1964). Investigation showed that toxins from the
pokeweed disrupt normal development of the fetal brain and pituitary and
result in hypoadrenalism. That fetal adrenal Cortisol is crucial for birth has
been shown by subsequent experiments demonstrating that lesions of the
hypothalamus, pituitary or adrenal all prevent labour (Liggins, Kennedy et al.
1967; Drost and Holm 1968; Gluckman, Mallard et al. 1991; McDonald and
Nathanielsz 1991). There is good evidence for increasing activity of the fetal
hypothalamus, and increasing circulating concentrations of
adrenocorticotrophin (ACTH) and Cortisol in the days before birth (Norman,
Lye et al. 1985; Hoffman, McDonald et al. 1991). Furthermore exogenous
Cortisol or ACTH given directly to the fetal sheep will induce premature labour
(Liggins, Kennedy et al. 1967; Liggins 1968). It was also noted that those
lambs delivered prematurely survived because of accelerated production of
lung surfactant. Indeed, the fetal adrenal through the secretion of Cortisol is a
major switch for many organ systems preparing them for extra uterine life
(Liggins 1976). By acting both as a trigger for labour and as a signal inducing
neonatal patterns of tissue gene expression, the ovine fetal adrenal ensures
the birth of an appropriately mature lamb.
The action of Cortisol to promote labour in the sheep is bought about
by a change in the placental production of the steroid hormones estradiol and
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progesterone (Liggins, Grieves et al. 1972). Early in gestation the placenta
becomes established as the major source of progesterone in maternal and
fetal circulations (Liggins 1983). Throughout pregnancy uterine activity is
suppressed by progesterone (Li, Perezgrovas et al. 1991; Gazal, Li et al.
1993). Yet at term all this changes: Cortisol induces placental C17-20 lyase
and 17-a hydroxylase activity which allows the placenta to metabolise
progesterone through to estradiol (Mason, France et al. 1989; Rose and JP
1994). There is also a modest Cortisol dependent increase in aromatase
activity (Mason, France et al. 1989). The placental output of progesterone
falls over several days as estradiol production rises. Concentrations of
progesterone in the maternal circulation decline from about 12 ng/mL a week
prior to delivery to 1 ng/mL on the day of delivery (Bassett, Oxborrow et al.
1969). At the same time the concentration of estradiol increases markedly
(Challis 1971). This change in the steroid environment from progesterone to
estrogen dominance leads to the onset of uterine muscular contraction and
remodelling of cervical connective tissue. Besides inducing the placental
enzymes for estrogen synthesis, the ovine fetal adrenal also contributes to
the surge in estrogen through the production of androgenic precursors that
the placenta aromatises to estrogen. In fact at term as much as one third of
estrogen production is from substrates provided by the fetal adrenal gland
(Mitchell, Lye et al. 1986).
The precise way in which the steroid hormones impinge upon the
complex regulatory networks controlling myometrial activity are not fully
understood. Antagonism or removal of progesterone during pregnancy
results in abortion or labour (Gazal, Li et al. 1993). Clearly in these
circumstances there is no rise in estradiol yet the utero-cervical canal
undergoes many if not all of the changes seen in spontaneous labour.
Conversely, estradiol infused in high doses will induce labour even though
progesterone production dose not fall (Cahill, Knee et al. 1976). At a
molecular level many of the structural proteins, receptors and hormones
controlling the myometrium are influenced in opposite ways by estrogen and
progesterone (Lye 1994).
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1.2.2 Primates (and other species)
An increase in the concentration of corticosteroid in the fetal circulation
late in gestation has been demonstrated in the numerous species including
the goat (Currie and Thorburn 1977), cow (Hunter, Fairclough et al. 1977))
horse (Silver 1990), rat (Martin, Cake et al. 1977; Chatelain, Dupouy et al.
1980; Boudouresque, Guillaume et al. 1988), rabbit (Hummelink and Ballard
1986), pig (Dvorak 1972), baboon (Pepe and Albrecht 1984), and rhesus
monkey (Jaffe, Seron-Ferre et al. 1978). Direct evidence for a rise in human
fetal corticosteroids with advancing gestation has been provided by studying
the levels of corticosterone sulphate in the maternal circulation in a woman
who had undergone bilateral adrenalectomy for Cushing's syndrome
(deFencI, Stillman et al. 1980). This is supported by measurements of
circulating corticosteroids in blood obtained at cordocentesis (Lopez-Bernal
and MacKenzie 1987; Nahoul, Daffos et al. 1988; Nahoul, Daffos et al. 1989;
Donaldson, Nicolini et al. 1991).
In humans and other primates, unlike the sheep, the placental
enzymes needed for estrogen synthesis are constitutively expressed and are
not Cortisol inducible (Liggins 1983; Albrecht and Pepe 1990). The fetal
adrenal still contributes to the increase in circulating estrogens by providing
the precursors for placental estrogen synthesis so that in primates, as in other
mammals, the balance of estrogen and progesterone changes in late
gestation. In humans it is estimated that near term 50% of estradiol and 90%
of estriol in maternal plasma is derived from precursors provided by the fetal
adrenal (Sitteri and MacDonald 1966; Barlow, Goldstein et al. 1967). Infusion
of androgenic precursors in late pregnancy in the rhesus macaque will
advance the onset of labour demonstrating the importance of the fetal adrenal
for primate parturition (Mecenas, Giussani et al. 1996).
Cortisol may have some facilitatory role in the onset of labour in
primates (Challis and Brooks 1989; Guller, Wozniak et al. 1993; Challis,
Matthews et al. 1995; Karalis, Goodwin et al. 1996). The major function of
Cortisol in the human fetus, however, is probably to prepare the lungs and
other organs for birth (Liggins 1976; Crowley, Chalmers et al. 1990). It is
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perhaps worth noting that even at 37 weeks of gestation the incidence of
respiratory distress in the newborn is higher than infants delivered at full term
(Morrison, Rennie et al. 1995).
In other species (for example, the goat, cow, pig, rat and rabbit) the
principal site of progesterone synthesis is the corpus luteum (Poyser 1995).
Parturition is initiated by luteolysis which results in a fall in progesterone
concentrations in the maternal circulation. In the goat, cow and pig the fetus
signals parturition with an increase in Cortisol which stimulates placental
estrogen synthesis. In turn, an increase in estrogen stimulates the release of
the luteolytic hormone prostaglandin F2a (PGF2a) from the placenta and
decidua (Poyser 1995).
Diagram summarising the contributions of the fetal HPA axis to the endocrine
events at parturition in the sheep and primate.
Fetal sheep HPA axis Fetal primate HPA axis
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1.3 Basic organisation of the hypothalamo-pituitary adrenal axis
1.3.1 The adrenal gland
Steroid synthesising cells in the adrenal cortex are essential for
survival for if the adrenal is removed or destroyed by disease processes,
intermediary metabolism, fluid balance, cardiovascular and immune functions
gradually deteriorate and death supervenes (Orth, Kovacs et al. 1992). The
principal steroid products of the adrenal are corticosteroids,
mineralocorticoids and sex steroid hormones. Within the adrenal cortex there
is a spatial distribution of the different cells expressing the enzymes
necessary for synthesis of each of the principal steroid hormones (Orth,
Kovacs et al. 1992). Mineralocorticoid synthesising cells are clustered
together in groups in the zona glomerulosa near the outer capsule of the
gland. Deeper in cells are arranged in rather irregular strings referred to as
the zona fasiculata and secrete corticosteroids. The inner layer of the adrenal
cortex, termed the zona reticularis, abutting on the adrenal medulla, consists
of sex steroid secreting cells.
The control of adrenal corticosteroid production involves cells located
in the pituitary and hypothalamus, along with the central nervous system
pathways afferent to the hypothalamus; Together these are referred to as the
hypothalamo-pituitary adrenal (HPA) axis. Stimulatory drive to adrenal
corticosteroid and androgen secretion is provided by the peptide hormone
ACTH secreted by corticotropin cells of the anterior pituitary. Specific
adenylate cyclase coupled receptors in the adrenal bind ACTH (Stocco and
Clark 1996). Adrenocorticotrophin not only stimulates steriodogenesis by
mobilising intracellular cholesterol, but increases expression of steroidogenic
enzymes and mitochondrial steroid acute regulatory protein (Clark and Stocco
1996; Stocco and Clark 1996).
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1.3.2 The pituitary gland
The pituitary gland can actually be divided into three separate regions
(Orth, Kovacs et al. 1992). The posterior pituitary consists of the
neurosecretory axons arising from magnocellular oxytocin and vasopressin
containing neurons in the supra-optic and paraventricular nuclei. The anterior
pituitary consists of glandular cells served by the hypothalamo-hypophysial
portal tract. There is little innervation of the anterior pituitary so that secretion
is regulated principally through endocrine and paracrine signals. The third
region of the pituitary is the neurointermediate lobe (NIL), a structure wrapped
around the bundle of neurosecretory nerve fibres passing to the posterior
pituitary. Cells of the NIL are thought to be directly innervated by
dopaminergic neurons with cell bodies located in the tuberal-hypophysial
region (Lookingland, Farah et al. 1985).
Anterior pituitary corticotropins synthesise and secrete ACTH. The 39
amino acid sequence of the peptide is highly conserved across species,
though full biological activity seems to reside with amino acids 1-24 of the
sequence (kapas, Cammas et al. 1996). The gene for ACTH actually
encodes the sequence of a larger precursor molecule, pro-opiomelanocortin
(POMC), from which ACTH is derived by proteolytic cleavage (Eipper and
Mains 1980). The POMC gene is also expressed in melanotrophs of the NIL
of the pituitary, but is post translationally processed to alternative products.
1.3.3 The hypothalamus
The secretion of ACTH from the anterior pituitary is stimulated by the
hypothalamic releasing factors arginine vasopressin (AVP) and corticotrophin
releasing hormone (CRH) (Plotsky 1991; Antoni 1993; Whitnall 1993). These
two peptides are secreted into the specialised hypothalamic-hypophysial
portal system at the median eminence by neurosecretory neurons located in
the parvocellular portion of the hypothalamic paraventricular nucleus (PVN).
Magnocellular neurons in the PVN and supraoptic nucleus (SON) also contain
AVP, and in the rat these neurons secrete AVP in the median eminence "en
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passant" from varicosities on the axons as they pass to the posterior pituitary
(Antoni 1993). It is not known if similar pathways are present in other
mammals.
The fine control of ACTH secretion is even more complex, though,
since a number of other peptides found in portal plasma can stimulate or
inhibit ACTH secretion (Plotsky 1991; Antoni 1993). It has also been
demonstrated in culture that basal electrical activity and secretion by some
pituitary corticotropin can continue in the absence of hypothalamic releasing
factors, though AVP and CRH do alter the pattern of electrical activity and
presumably enhance ACTH secretion from these cells (Kwiecieu and
Hammond 1998).
Many brain structures are involved in integrating the internal and
external stimuli to appropriately control corticosteroid secretion. Responses
to metabolic stress and to injury are probably mediated through brainstem
and circumventricular structures and the hypothalamic PVN directly, wheras
responses requiring interpretation in the light of previous experience involve
pathways in the prefrontal cortex, hippocampus and amygdala (Antoni 1993;
Whitnall 1993; Herman, Prewitt et al. 1996).
1.3.4 Corticosteroid action and negative feedback
Feed back by adrenal corticosteriods at the level of the central nervous
system and pituitary completes a simple feedback loop limiting further drive to
the adrenal gland. Acutely, corticosteroids decrease ACTH secretion, and
over the course of several hours decrease CRH, AVP and POMC expression
(Drouin, Sun et al. 1989; Reichardt and Schutz 1998). Rapid actions of
steroids in excitable tissues probably occur through modulation of cell surface
receptors (Revelli, Massobrio et al. 1998). The slower effects of
corticosteroids on the genome are classically mediated through intracellular
receptors which bind to the genome and regulate gene expression (Evans
1988; Beato 1989; Tsai and O'Malley 1994; Beato, Herrlich et al. 1995).
The intracellular events regulating corticosteroid action on the genome
are complex and only partly characterised. Separate corticosteroid
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(glucocorticoid) and mineralocorticoid receptors exist, but in fact
corticosteroids are capable of binding to both receptors in vitro with near
equal affinity (Funder 1997). In classical mineralocorticoid sensitive tissues,
such as the renal distal tubule, corticosteroids are prevented from binding
mineralocorticoid receptors in vivo, by an intracellular enzyme, 11-(3
hydroxysteroid dehydrogenase (11 (3HSD), which serves to protect the
mineralocorticoid receptor by metabolising corticosteroids (Funder 1997).
During studies on the 11 (3HSD enzyme it has become apparent that there are
at least two different isoforms (Gomez-Sanchez and Gomez-Sanchez 1997),
and that in non-mineralocorticoid receptor expressing tissues, and in the
brain, an isoform with lower affinity, and which is bidirectional operates to
regulate intracellular corticosteroid concentrations. Since this latter
isoenzyme is bidirectional it may be important for maintaining corticosteroid
concentrations rather than simply inactivating them.
Glucocorticoid and mineralocorticoid receptors are transcription
factors, which once they have bound biologically active steroid form a dimer
with another transcription factors before binding to the promoter sequence of
corticosteroid regulated genes. In the case of the glucocorticoid receptor it
appears that homodimers with other glucocorticoid receptors, or homodimers
with other steroid receptors, or other transcription factors, may be formed,
and that the different dimers have different effects on gene expression
(Reichardt and Schutz 1998). An additional complexity is that full activity of
the transcriptional complex is determined by coactivators and corepressors
(Chen and Evans 1995; Onate, Tsai et al. 1995; Horwitz, Jackson et al.
1996).
There is debate about the relative importance of mineralocorticoid and
glucocorticoid receptors in the various brain regions implicated in
corticosteroid feedback (de Kloet, Vrengdenhil et al. 1998). It has been
suggested that severe physiological stress activates the HPA axis through
brainstem and circumventricular structures, wheras stressors requiring
interpretation in the light of previous experience involve pathways in the
prefrontal cortex, hippocampus and amygdala (Herman, Prewitt et al. 1996)
and all these regions express glucocorticoid and mineralocorticoid receptors
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(de Kloet, Vrengdenhil et al. 1998). To maximise adaptability in the system it
is likely that the actions of glucocorticoids will be different in the different brain
regions.
1.3.5 The fetal HPA axis: unresolved issues
The concomitant rise in plasma ACTH and Cortisol seen in late
gestation is a paradox, since normally elevated corticosteroid concentrations
suppress further ACTH synthesis and secretion. Two simplistic explanations
may be evoked: firstly that there is a reduction in negative feedback sensitivity
occurring specifically around the time of parturition, and secondly that there is
increasing hypothalamic drive to ACTH secretion which overcomes Cortisol
negative feedback. Increasing drive is not simply a resetting of the set-point
around which the level of Cortisol is regulated, because it implies that once
the stimulus for increased ACTH secretion is removed, the system will return
to its original state. A rather more complicated explanation is that the
increase in ACTH derives from a non-pituitary source that cannot be
suppressed by corticosteroids. In the discussion that follows the functional
development of the hypothalamus, pituitary and adrenal are described and
the evidence for altered negative feedback sensitivity considered.
Aside from trying to understand the mechanisms allowing a sustained
increase in corticosteroid secretion, the issue of what initiates a decline in
feedback sensitivity, or increasing hypothalamic drive still remains
unresolved. The characteristic species specific duration of gestation
suggests some counting or timing process is involved, and certainly
genetically programmed patterns of development could be interpreted as an
intrinsic biological clock. An alternative explanation is that signals from the
mother or placenta, perhaps relating to fetal size or maturity, provide the
stimulus for ACTH and Cortisol secretion. In other words, peripheral
epigenetic factors regulate the final timing of parturition. The last sections of
this review consider metabolic and placental signals which may drive the
hypothalamus, and finally the hypothalamic pathways themselves that may be
important for the regulation of ACTH secretion in the fetus.
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The diagram below summarises the putative mechanisms leading to




1.4 Development of the hypothalamus
1.4.1 Differentiation of the paraventricular nucleus
The co-ordinated response of the HPA axis during fetal and adult life
depends upon the establishment of properly connected neuroendocrine
pathways during development. Developing PVN neurons must establish
synaptic contact with incoming axons from both intrinsic hypothalamic
neurons and remote brain regions, and at the same time form neurosecretory
contacts with developing median eminence capillaries. Similarly, the
specialised hypothalamo-hypophyseal portal vasculature must form correctly
to allow the hypothalamus to exert control over anterior pituitary corticotropins.
Much of the embrogenesis of the HPA axis is complete relatively early in
gestation but it is not clear when the forming hypothalamic-hypophyseal unit
establishes functional control over adrenal secretion. By about 0.7 of
gestation, however, circulating fetal adrenal steroids start to increase and this
does not happen where the hypothalamic neurons are absent, for example in
anencephalics or following experimental destruction, indicating that some
functional hypothalamic control over the adrenal has been established by this
period of gestation (Allen, Greer et al. 1974; McDonald, Rose et al. 1988).
Equally, full maturation of the HPA axis and its integration with the autonomic
and behavioural responses to stress may not be complete until many months
into post-natal life (Meaney, Tannenbaum et al. 1994).
The genes involved in the differentiation of PVN neurosecretory
neurons and the migration of their axons to the median eminence have not
been identified. Mapping of the formation of hypothalamic nuclei using
tritiated thymidine incorporation into dividing neural progenitor cells reveals
that in primates, rodents and the cat the hypothalamic nuclei are formed by
0.3, 0.7, and 0.5 of gestation respectively (Ifft 1972; Wyss and
Sripandidkulchai 1985; Van Eerdenburg and Rakic 1994). Early in
development most cells of the hypothalamus (and other forebrain regions)
express the homeodomain regulatory protein POU 4 but later POU 4
expression is restricted to PVN neurons (Mathis, Simmons et al. 1992; Treacy
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and Rosenfeld 1992). The protein is a transcription factor that by analogy to
other homeodomain proteins plays a role in pattern formation in the embryo.
The restriction to PVN neurons in later life suggests that it may also be
important in directing the differentiation of these cells. Interestingly POU 4
may bind to the CRH promoter region and could thus play a role in switching
on or maintaining CRH synthesis (Treacy and Rosenfeld 1992). The
promoter regions of the gene for CRH also contains an estrogen response
element consensus sequence (Vamvakopoulos and Chrousos 1994) so that
the intriguing possibility exists that estrogen, provided by the placenta may
have a role in the differentiation of these neurons.
1.4.2 Expression of AVP and CRH message and peptide
Gestation in sheep is about 145 days with some minor strain
differences. It is not known when AVP and CRH first make their appearance
in the hypothalamus of the fetal sheep but protein can be detected from at
least 40 days gestation by immunocytochemistry. Immunoreactive fibres are
seen in the median eminence at a similar time (Levidiotis, Oldfield et al. 1987;
Watabe, Levidiotis et al. 1991). The hypothalamic content of extractable
immunoreactive AVP and CRH increases from about day 60, when peptide is
first detected, to around day 135 (Watabe, Levidiotis et al. 1991; Currie and
Brooks 1992; Keiger, O'Steen et al. 1994). There is a small decrease in CRH
and AVP content at term and then content increases again in the neonatal
lamb (Brieu, Tonon et al. 1989). The total hypothalamic content of AVP is
about 5 times that of CRH from early in gestation to about 125 days, but then
the relative amounts of CRH increase through to term (Brieu, Tonon et al.
1989). Since not all of the AVP and CRH containing neurons of the
hypothalamus project directly to the median eminence it is difficult to know
how much of this peptide content relates to ACTH secretion.
When messenger ribonucleic acid (mRNA) content is examined by in
situ hybridisation it is found that expression of CRH gene in the PVN parallels
the changes seen in peptide content with the exception of a pool of laterally
placed neurons which maintain high expression of CRH message upto
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parturition. (Myers, Myers et al. 1993; Matthews and Challis 1995). In
contrast, others using an RNAase protection assay find an increase in
hypothalamic CRH message at term (Keiger, O'Steen et al. 1994). There is
no change in the expression of AVP message in parvocellular neurons of the
ovine fetal hypothalamus in animals in labour compared with non-labouring
late gestation fetuses (Matthews and Challis 1995).
1.4.3 Hypothalamic regulation of the fetal pituitary
The critical role of the ovine fetal hypothalamus in ACTH secretion
during development has been demonstrated in hypothalamo-pituitary-
disconnected and PVN lesioned animals. In the fetal sheep, bilateral
destruction of the PVN abolishes the preparturient surge of ACTH and
Cortisol, and prevents birth (McDonald, Rose et al. 1988; Gluckman, Mallard
et al. 1991; McDonald and Nathanielsz 1991). Similarly disconnection of the
hypothalamus from the pituitary prevents the preparturient rise in Cortisol and
postpones birth (Antolovich, Clarke et al. 1990; Antolovich, McMillen et al.
1991; Canny, Young et al. 1998). Replacement of ACTH in
hypophysectomised sheep by constant low dose infusion of ACTH results in
increasing Cortisol secretion (Jacobs, Young et al. 1994; Poore, Young et al.
1998). Together these findings imply that the fetal hypothalamus is obligatory
for the secretion of biologically active ACTH and hence the late gestation
increase in Cortisol, although the adrenal may not actually need an increase in
circulating ACTH to mount an increase in Cortisol.
In adult and fetal sheep hypothalamo-pituitary disconnection has been
developed as a model to examine hypothalamic regulation of pituitary
secretion. Following hypothalamo-pituitary disconnection in the ovine fetus
there is a failure to initiate the pre-parturient surge in Cortisol and
consequently pregnancy is prolonged (Antolovich, McMillen et al. 1991;
Deayton, Young et al. 1994; Phillips, Ross et al. 1996). The failure of the
Cortisol surge seems to be due to immaturity of the fetal adrenal steroidogenic
enzyme systems (Phillips, Ross et al. 1996; Ross, Phillips et al. 1997), though
low levels of Cortisol secretion are maintained (Canny, Young et al. 1998).
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Studies examining plasma ACTH concentrations after hypothalamo-
pituitary disconnection have produced somewhat conflicting results.
Measurement of ACTH concentration by radioimmunoassay (which recognise
only one epitope on the ACTH molecule and so may cross react with smaller
and larger molecular weight POMC products) generally finds that there is no
change or a modest increase in ACTH immunoreactivity following
disconnection (Ozolins, Young et al. 1990; Antolovich, McMillen et al. 1991;
Antolovich, McMillen et al. 1992; Ozolins, Young et al. 1992; Canny, Young et
al. 1998). Similar observations have been made in adult sheep and
interpreted as evidence of an inhibitory hypothalamic regulation of basal
ACTH secretion (Engler, Pham et al. 1988; Mercer, Clements et al. 1989).
When a specific two-site immunoradiometric assay is used, basal plasma
concentrations of ACTH do not differ between intact and hypothalamo-
pituitary disconnected fetuses (Deayton, Young et al. 1994; Phillips, Ross et
al. 1996; Ross, Phillips et al. 1997). Interestingly, ACTH secretion in the
hypothalamo-pituitary disconnected fetus continues to be pulsatile and pulse
characteristics are not significantly different from intact fetuses (Canny,
Young et al. 1998).
The observations in the hypothalamo-pituitary disconnected fetuses
are in contrast to the findings after PVN lesioning where the late gestation
increase in ACTH is abolished once PVN neurosecretory neurons are
destroyed (McDonald, Rose et al. 1988; McDonald and Nathanielsz 1991). It
is not clear why basal secretion fails after PVN lesioning, but continues after
hypothalamo-pituitary disconnection. One explanation is that after transection
of the pituitary stalk, and in the absence of dopaminergic stimulation, the
melanotrophs of the NIL synthesise ACTH. Evidence from transgenic mice
supports this interpretation: in the dopamine (D2) receptor knockout mouse,
the expression of mRNA for POMC in the NIL is increased, and there is also a
change in the expression of the convertase enzymes processing POMC, so
that the NIL secretes more ACTH (Saiardi and Borreli 1998).
Supra-pituitary pathways do regulate stimulated ACTH secretion.
Stress responses seem to develop relatively early in utero in the ovine fetus
and require an intact hypothalamic-pituitary connection. Between 74 and 84
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days the ovine fetus is capable of a modest ACTH and Cortisol response to
acute haemorrhage (McFarlane, Potocnik et al. 1995). The stress responses
to hypoglycaemia, nitroprusside-hypotension and prostaglandin E2 are
prevented by hypothalamo-pituitary disconnection (Ozolins, Young et al.
1992; Young, Loose et al. 1996). Glucocorticoids will suppress plasma ACTH
concentrations in intact but not in hypothalamo-pituitary disconnected fetuses
at day 138 gestation (Ozolins, Young et al. 1990).
The principal hypothalamic peptides responsible for stimulating the
release of ACTH from the anterior pituitary corticotroph are AVP and CRH.
Immunoneutralisation studies in adult sheep suggest that AVP and CRH are
involved in different modes of ACTH secretion, so that CRH is important for
maintaining ACTH secretion by the pituitary gland in the unstressed state,
wheras AVP is more important for the stress response (Guillaume, Conte-
Devolx et al. 1992; Guillaume, Conte-Devolx et al. 1992). In the ovine fetus in
late gestation, antagonism of AVP does not affect resting levels of ACTH but
does impair the response to stress (Apostolakis, Long et al. 1991). More
recently, it has been demonstrated that infusion of a specific CRH receptor
antagonist into the ovine fetus in late gestation prevents the normal rise in
plasma ACTH concentrations (Chan, Falconer et al. 1998). Further evidence
that CRH neurons are important in driving the pituitary adrenal axis comes
from the CRH-knockout transgenic mouse, where homozygous fetuses are
born with evidence of failed lung maturation which can be reversed with
glucocorticoid treatment (Muglia, Jacobson et al. 1995). These observations
imply that the hypothalamic drive to the fetal pituitary in late gestation is
mediated through CRH containing neurons in the parvocellular PVN.
1.5 Development of the pituitary
1.5.1 Differentiation and maturation of the corticotroph
The pituitary corticotroph differentiates and matures in parallel with the
developing hypothalamus (Trier and Rosenfeld 1996). In mice, a common
progenitor gives rise to the five specialised cell types secreting the
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polypeptide hormones of the anterior pituitary but there is a temporal and
spatial pattern to the appearance of each of these (Simmons, Voss et al.
1990; Japon, Rubinstein et al. 1994). The earliest cells to appear are the
corticotropins and these seem to be distributed mostly around the periphery of
the gland (Japon, Rubinstein et al. 1994). Proopiomelanocortin message and
immunoreactivity are readily detectable at 60 days gestation in the anterior
pituitary of the ovine fetal pituitary and, as in the mouse, are situated
peripherally (Matthews, Han et al. 1994). During development the volume of
the pituitary increases and at the same time the number of ACTH
immunopositive cells increases from about 6% at day 60 to 10% by day 100,
whereafter the number of ACTH immunopositive cells remains relatively
constant until delivery (Matthews, Han et al. 1994). The morphology of ACTH
immunoreactive cells changes during gestation. From at least day 90
onwards, the ovine fetal pituitary contains both large columnar cells staining
weakly for ACTH that have been termed "fetal corticotropins" and smaller
stellate cells staining intensely for ACTH termed "adult corticotropins" (Perry,
Mulvoque et al. 1985). In later gestation the adult type corticotropin becomes
predominant. Adrenal peptide or steroid hormones may be important in
initiating differentiation to the adult type corticotropin since fetal adrenalectomy
prevents the switch from fetal to adult corticotropin (Antolovich, Perry et al.
1989). Hypothalamo-pituitary disconnection also disrupts development of the
corticotropin, though this may be a consequence of the failure of adrenal
maturation (Antolovich, McMillen et al. 1991).
The genes controlling the differentiation and maturation of the
corticotropin are unknown. For lactotrophs, sommatotrophs and thyrotrophs
the pit-1 gene has been identified as an important trans acting factor
controlling phenotype, and some progress made towards defining the factors
controlling pit-1 expression (Ingraham, Chen et al. 1988; Ingraham, Flynn et
al. 1990; Simmons, Voss et al. 1990). The pit-1 protein is a transcription
factor that binds to the promoter of the GH and PRL genes, and also to its
own promoter (Ingraham, Flynn et al. 1990). During development pit-1
expression becomes activated in response to an as yet uncharacterised stage
specific factor and there then follows an induction of pit-1 expression that is
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responsible for the differentiation and proliferation of somatotrophs and
lactotrophs. In the Snell mouse, which has a mutant Pit-1 gene, the pituitary
is hypoplastic and lacks somatotrophs, lactotrophs and thyrotrophs (Li,
Crenshaw et al. 1990). The pit-1 promoter is activated by pit-1 and also by
growth hormone releasing hormone (GHRH) through cyclic AMP, so that the
hypothalamus plays a part in induction of pit-1 expression.
1.5.2 Expression of POMC message and peptide
Measurement of ACTH content of the pituitary is problematic since
there is differential post-translational processing of the POMC peptide in the
NIL and anterior pituitary. In adult animals, corticotrophs in the anterior
pituitary and melanotrophs in the NIL express different prohormone
convertase enzymes (Day, Schafer et al. 1992; Zhou, Bloomquist et al. 1993).
The principal products of POMC processing in the adult anterior pituitary are
ACTH, p-endorphin and p-lipotropin, wheras in the NIL desacetyl a-MSH and
p-endorphin (which are further converted to a-MSH and acetyl p-endorphin)
predominate (Smyth, Massey et al. 1979; Eipper and Mains 1980; Miller,
Johnson et al. 1980; Browne, Bennett et al. 1981; Donohue and Dorsa 1982;
Smith and Funder 1988).
It is likely that the anterior pituitary and NIL differentially process the
POMC peptide in fetal life. The fetal sheep anterior pituitary contains
message and immunoreactive proconvertase 1 activity (which is involved in
cleaving POMC to ACTH), but not proconvertase 2 (which further processes
ACTH), wheras the fetal NIL expresses both enzymes (Bell, Myers et al.
1998). Following homogenisation of whole fetal pituitary, three large
molecular weight ACTH precursors can be separated from the smaller ACTH,
P-Melanocyte stimulating hormone (pMSH), p-lipotropin (pLPH), yLPH, and p-
endorphin molecules (Silman, Holland et al. 1979). If the NIL is dissected
from the anterior pituitary, then only ACTH and the larger POMC fragments
are identified (Challis and Brooks 1989). There is evidence that the
corticotropin processing of POMC matures through gestation: cultured fetal
pituitary cells release increasing amounts of bioactive ACTH, relative to the
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larger molecular weight precursors, with increasing gestation (Brieu and
Durand 1987).
The expression of POMC message has been examined by Northern
analysis and by in-situ hybridisation. Message levels for POMC in the
pituitary as measured by Northern blot show either a progressive rise upto
day 140 which is maintained in the neonate (Yang, Challis et al. 1991; Myers,
Myers et al. 1993) or a fall in late gestation (McMillen, Mercer et al. 1988;
Brooks, Currie et al. 1992; Merei, Rao et al. 1993). In-situ hybridisation
demonstrates that there is high and increasing expression of POMC in late
gestation in the inferior (peripheral) aspect of the anterior pituitary, and lower
unchanging expression in the superior aspect of the gland in the region
adjacent to the NIL (Matthews, Han et al. 1994). Presumably, the earlier
Northern analyses have been confounded by sampling both areas.
Expression of POMC message in the NIL is higher than in the anterior
pituitary (Matthews, Han et al. 1994). Levels in the NIL reach a plateau at
about day 120 and remain high into neonatal life. It is worth noting that
measurement of steady state mRNA levels does not necessarily reflect
translation to protein, since for many genes there is a considerable amount of
post-transcriptional regulation (Day and Tuite 1998).
1.5.3 Circulating ACTH and other POMC peptides
In intact animals mean circulating levels of ACTH start to increase
before Cortisol (Norman, Lye et al. 1985). The secretion of ACTH in the fetus
is pulsatile, at least from day 126 gestation (Brooks and Challis 1991;
Apostolakis, Longo et al. 1992; Canny, Young et al. 1998). The presence of
pulses of ACTH implies relatively mature neuroendocrine mechanisms
controlling ACTH secretion. Recently, however, the persistence of ACTH
pulses in hypothalamo-pituitary disconnected fetuses has been demonstrated
suggesting that pulsatile secretion is an intrinsic property of the pituitary
(Canny, Young et al. 1998). There are no studies that have systematically
examined the ontogeny of pulsatile ACTH secretion. In premature human
infants sampled on the neonatal unit, deconvolutional analysis suggests the
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characteristics of the ACTH pulse change with increasing post-natal age,
indicating continued maturation of the pulse generator over this period
(Metzger, Wright et al. 1993). The physiological significance of pulsatile
ACTH secretion is unclear since the ovine fetal adrenal responds equally well
to continuous and pulsatile ACTH administration with no evidence of
desensitisation (Lye, Sprague et al. 1983; Jacobs, Young et al. 1994).
With increasing gestation there is a change in the pattern of POMC-
derived products present in the circulation. The plasma of the late gestation
fetus contains proportionally more low molecular weight, bioactive ACTH
relative to higher molecular weight precursors (Brieu and Durand 1987;
Saphier, Glynn et al. 1993; Carr, Jacobs et al. 1995). Using specific
antibodies directed at epitopes near the carboxy and amnio terminals of the
various POMC peptides the relative changes in ACTH and the large N-
terminal fragment of POMC, N-POMC (1_77), in late gestation have been
examined (Saphier, Glynn et al. 1993). Concentrations of N-POMC (1_77) are
found to be 20 to 50 times greater than ACTH up to the last week of gestation
in the ovine fetus. As concentrations of ACTH increase during the surge in
HPA axis activity, there is a fall in the concentration of N-POMC (1_77) and an
increase in gMSH (a product of N-POMC (1_77) cleavage). The much greater
amounts of N-POMC (1_77) relative to ACTH have led to the suggestion that
these alternative POMC gene products arise from the NIL, rather than the
anterior pituitary (Saphier, Glynn et al. 1993).
The physiological role of N-POMC {1.77) is unknown, but N-terminal
peptides may play a role in controlling adrenal growth. Adrenal regeneration
in adult rats has been shown to be mediated by N-terminal POMC peptides
(Estivariz, Morano et al. 1988). Others have demonstrated that ACTH
precursors antagonise the response of cultured adrenal cells to ACTH
(Schwartz, Kleftogiannis et al. 1995). Studies on the cloned ACTH receptor,
however, indicate that the ACTH receptor binds ACTH alone and not other
POMC products (kapas, Cammas et al. 1996).
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1.5.4 Pituitary responses to hypothalamic releasing factors
The pituitary of ovine fetuses from at least day 70 onwards is capable
of responding to both AVP and CRH (Maclsaac, Congiu et al. 1989;
McFarlane, Potocnik et al. 1995). In vivo and in vitro both peptides cause a
dose dependent increase in ACTH secretion and are found to synergise with
each other when co-administered (Norman and Challis 1987; Maclsaac,
Congiu et al. 1989). Vasopressin administered in vivo elicits a rapid short
term increase in plasma ACTH concentrations wheras CRH causes a slower
more sustained increase in ACTH concentration (Pradier, Davicco et al. 1986;
Norman and Challis 1987). Some of the differences in ACTH response are
probably due to the different circulating half-lives of the two peptides, but
there may be separate subpopulations of corticotrophs respond either to CRH
or to AVP (Schwartz, Ash et al. 1994).
The relative sensitivity to AVP and CRH seems to change in later
gestation. With increasing gestation there is a decline in the ACTH response
to challenge with a bolus of AVP (Norman and Challis 1987). In contrast,
over the period from 110-130 days the ACTH response to CRH increases
(Norman, Lye et al. 1985; Norman and Challis 1987). After 130 days the
response to CRH declines somewhat and this has been correlated with a
decrease in the number of pituitary binding sites. Down regulation of the
receptor and diminished ACTH response may be a consequence of increased
CRH secretion at this time, as CRH is known to down-regulate its own
receptor (Hauger and Aguilera 1993), or to the negative feedback actions of
high concentrations of Cortisol.
Attempts to induce parturition in the sheep by administration of CRH or
AVP to the fetus have produced conflicting results. Continuous infusion of
large amounts of CRH (2.4 pig/h) into the fetal circulation from day 125 result
in premature delivery after a period of 5-10 days (Wintour, Bell et al. 1986).
In those animals that lambed, however, maternal plasma progesterone
concentration did not decrease in the manner normally seen prior to
spontaneous term labour (and premature labour induced by ACTH treatment)
so that it is difficult to know the physiological relevance of this observation.
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Others find that pulsatile administration of CRH (1 pg) or CRH (1 pg) and AVP
(200 ng) every 4 h to the fetus over a period of 7 days results in a modest
elevation of Cortisol but a reduction in the amount of ACTH secreted in
response to each bolus of releasing factor (Brooks, Challis et al. 1987; Brooks
and White 1990). The net result is that a new steady state of pituitary-adrenal
function is achieved which does not result in parturition. A similar effect is
seen with chronic exposure to stress and is presumably due to Cortisol
negative feedback (Gagnon, Challis et al. 1994).
1.5.5 Pituitary CRH and AVP receptors
The action of AVP and CRH at the pituitary is mediated through distinct
7-transmembrane spanning G-protein coupled receptors. The receptor for
CRH has been cloned and sequenced in rats and humans, and its distribution
determined in adult animals (Chen, Lewis et al. 1993; Perrin, donaldson et al.
1993; Grigoriadis, Lovenberg et al. 1996). There are as yet no reports of
message levels in the fetal pituitary of any species. Instead CRH binding
capacity has been used to measure receptor number. In the ovine fetus, the
CRH binding capacity of the pituitary expressed per unit tissue weight,
increases to a maximum at day 130 and then declines at term in a manner
very similar to the observed sensitivity to exogenous CRH (Lu, Yang et al.
1990). It is not known if mature and immature corticotropins express the CRH
receptor differently. The decline in CRH binding in late gestation can be
explained in terms of receptor down regulation in response to increasing
secretion of AVP and CRH (Hauger and Aguilera 1993).
The AVP receptor (V1-b receptor) in the pituitary gland is distinct from
renal V2 and vascular and liver V1-a receptors (Arsenijevic, Dubois-Dauphin
et al. 1994; Peter, Burbach et al. 1995) There is no information on pituitary
AVP binding or receptor expression in the fetal sheep. In models of chronic
stress, where concentrations of glucocorticoids are persistently elevated, the
pituitary ACTH response to AVP remains refractory to the negative feedback
actions of glucocorticoids, in contrast to CRH (Harbuz and Lightman 1992;
Aguilera 1994). Paradoxically, glucocorticoid treatment reduces the number
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of pituitary V1-b receptors but actually increased the inositol triphosphate
response to AVP (Rabadan-Diehl and Aguilera 1998). These observations
indicate that the pituitary V1-b receptor may have a role in mediating the late
gestation increase in ACTH secretion in the presence of elevated circulating
concentrations of Cortisol.
1.6 Development of the adrenal gland
1.6.1 Differentiation and maturation of the adrenal cortex
The adrenal gland undergoes marked hypertrophy and hyperplasia in
late gestation. The sheep fetal adrenal doubles in weight over the last 12-14
days of gestation, the period of increasing Cortisol secretion. This is
correlated with the appearance of an adult type glandular histology with
definitive zona glomeulosa, fasiculata and reticularis (Robinson, Rowe et al.
1979; Tangalakis, Coghlan et al. 1989). Similarly in the primate (Mesiano,
Coulter et al. 1993), cow (Conley, Head et al. 1992) and pig (Conley, Rainey
et al. 1994) patterns of enzyme activity and distribution in the fetal adrenal
gland only come to resemble the adult late in gestation. Earlier in gestation,
between 90 and 120 days of gestation the ability of the fetal ovine adrenal to
synthesise Cortisol is poor with low levels of expression of steroid synthetic
enzymes (Tangalakis, Coghlan et al. 1989). Even earlier in gestation,
however, the very immature fetal ovine adrenal possesses the capability for
steroid synthesis and is able to respond in vitro to ACTH (Wintour, Brown et
al. 1975; Tangalakis, Crawford et al. 1994). A role for fetal adrenal steroids in
early gestation has not yet been established and it is not clear if the immature
adrenal is functional in vivo.
Early in embryonic development cells of the urogenital ridge destined
to become steroid synthesising cells express the nuclear transcription factor
steroidogenic factor-1 (SF-1), which binds to the promoter of the cytochrome
P450 steroid hydroxylases and is present in all steroidogenic cells (Parker and
Schimmer 1997). The factors controlling early differentiation and expression
of SF-1 are unknown. Further growth and differentiation of adrenal cortical
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cells is dependent upon the fetal pituitary. Following hypophysectomy in the
ovine fetus or in anencephalic human fetuses, the adrenals remain small
(Chez, Hutchinson et al. 1970; Gray and Abramovich 1980).
Much of the pituitary control of adrenal growth seems to be due to
ACTH. Premature exposure of the ovine adrenal to continuous or pulsatile
ACTH infusion is sufficient to produce hypertrophy, induce enzyme activity
and increase Cortisol output (Durand, Cathiard et al. 1982; Lye, Sprague et al.
1983). Maternal dexamethasone treatment at around day 50-60 in the sheep
results in a decrease in expression of messenger RNA for steroid synthetic
enzymes in the fetal adrenal. This has been interpreted as showing that the
low levels of ACTH present in the fetal circulation (and which are suppressed
by dexamethasone) are important for adrenal development (Tangalakis,
Crawford et al. 1994).
The actions of ACTH are probably mediated by locally produced
growth factors (Feige, Vilgrain et al. 1998). In the adult animal adrenal cells
are renewed from a stem cell pool situated adjacent to the capsule of the
gland. As the cells are pushed centripedally towards the medulla, they
express the sequentially the enzymes of the glomerulosa, fasiculata and
reticularis (Feige, Vilgrain et al. 1998). Similar centripedal migration seems to
occur in the developing adrenal gland (Mesiano and Jaffe 1997).
Differentiation of cell phenotype is dependent upon ACTH since deletion of
POMC expressing cells in adult transgenic mice results in a loss of fasiculata
and reticularis cells, while the glomerulosa layer (aldosterone synthesis)
remains functional (Allen, Carey et al. 1995). Alternative products of POMC
processing have also been identified as candidate trophic factors for the fetal
adrenal (Challis and Torosis 1977; Glickman, Carson et al. 1979; Llanos,
Ramachandran et al. 1979; Baird, Kan et al. 1983; Saphier, Glynn et al.
1993).
1.6.2 Circulating adrenal steroids
An increase in the concentration of corticosteroid in the fetal sheep
circulation late in gestation has been demonstrated by many authors
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(Nathanielsz, Comline et al. 1972; Jones, Boddy et al. 1977; Hennessey,
Coghlan et al. 1982). Corticosteriods in the fetal circulation arise from the
fetal adrenal glands and by transplacental passage from the maternal
circulation. Early in gestation the fetal adrenal glands are a minor source of
steroid synthesis. Instead corticosteriods are derived largely from the
maternal circulation. Fetal adrenalectomy before day 120 makes very little
difference to circulating levels of corticosteroids in the fetal sheep (Wintour,
Coghlan et al. 1980). Maternal corticosteroid concentrations are about 10
fold greater than fetal concentrations at this time (Hennessey, Coghlan et al.
1982). Fetal Cortisol levels increase progressively over the last 15 days or so
of gestation so that at term fetal Cortisol concentrations are higher than
maternal concentrations (Nathanielsz, Comline et al. 1972; Hennessey,
Coghlan et al. 1982). Studies infusing tritiated Cortisol into the maternal
circulation demonstrate that placental transfer of Cortisol accounts for all of
the Cortisol in the fetal circulation before day 120, 37% between days 122 and
135, and from day 135 onwards only 12% or less (Hennessey, Coghlan et al.
1982). This is consistent with an increase in fetal adrenal production of
Cortisol. After birth levels of Cortisol decline (Nathanielsz, Comline et al.
1972) indicating that the increase in Cortisol in late gestation is specifically
driven in utero. Data in the primate also indicate that fetal corticosteroids are
largely of maternal origin until quite late in gestation (Pepe, Waddell et al.
1990).
The ovine fetal adrenal is also a source of androgenic precursors that
can be aromatised in the placenta to estrogens. The principal androgen
produced by the ovine adrenal is androsteinedione which is metabolised to
estradiol in the placenta. Little unconjugated estradiol is present in the
circulation until near term when there is a dramatic increase during the
preparturient surge in estradiol concentrations (Challis 1971). It is estimated
that the ovine fetal adrenal contributes precursors for as much as one third of
the estrogen produced during the surge (Mitchell, Lye et al. 1986).
Both maternal and fetal adrenals contribute androgenic precursor for
aromatisation in primate pregnancy and this may explain why birth in the
primate is not so crucially dependent upon a functioning fetal adrenal. There
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are, however, interspecies differences in the contributions of the various
precursors to overall estrogen synthesis (Honnebier and Nathanielsz 1994).
The human fetal adrenal zone produces mainly dehydroepiandrosterone
(DHEA) and 16-hydroxy DHEA from which estradiol and estriol respectively
are formed. Nearly 90% of estriol in the maternal circulation is produced from
fetal adrenal precursors (Sitteri and MacDonald 1966). By about 35 weeks of
gestation there is a dramatic increase in estriol levels paralleling the increase
in fetal Cortisol levels. It seems likely that both Cortisol and androgen are
driven by rising ACTH concentrations (Walsh, Norman et al. 1979) but there
is debate over the existence of a separate factor capable of influencing
androgen secretion independently of Cortisol (McKenna and Cunningham
1991)
1.6.3 Adrenal responsiveness to ACTH
In contrast to the declining pituitary response to AVP and CRH in late
gestation, the ovine fetal adrenal response to ACTH increases from day 120
onwards (Rose, Meis et al. 1982). Associated with this the number of ACTH
binding sites in ovine fetal adrenal membranes are increased (Durand 1979).
Pulsatile, or continuous administration of ACTH accelerates the increase in
adrenal sensitivity, and results in increasing production of Cortisol and
parturition (Lye, Sprague et al. 1983; Jacobs, Young et al. 1994). This self-
priming action of ACTH on adrenal responsiveness may be mediated by
Cortisol itself since concurrent treatment with metopirone prevents the
increase in fetal adrenal weight stimulated by ACTH infusion (Challis,
Huhtanen et al. 1985). Between day 90-120, during the period when the
adrenal expression of steroidogenic enzymes is low, the ovine fetal adrenal
mounts only a small Cortisol response to challenge with ACTH in vitro and in
vivo (Rose, Meis et al. 1982).
Other POMC derived peptides are also reported to stimulate adrenal
steroid synthesis and secretion. For instance, a-MSH stimulates Cortisol
secretion from the fetal rabbit and sheep adrenal in vivo (Challis and Torosis
1977; Llanos, Ramachandran et al. 1979) and human adrenal in vitro
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(Glickman, Carson et al. 1979; Baird, Kan et al. 1983), though others have
been unable to demonstrate any stimulatory effect of a-MSH on a primate
species in vivo (Walsh, Norman et al. 1979). Not all of these endogenous
opioid-like peptides are acting directly at the adrenal (Bousquet, Lye et al.
1984). The different zonation and steroid products of the primate fetal
adrenal have led to speculation that fetal Cortisol and androgens may be
differentially controlled. In culture a-MSH stimulated DHEA production at
lower doses and Cortisol at higher doses. The dose of a-MSH used, however,
was 10-100 times greater than that of ACTH to elicit the secretion of both
hormones (Baird, Kan et al. 1983).
1.7 Cortisol negative feedback
1.7.1 The establishment of negative feedback
Considerable evidence supports the existence of a functioning
negative feedback loop from around day 100 upto about day 140 in the ovine
fetus. Short term infusion of Cortisol or dexamethasone will lower basal levels
of ACTH and inhibit the response to CRH and AVP, hypoxaemia or
nitroprusside between d110 and d130 gestation (Jones and Ritchie 1977;
Wood and Rudolph 1983; Dix, Rose et al. 1984; Rose, Hargrave et al. 1985;
Norman and Challis 1987; Ozolins, Young et al. 1990; Wood and Keller-Wood
1991). Conversely adrenalectomy results in elevated ACTH secretion
(Wintour, Coghlan et al. 1980; Rose, Turner et al. 1988; McMillen, Antolovich
et al. 1990). Associated with the increase in plasma ACTH after
adrenalectomy there is approximately a 200% increase in message for CRH
in the PVN and POMC message in the anterior pituitary as measured by
Northern blot analysis (McMillen, Antolovich et al. 1990; Myers, Ding et al.
1991; Myers, Myers et al. 1993).
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1.7.2 Does negative feedback sensitvity decline?
The sustained increase in plasma concentrations of ACTH in the face
of elevated levels of corticosteroids in late gestation presents a paradox,
since normally corticosteroid negative feedback would be expected to limit the
activity of the hypothalamo-pituitary-adrenal axis. Earlier in gestation
repeated stimulus to the HPA axis does not lead to sustained increases in
plasma Cortisol to levels capable of inducing parturition (Brooks, Challis et al.
1987; Brooks and White 1990; Gagnon, Challis et al. 1994). The steady
increase in plasma ACTH and Cortisol in late gestation suggest that there are
specific mechanisms operating to allow the hypothalamus and pituitary to
escape from adrenal steroid negative feedback.
Several studies have examined the effects of exogenous Cortisol
during the last few days of gestation when ACTH and Cortisol levels are
changing dramatically. One study (Wood 1988) conducted between 138-142
days gestational age concluded that elevation of Cortisol to 50-60 ng/ml did
not affect basal secretion or the ACTH response to nitroprusside at this
gestation. On the basis of these results it has often been accepted that there
is a decline in negative feedback sensitivity near term. In contrast, basal
ACTH secretion at term (d138-140) is suppressed by Cortisol infusion
achieving levels of 40-80ng/ml (Ozolins, Young et al. 1990; Wood and Keller-
Wood 1991). Others have even found that infusion of Cortisol enhances
ACTH secretion (Apostolakis, Longo et al. 1994).
One way of rationalising these results is to postulate that the action of
Cortisol on the fetal HPA axis is akin to the positive feedback actions of
estrogen during the luteinising hormone (LH) surge (Moenter, Caraty et al.
1990; Karsch, Bowen et al. 1997; Levine 1997; Spies, Francis Pan et al.
1997). If the analogy is correct then the discrepancy between studies on
positive and negative feedback effects of Cortisol can be partly explained by
methodology: negative feedback effects may be apparent at relatively lower
concentrations and shorter exposures to Cortisol but elevation above a
threshold for a critical period of time is associated with positive feedback to
reinforce increasing ACTH secretion.
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1.7.3 Anatomic sites of negative feedback
Glucocorticoid receptors are found in multiple sites throughout the HPA
axis indicating the potential for feedback directly at the pituitary,
hypothalamus or other brain areas important in the regulation of ACTH
secretion. Pituitary glucocorticoid receptor concentration measured by
triamcinolone binding to dispersed cells is highest at day 110 and then
declines threefold through to day 130. By term receptor concentration has
risen again though not to the same levels as at day 110 (Yang, Jones et al.
1990). The number of hypothalamic triamcinolone binding sites was always
less than that of the pituitary, and after peaking at day 110 declined steadily
through to term. The decline in glucocorticoid receptor number is attributed to
the down regulation of receptor produced by Cortisol itself. In support of this
treatment with ACTH at day 125 for 100 hours produced a 30% decline in
receptor number (Yang, Jones et al. 1990). In contrast to studies measuring
receptor binding sites, Northern analysis reveals message for glucocorticoid
receptor is present in the hypothalamus, pituitary and adrenal from day 60 to
term in unchanging concentrations (Yang, Hammond et al. 1992). A more
recent analysis of message for the glucocorticoid receptor by in situ
hybridisation finds that the level of message in the pituitary gland increases
markedly with the transition into active labour (Matthews, Yang et al. 1995).
The relative sensitivity of pituitary and suprapituitary feedback
pathways and their development during fetal life is poorly characterised.
Corticosteroids have a direct action on the pituitary gland to suppress ACTH
secretion. Treatment with Cortisol or dexamethasone inhibits the ability of
CRH and AVP to stimulate ACTH secretion from at least day 120 onwards,
but crucially, pituitary sensitivity during the preparturient surge in ACTH and
Cortisol has not been examined (Rose, Hargrave et al. 1985; Norman and
Challis 1987; Ozolins, Young et al. 1990). Studies on suprapituitary sensitivity
to feedback have produced conflicting results. Evidence from the
hypothalamo-pituitary disconnected preparation indicates that corticosteroid
suppression of basal ACTH secretion near term (138 days) requires an intact
hypothalamo-pituitary axis, but that before 130 days gestation basal ACTH
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secretion is not affected by a similar levels of corticosteroids in either intact or
hypothalamo-pituitary disconnected fetuses (Ozolins, Young et al. 1990). In
other words suprapituitary feedback does not seem to be important before
day 130 gestation. Others, however, find that around day 125 gestation
placement of dexamethasone implants bilaterally adjacent to the PVN
decreases CRH and AVP immunostaining within the PVN and prevents the
ACTH response to stress (McDonald, Hoffmann et al. 1990). The same
treatment also reduces CRH message content of PVN micropunches as
measured by Northern analysis but not pituitary POMC message content
(Myers, McDonald et al. 1992). Plasma concentrations of ACTH are similarly
unaffected by dexamethasone implants (McDonald, Hoffmann et al. 1990).
The degree to which CRH message in the micropunches is depressed by the
dexamethasone implants decreases nearer term consistent with a decline in
negative feedback sensitivity.
1.7.4 Corticosteroid binding globulin
Circulating corticosteroid is largely bound to corticosteroid-binding
globulin (CBG). In vitro experiments demonstrate that CBG serves to
sequester free active corticosteroid and reduce its biological potency
(Berdusco, Yang et al. 1995), though others have argued that some cells may
actually possess receptors for unliganded CBG (Maitra, Khan et al. 1993). An
increase in CBG offers a mechanism for overcoming feedback by reducing
the amount of free bioactive steroid. Although concentrations of CBG
increase in the fetal circulation throughout gestation, levels of free Cortisol
also increase (Fairclough and Liggins 1975; Ballard, Kitterman et al. 1982).
The main site of CBG production is the fetal liver (Seralini, Smith et al. 1990).
There is evidence that Cortisol itself can stimulate hepatic synthesis of CBG in
the fetal sheep (Challis, Nancekievill et al. 1985; Berdusco, Hammond et al.
1993; Berdusco, Milne et al. 1994). The fetal pituitary expresses the gene for
CBG adding the possibility of paracrine mechanisms that overcome the
negative feedback action of Cortisol (Berdusco, Yang et al. 1995).
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1.7.5 11 p hydroxysteroid dehydrogenase
Access to intracellular glucocorticoid receptors can be controlled by
cytoplasmic enzyme activity. The enzyme 11 p hydroxysteroid
dehydrogenase (11 pHSD) converts the biologically active steroids Cortisol
and corticosterone to the inactive metabolites cortisone and 11-
dehydrocorticosterone respectively. There are at least two isoenzymes with
different tissue distributions and different functions (Steward, Whorwood et al.
1995; Gomez-Sanchez and Gomez-Sanchez 1997; Penning 1997). An
NADP+ dependent enzyme (11PHSD-1) is present predominantly in liver and
proximal collecting tubules of the kidney. The enzyme appears to be
bidirectional and has a Km for corticosterone of 2 pM. The tissue distribution,
bidirectionality and low affinity for corticosterone of this isoform suggest that it
is not involved in protecting mineralocorticoid and glucocorticoid receptors
from corticosteroids. Under physiological conditions 11PHSD-1 may function
as a oxo-reductase to increase local cellular concentrations of active steroid
(Duperrex, Kenouch et al. 1993; Gomez-Sanchez and Gomez-Sanchez
1997). In contrast, 11 pHSD-2 is unidirectional, uses NAD+ as a cofactor, has
a Km for corticosterone of 30-50 nM and colocalises with the
mineralocorticoid receptor in the rat kidney (Penning 1997). Both isoforms
can be inhibited by progesterone metabolites (Souness, Latif et al. 1995).
The sensitivity of the HPA axis to corticosteroid feedback can
potentially be modulated by 11 pHSD activity. The enzyme is present in the
pituitary, PVN and limbic areas in adult rats (Moisan, Seckl et al. 1990;
Lakshsmi, McEwen et al. 1991; Seckl, Dow et al. 1993) and treatment with an
inhibitor of 1 ipHSD results in decreased release of CRH and increased
release of AVP into portal blood (Seckl, Dow et al. 1993). The concentration
of circulating corticosteroid in these experiments, however, remained
unchanged despite inhibition of 11 pHSD activity. In the fetal sheep message
for 11 pHSD-1 is present in the hypothalamus and pituitary, and levels of
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expression and enzyme activity in the anterior pituitary are increased at term
(Yang, Smith et al. 1992; Yang, Matthews et al. 1995). In the sheep 11pHSD-
I seems to act predominantly as a dehydrogenase and so can prevent
corticosteroids from gaining access to the glucocorticoid receptor (Yang
1997). Critical studies such as inhibition of 11 pHSD activity in the late
gestation fetal sheep have not been conducted.
Besides the HPA axis, 11(3HSD is present in other steroid sensitive
tissue including the placenta and fetal kidney, lungs, gonads, liver and colon
(Lopez-Bernal, Flint et al. 1980; Yang, Smith et al. 1992; Brown, Chapman et
al. 1993; Albiston, Obeyesekere et al. 1994; Stewart, Murry et al. 1994). Both
II (3HSD-1 and 11 (3HSD-2 are present in human placenta (Sun, Yang et al.
1998). Placental 11 (3HSD is likely to be important for controlling
transplacental passage of Cortisol as well as the actions of Cortisol within the
placenta itself (Sun, Yang et al. 1998). It has been suggested that 11|3HSD
additionally protects progesterone or androgen regulated genes from
activation by corticosteroids (Funder 1994).
In baboons placental NAD+ dependent 11|3HSD activity is estrogen
regulated (Pepe and Albrecht 1998). Infusion of estrogenic precursor to the
mother at d100 gestation (term=184) increases placental 11 pHSD activity
wheras fetectomy (which removes the source of endogenous estrogenic
precursor) decreases activity (Baggia, Albrecht et al. 1990). Functionally, it is
argued, the action of estrogen is to lower the circulating Cortisol
concentration, which at this time in gestation is largely of maternal origin
(Pepe, Waddell et al. 1990), and so allow activation of the fetal HPA axis, as
inferred by higher levels of expression of POMC message in the fetal pituitary
(Pepe, Davies et al. 1994). It is difficult to reconcile the fact that Cortisol in
these mid-gestation estrogen treated fetuses was not significantly lower than
controls and yet still POMC expression was enhanced. Another interpretation
is that estrogen directly activates the fetal HPA axis, perhaps by inducing
brain and/or pituitary 11 (3HSD.
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1.7.6 Transcription factors
Glucocorticoids regulate the activity of specific genes in a positive or
negative manner through a complex nuclear pathway involving glucocorticoid
receptors and other nuclear proteins (Horwitz, Jackson et al. 1996; Reichardt
and Schutz 1998). The sensitivity to glucocorticoids can be modulated by
alterations in the concentrations or biological activity of these nuclear
proteins. Positive actions mediated by the glucocorticoid receptor require the
formation of a homodimer with a second glucocorticoid receptor before
binding to the glucocorticoid response element in the upstream promoter
sequence of the gene in question (Reichardt and Schutz 1998). Full activity
of the transcription complex then requires the participation of steroid
coactivator proteins (Horwitz, Jackson et al. 1996).
Many genes that are inhibited by glucocorticoids do not have a
classical glucocorticoid response element, and a number of mechanisms of
gene repression by glucocorticoids have been described, involving steric
hindrance by the glucocorticoid receptor bound to DNA preventing the binding
of other transcription factors, direct interactions between the glucocorticoid
receptor and other proteins required for gene activation and the induction of
inhibitor proteins (Bamberger, schulte et al. 1996; Cato and Wade 1996;
McEwan, Wright et al. 1996; Wissink, Van Heerde et al. 1998). For example,
in vitro the negative regulation of the naked POMC gene sequence involves
binding of three molecules of glucocorticoid receptor to a site in upstream
promoter sequence of the POMC gene. The glucocorticoid receptors then
interact with unknown transcription factors or components of the transcription
activation complex binding to nearby sites in the promoter sequence to
interfere with their normal function (Riegel, Lu et al. 1991).
In another model of negative glucocorticoid action, the interaction
between the glucocorticoid factor and the transcription factor, activator
protein-1 (AP-1) which is itself a dimer, can either enhance or repress gene
activity depending upon the particular subunits making up AP-1. The mouse
proliferin gene promoter binds both AP-1 and the glucocorticoid receptor. If
the AP-1 is a heterodimer of c-jun/c-fos, then the glucocorticoid receptor
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represses gene transcription. On the other hand, if the AP-1 is a heterodimer
of c-jun/Fra-1, then the glucocorticoid receptor enhances transcription (Cato
and Wade 1996). Changes in the ratio of Fos and Fra-1 might then be
expected to alter the effects of glucocorticoids on expression of particular
genes. It is not known whether such mechanisms are operational in the fetal
HPA axis, but it is worth noting that the expression of Fos in the ovine fetal
hypothalamus is increased in late gestation (Hoffman, McDonald et al. 1991).
Others have identified a negative glucocorticoid response element that
binds the glucocorticoid receptor in vitro and inhibits expression of the POMC
gene (Drouin, Sun et al. 1993). The same negative response element binds
Nur77, an orphan steroid receptor with as yet no known ligand (Okabe,
Takayangi et al. 1998), and in a mouse pituitary cell line (AT20) stabily
expressing the human homologue of Nur77 there is a reduction in
dexamethasone suppression of POMC synthesis and ACTH secretion
(Okabe, Takayangi et al. 1998). The expression of native Nur77 in AT20 cells
is increased by exposure to CRH (Okabe, Takayangi et al. 1998). Thus in the
context of chronic stress, the expression of Nur77 in corticotropins is
increased and this acts to reduce glucocorticoid negative feedback.
Finally, the anti-inflammatory actions of glucocorticoids seem to be
mediated partly through protein-protein interactions between glucocorticoid
receptors and NF-kB, and partly through induction of an inhibitor protein IkB,
which prevents NF-kB from being transcriptionally active (Wissink, Van
Heerde et al. 1998).
1.8 Peripheral signals to the fetal HPA axis
1.8.1 Metabolic factors
The HPA axis is important not only for the response to stressful stimuli,
but also for the maintenance of internal homeostasis. The HPA axis is active
during the metabolic transition between the fed and fasted states (Dallman,
Strack et al. 1993), and in turn metabolic signals influence the HPA axis. The
role of the HPA axis in regulating fetal metabolism has not been investigated.
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Metabolic substrates available to the fetus by passive transfer across the
placenta fluctuate in concert with levels present in the maternal blood, and
even for actively transported substances fetal plasma concentrations are
ultimately dependent upon the availability of the metabolite in the maternal
plasma (Hay 1995). The fetus is uniquely dependent upon the maternal
organism for provision of oxygen and metabolic substrate, but it does seem to
be able to modify maternal metabolism through placental hormones secreted
into the maternal circulation (Petraglia 1991).
As the fetus grows there is an increasing requirement for oxygen and
metabolic substrate to maintain growth and it has been hypothesised that
fetal demands overtake the capacity of placental transfer and maternal
metabolism to sustain delivery of carbohydrates, amino acids and fatty acids
in late gestation (Schneider 1996). Fetal growth in late gestation is rapid: the
ovine fetus grows at a rate of approximately 1% bodyweight/day (Fowden
1995) and this imposes high demands for metabolic substrate. Oxygen and
glucose uptake by the near term fetal sheep are calculated at 315 and 30
M,mol/min/kg respectively (Fowden 1995). A teleological argument could be
made that the fetus initiates parturition to escape from a hostile in utero
environment. Some evidence supports the idea that metabolic factors trigger
birth. Fasting of sheep and humans late in gestation results in premature
delivery (Alexander 1956; Kaplan, Eidelman et al. 1983). In human
pregnancy, low pre-pregnancy maternal weight, poor weight gain and fetal
growth arrest, have been associated with spontaneous premature delivery
(Arias, Rodriquez et al. 1993; Hediger, Scholl et al. 1995; Carmichael and
Abrams 1997). The contribution of metabolic signals to activation of the fetal
HPA axis and the initiation of parturition has not been systematically
investigated.
Mild insulin-induced hypoglycaemia is known to be a stimulus for
increased ACTH secretion in adult animals (Caraty, Grino et al. 1990;
Dohanics, Hoffman et al. 1991) and long term restriction of food intake
elevates ACTH and Cortisol in all species that have been studied (Dallman,
Strack et al. 1993). The hypothalamus in vitro can increase the release of
CRH into the bathing media in response to lowering concentrations of glucose
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in the extracellular fluid (Widmaier, Plotsky et al. 1988). Under normal
physiological conditions hypoglycaemia is accompanied by hypoinsulinaemia,
and a fall in plasma insulin concentrations will also stimulate ACTH secretion
through a pathway involving insulin receptors in the arcuate nucleus
(Schwartz, Figlewicz et al. 1992; Dallman, Strack et al. 1993). Similarly,
acute hypoxaemia is a stimulus for ACTH and Cortisol secretion (Braems,
Matthews et al. 1996). When hypoxia is maintained, plasma ACTH levels
return to normal, but anterior pituitary expression of POMC is increased, and
plasma Cortisol levels remain elevated (Braems, Matthews et al. 1996).
1.8.2 Prostaglandin E2
The suggestion has been made that increasing placental prostaglandin
E2 (PGE2) production provides the drive to the fetal HPA axis leading to
labour (Thorburn 1991). The placenta and fetal membranes of all species
synthesise PGE2. In the ovine fetus circulating PGE2 metabolites are found in
increasing concentrations throughout gestation and rise still further in labour
(Challis, Dilley et al. 1976; MacKenzie, MacLean et al. 1980; Thorburn 1991).
Prostaglandin E2 sensitises all components of the HPA axis: increasing
adrenal sensitivity to ACTH, synergising with AVP to promote secretion of
bioactive ACTH (Brooks and Gibson 1992; Hollingworth, Deayton et al. 1995),
and promoting the release of hypothalamic factors when given
intracerebroventricularly (Brooks 1992). Placental synthesis of PGE2 appears
to be part of a stress adaptive pathway: the concentration of PGE2 metabolite
in fetal plasma is increased in response to maternal hypoxia (Hooper, Harding
et al. 1992), fetal intravascular volume expansion (Weiner and Robillard
1989) and maternal fasting (Fowden, Harding et al. 1987).
1.8.3 Corticotrophin releasing hormone
In primates trophoblasts of the placenta and fetal membranes express
the genes for CRH and for POMC (Cheng, Chang et al. 1986; Riley and
Challis 1991; Wu, Unno et al. 1995) and a placental-fetal HPA axis interaction
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culminating in parturition has been proposed (Challis and Brooks 1989;
Karalis, Goodwin et al. 1996). Placental production of CRH is stimulated by
corticosteroids both in vitro and in vivo (Robinson, Emanuel et al. 1988;
Korebritis, Yu et al. 1998; Marinioni, Korebritis et al. 1998) creating a potential
positive feedback cascade whereby corticosteroids stimulate placental CRH
production, which then stimulates the maternal and fetal pituitary-adrenal axis
to secrete more Cortisol which in turn promotes further CRH synthesis (Challis
and Brooks 1989; Karalis, Goodwin et al. 1996). As a consequence of
increasing CRH secretion the fetal and maternal adrenals are also stimulated
to secrete precursors for placental estrogen synthesis. Rising concentrations
of estrogens in turn result in labour (Mecenas, Giussani et al. 1996) and
eventual escape from this positive feedforward cascade.
There is reasonable evidence in primates that placental CRH does
have some role in the control of parturition. In human pregnancy maternal
plasma concentrations rise to high levels (1300-1700 pg/ml) comparable to
those estimated to be present in rat portal plasma (Linton, Wolfe et al. 1991).
Interestingly, high frequency blood sampling shows that there are
approximately hourly pulses of CRH in maternal plasma with an amplitude of
250pg/ml (Petraglia, Genazzani et al. 1994). Much of the CRH in maternal
plasma is bound to a specifc CRH-binding protein which is also produced by
the placenta (Petraglia, Potter et al. 1993). From about 35 weeks gestation
onwards, however, the concentration of the binding protein in the plasma
falls, and concentrations of CRH increase (McLean, Bisits et al. 1995). It has
been demonstrated that women destined to labour prematurely have
persistently elevated plasma concentrations of CRH compared to gestation
matched controls labouring at term, and that women who do not labour until
after 42 weeks have persistently lower circulating CRH concentrations
(McLean, Bisits et al. 1995). Concentrations of CRH in cord plasma at term
are about 2-10-fold lower than those in maternal plasma (Goland, Wardlaw et
al. 1986; Economides, Linton et al. 1987; Linton, Wolfe et al. 1991).
The human placenta also synthesises ACTH, and a paracrine pathway
regulating placental ACTH secretion is suggested since CRH stimulates the
release of ACTH from perifused human placentae in a dose dependent
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manner (Margioris, Grino et al. 1988). The placental contribution to the
concentration of ACTH in the maternal and fetal circulations is unknown.
Associated with increased CRH concentrations in human pregnancy, there is
a modest elevation of maternal plasma ACTH (to the upper end of the normal
range) and plasma free Cortisol, and increased 24hr excretion of urinary free
Cortisol as pregnancy advances (Linton, Wolfe et al. 1991; Goland, Conwell et
al. 1992). Unfortunately, studies in humans and another primate species
have shown that a bolus injection of CRH into the maternal circulation fails to
elevate ACTH concentrations (Goland, Stark et al. 1990; Schulte, Weisner et
al. 1990). This seems to indicate that placental CRH and ACTH secreted into
the circulation do not have a major effect on maternal or fetal HPA axes. It is
possible that CRH facilitates labour through other mechanisms: the placenta
and myometrium expresses CRH receptors (Hillhouse, Grammatopoulos et
al. 1993; Clifton, Owens et al. 1995; Wu, Unno et al. 1995; Grammatopoulos,
Dai et al. 1998) and CRH synergises with oxytocin to stimulate the
myometrium, at least in vitro (Quartero and Fry 1989).
There are considerable species differences in the concentrations of
CRH in maternal plasma during pregnancy. In the sheep CRH only becomes
detectable in maternal plasma very late in gestation and the concentrations
are comparatively low (20-50pg/ml). (Jones, Gu et al. 1989; Wood and
Keller-Wood 1991). The ovine placenta does not appear to synthesise or
secrete ACTH in vivo (McMillen, Antolovich et al. 1990; Keller-Wood and
Wood 1991).
1.8.4 Placental steroids
Estrogen can stimulate the fetal and maternal HPA axis. In adult
animals there is a well documented sex difference in resting HPA activity with
females having higher resting plasma ACTH and corticosteroid
concentrations. In female rats the ACTH and Cortisol responses to stress are
estrous cycle dependent (Viau and Meaney 1991; Carey, Deterd et al. 1995).
Replacement of estrogen in ovariectomised animals results in enhanced
secretion of ACTH and Cortisol in response to stress (Viau and Meaney 1991;
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Burgess and Handa 1992; Carey, Deterd et al. 1995). The mechanism
whereby estrogen enhances ACTH and Cortisol secretion is not fully
understood. In female rats estrogen inhibits corticosteroid induced down-
regulation of the hippocampal glucocorticoid receptor (Burgess and Handa
1992). The receptor is still present in unchanged concentration but somehow
its efficacy is reduced. At a molecular level the 5'-upstream sequences of the
CRH and POMC genes contain potential progesterone/glucocorticoid and
estrogen response elements (Lundblad and Roberts 1988; Vamvakopoulos
and Chrousos 1994).
The action of estrogen on the fetal HPA axis has been examined in
primates and sheep. In the baboon, infusion of androgenic precursors for
placental estrogen synthesis into the maternal circulation increases POMC
expression in the fetal pituitary (Pepe, Davies et al. 1994). Estradiol
produced in the placenta from these androgenic precursors is postulated to
contribute to increasing ACTH synthesis by increasing placental 11|3HSD
production, which in turn removes Cortisol from the fetal circulation (Pepe,
Davies et al. 1994; Pepe and Albrecht 1998). In contrast, in the sheep fetus
the potential for estradiol to stimulate the fetal HPA axis has been
investigated in several studies with conflicting results despite all three studies
using similar doses of estrogen (Saoud and Wood 1997; Wang, Matthews et
al. 1997; Wood and Saoud 1997).
1.9 Hypothalamic pathways regulating ACTH secretion in utero
The hypothalamic pathways regulating HPA activity in the fetus remain
little investigated. Inference from the adult is not always satisfactory since it
is not known when many of the neurotransmitter pathways and their receptor
systems mature. Additionally, receptors for various neurotransmitters often
display developmentally regulated patterns of expression and phosphorylation
that mean that their functions are subtly different during fetal and neonatal life
(Lanius, Pasqualotto et al. 1993). In adult animals a number of pathways
mediating the stress response and the diurnal rhythm in HPA activity have
been partially characterised pharmacologically and neuroanatomically
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(Harbuz and Lightman 1992; Antoni 1993; Dallman, Strack et al. 1993;
Whitnall 1993; Chrousos 1995). The following sections briefly review the
neuroanatomy of the PVN and those neurotransmitters for which there is
experimental evidence indicating a role in regulating the HPA axis in fetal life.
In addition the potential role of Neuropeptide-Y in mediating the fetal HPA
axis response to metabolic challenge is also considered.
1.9.1 Structure of the paraventricular nucleus
The PVN is a complex structure integrating endocrine and autonomic
responses to the environment (Swanson and Sawchenko 1980). Probably
most is known about the organisation of the PVN from study of the laboratory
rat. In this species, several subdivisions of the nucleus can be recognised.
Parvocellular CRH containing neurons projecting to the median eminence are
contained in the dorsal medial parvocellular subdivision (Whitnall 1993).
About 50% of these neurons co-express AVP. After adrenalectomy nearly all
of these neurons express AVP (Whitnall 1988), but generally it seems likely
that there are two separate populations of neurosecretory neurons with
different locations within the dorsal medial subdivision of the nucleus, that
receive different innervation and presumably have different roles in the
regulation of ACTH secretion (Whitnall 1993). Magnocellular AVP containing
neurons of the SON and PVN projecting to the posterior pituitary may also
secrete AVP at the median eminence "en passant" (Antoni 1993).
Lesion studies, electrical stimulation, immunocytochemistry and tract
tracing studies have defined a number of brain regions projecting to, and
capable of influencing CRH and AVP neurons in the PVN. The hippocampus
and amygdala mediate corticosteroid negative feedback, but probably do so
by innervating interneurons adjacent to the PVN and in the bed nucleus of the
stria terminalis and septal areas (Jacobson and Sapolsky 1991). The
suprachiasmatic nucleus, important as the circadian pacemaker, projects to
the PVN and drives the diurnal rhythm in HPA axis activity (Cascio, Shinsako
et al. 1987). Ascending adrenergic and noradrenergic pathways from the
brain stem are activated during stress (Ceccatelli, Villar et al. 1989) and
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provide stimulatory input to CRH and AVP containing neurons (Sawchenko
1988; Plotsky, Cunningham et al. 1989). Some of these catecholamine
containing neurons also express Neuropeptide-Y (NPY), but the largest
projection of NPY immunoreactive fibres arises from the hypothalamic
arcuate nucleus (Bai, Yamano et al. 1985). Midbrain serotonergic neurons
also provide stimulatory input to the PVN (Whitnall 1993).
1.9.2 N-methyl-D-aspartate receptor coupled pathways
Excitatory amino acid transmitters are widely distributed in the
mammalian brain and are important for synaptic plasticity in both developing
and adult brain (McDonald and Johnston 1990; Ruzika and Jhamander 1993).
As such they might be expected to be important in the developing HPA axis.
Pharmacologically, two distinct classes of ion channel coupled receptor are
identified, based upon response to the agonist N-methyl-D-aspartate (NMDA):
1/. the NMDA receptor and 2/. the non-NMDA receptor. Molecular
characterisation of the NMDA receptor reveals that there are multiple subunits
involved in the formation of a receptor complex (Barnes and Henley 1992;
Monyer, Sprengel et al. 1992; Hollmann and Heinemann 1994; Seeburg,
Burnashev et al. 1995). A common NMDAR1 subunit is found in all functional
receptors. At least four NMDAR2 subunits have been identified by screening
brain derived cDNA libraries for conserved sequences found in glutamate-
operated ion channels (Seeburg, Burnashev et al. 1995). Expression of
NMDAR1 with different NMDAR2 subunits in Xenopus oocytes results in
functional receptors with differing kinetics (Seeburg, Burnashev et al. 1995).
The NMDAR1 subunit is ubiquitously expressed throughout the central
nervous system, but the expression of the other subunits varies in different
brain regions as well as during development (Farrant, Feldmeyer et al. 1994;
Monyer, Burnashev et al. 1994; Sheng, Cummings et al. 1994; Seeburg,
Burnashev et al. 1995).
A considerable body of evidence indicates that NMDA receptors are
involved in neuroendocrine control of ACTH secretion in the adult animal
(Brann and Mahesh 1994; Brann 1995; Brann and Mahesh 1997). Receptors
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have been localised in the hypothalamus by radioligand binding, by in situ
hybridisation studies and by immunocytochemistry (Monyer, Sprengel et al.
1992; Meeker, Greenwood et al. 1994; Urbanski, Fahy et al. 1994; Bhat,
Mahesh et al. 1995). Nerve fibres containing glutamate or aspartate,
putative excitatory amino acid transmitters, are found in most hypothalamic
nuclei including the parvocellular PVN, the SON and the arcuate nucleus
(Van den Pol, Waurin et al. 1990; Van den Pol 1991; Goldsmith, Thind et al.
1994; Thind and Goldsmith 1995). Administration of NMDA stimulates ACTH
or Cortisol secretion in adult rats, primates and sheep (Gay and Plant 1987;
Reyes, Luckhaus et al. 1990; Farah, Rao et al. 1991; Chautard,
Boudouresque et al. 1993; Brooks and Howe 1996). One study has
demonstrated that NMDA stimulates ACTH secretion in the ovine fetus
(Brooks and Howe 1996).
The precise site at which NMDA acts to stimulate ACTH secretion is
unknown. Although NMDA receptors are found in the pituitary (Meeker,
Greenwood et al. 1994; Bhat, Mahesh et al. 1995) it is thought the
neuroendocrine effects of NMDA are mediated through supra-pituitary
mechanisms. In the case of NMDA stimulated LH secretion there is good
evidence for a suprapituitary site of action (Urbanski, Kohama et al. 1996).
Microdialysis studies reveal an increase in glutamate release in the preoptic
area during the preovulatory LH surge in the ovariectomised steroid primed
female rat (Jarry, Leonhardt et al. 1995). Direct sampling of portal plasma by
push-pull perfusion in the pre- and peri-pubertal female rhesus macaque
shows that NMDA stimulates the release of luteinizing hormone releasing
hormone (LHRH) (Claypool and Terasawa 1989). Furthermore the
stimulatory effect of NMDA on LH secretion is blocked by pretreatment with
an LHRH receptor antagonist (Plant, Gray et al. 1989). Limited evidence also
supports a suprapituitary site of action to stimulate ACTH secretion. The
relatively rapid ACTH response to NMDA suggests that the action is likely to
involve direct stimulation of AVP and CRH neurons in the PVN or closely
associated interneurons. One study has demonstrated in vivo that injection of
glutamate into the amygdala increases median eminence CRH release (Gabr,
Birkle et al. 1995), whilst in vitro NMDA stimulates the release of both AVP
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and CRH from hypothalamic explants and slices (Costa, Yasin et al. 1992;
Patchev, Karalis et al. 1994; Joanny, Steinberg et al. 1997). Recently,
however, it has been demonstrated that the ACTH response to NMDA in the
ovine fetus cannot be blocked with AVP or CRH antagonists (Szeto, Soong et
al. 1999).
The role of endogenous excitatory amino acids in the regulation of
HPA axis activity during fetal life has not been characterised. In the ovine
fetus, the ACTH response to a bolus of NMDA increases with gestation,
compatible with a role for excitatory amino acids in driving the late gestation
increase in HPA axis activity (Brooks and Howe 1996). It should be
remembered, however, that this does not necessarily convincingly
demonstrate that the endogenous ligand(s) acting at the NMDA receptor
regulate ACTH secretion. Furthermore, there are no reported studies on the
ontogeny of NMDA receptor distribution, binding or expression in the
neuroendocrine hypothalamus.
1.9.3 Neuropeptide-Y and the arcuate nucleus
Neuropeptide-Y is 36 amino acid peptide neurotransmitter found in
several brain regions including the hypothalamus where it is localised most
intensely in cell bodies in the arcuate nucleus (Leibowitz 1991; Kalra and
Crowley 1992). From the arcuate nucleus there is a strong projection to the
PVN where NPY-immunoreactive fibres are seen to contact CRH neurons
(Bai, Yamano et al. 1985; Liposits, Sievers et al. 1988). Ascending
noradrenergic and adrenergic fibres also contain NPY and after transection of
these pathways there is an appreciable decline in hypothalamic NPY content.
These hypothalamic and extrahypothalamic pathways are able to modulate
pituitary-adrenal function. For example, injection of NPY directly into the PVN
or infusion via the third cerebral ventricle stimulates ACTH and corticosteroid
secretion in the dog, rat and adult sheep (Wahlestedt, Skagerberg et al. 1987;
Inoue, Inui et al. 1989; Porter, Naylor et al. 1993; Zarjevski, Cusin et al. 1993)
and immunoneutralisation of central NPY prevents the ACTH and Cortisol
response to insulin-induced hypoglycaemia (Inui, Inoue et al. 1990). At a
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hypothalamic level NPY stimulates CRH synthesis and release (Haas and
george 1987; Haas and George 1989).
Many of the functions of NPY in the hypothalamus are concerned with
co-ordinating the behavioural and endocrine responses to energy deprivation
(Leibowitz 1991; Friedman and Halaas 1998). Levels of NPY message in the
arcuate nucleus are increased after fasting and decreased in the fed state
indicating that NPY expression is regulated by metabolic state (Brady, Smith
et al. 1990; Adam, Findlay et al. 1997).
Metabolic feedback onto hypothalamic NPY systems is provided by
several peptides present in the peripheral circulation. Circulating insulin and
insulin-like growth factor concentrations are acutely elevated in the fed state
in adult animals (Dallman, Strack et al. 1993; Thissens, Ketelslegers et al.
1994) while the adipocyte product leptin signals the longer term state of the
body fat stores (Zhang, Proenca et al. 1994; Bennett 1995; Lindpainter 1995;
Bray 1996; Wurtman 1996). The well nourished animal has high circulating
leptin, insulin and insulin growth factor concentrations. These peripheral
hormones are able to reach the arcuate nucleus because of a deficiency in
the blood brain barrier at this site, or are specifically transported into the
cerebrospinal fluid by the choroid plexus (Schwartz, Figlewicz et al. 1992;
Reinhardt and Bondy 1994; Caro, Kolaczynski et al. 1996; Schwartz, Peskind
et al. 1996).
Intracerebroventricular administration of insulin decreases NPY
message expression in the arcuate nucleus (Schwartz, Sipols et al. 1992).
Similarly, leptin decreases NPY synthesis (Stephens, Basinski et al. 1995).
As a result arcuate drive to the PVN is reduced, and circulating ACTH and
Cortisol concentrations fall. In the transition to the fasting state, insulin and
leptin concentrations are lowered, and the NPY system is disinhibited so
increasing HPA axis activity. In turn corticosteroids increase tissue insulin
resistance and stimulate insulin and leptin synthesis (Saladin, De Vos et al.
1996). Thus there is an endocrine loop regulating body mass and energy
balance that involves NPY neurons in the arcuate nucleus, the parvocellular
PVN, and peripheral corticosteroids, insulin and leptin.
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There are no studies that have examined the ontogeny of the fetal
HPA axis response to NPY in any species. Certainly, there is expression of
NPY message in the mediobasal hypothalamus of the fetal sheep from at
least day 110 onwards as measured by in situ hybridisation, and the
expression of message increases with gestation (Warnes, Morris et al. 1998).
Maternal undernutrition or Cortisol infusion increased NPY gene expression
and the authors speculate that metabolic cues may participate in initiating
parturition (Warnes, Morris et al. 1998). Since NPY containing neurons are
involved in pathways other than those regulating HPA axis activity, it remains
possible that the increase in mediobasal hypothalamic NPY gene expression
with increasing gestation is not coupled to HPA axis activity. Studies
administering NPY in to the fetal hypothalamus are required to establish
functionality.
1.9.4 Opiates
Opioids function generally to pre-synaptically inhibit neurotransmitter
release, and to generate inhibitory post-synaptic potentials. Several
hypothalamic nuclei either contain opioidergic neurons or receive opioid
projections. The rat PVN receives a projection from the arcuate nucleus of
fibres that are immunoreactive for ACTH, a-MSH and p-endorphin (Akil,
Watson et al. 1984; Khachaturian, Lewis et al. 1985). In situ hybridisation
studies in the adult sheep brain find POMC message in the arcuate nucleus
and pre-proenkephalin in the PVN (Whisant, Curto et al. 1992; Broad,
Kendrick et al. 1993). Opioid receptors are present in the fetal sheep
hypothalamus in late gestation, but not in the pituitary (Yang and Challis
1991). The effect of opioid receptor activation is likely to be complex, since it
is possible for opioids to have a stimulatory action through disinhibition of
inhibitory pathways, to presynaptically inhibit excitatory pathways and to be
directly inhibitory to post-synaptic neurons. Opioid pathways are active in the
ovine fetus in late gestation since intravenous infusion of the mu receptor
antagonist naloxone during the pre-parturient surge in ACTH secretion
decreases circulating ACTH concentrations (Brooks and Challis 1991). In
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fact from about day 125 gestation, a specific Met-enkephalin analogue will
stimulate ACTH and Cortisol secretion and this effect is antagonised by
naloxone (Brooks and Challis 1988). In contrast to the effects of opioids
during the increase in ACTH secretion at term, naloxone has no effect on the
ACTH response to acute intra-uterine hypoxia (Brooks and Challis 1992).
Others report that the kappa agonist dynorphin A1-13 given systemically
stimulates ACTH secretion in the ovine fetus, and since the response is not
attenuated by CRH or AVP antagonists, suggest a pituitary site of action
(Szeto, Soong et al. 1999).
1.9.5 Endothelin
Several central peptidergic neurotransmitters may modulate HPA axis
activity, but there is little information on the ontogeny and activity of such
pathways during fetal life. Members of the endothelin family of peptides and
their receptors have been localised by immunocytochemistry and in situ
hybridisation to the PVN and other hypothalamic sites in adult human brains
(Takahashi, Ghatei et al. 1991). The actions of endothelin-3 in the ovine fetus
have been examined. Both central and peripheral administration of
endothelin-3 stimulate ACTH and Cortisol secretion, though peripheral
administration of endothelin-3 was associated with transient hypoxia and
acidosis that may have provided a non-specific stimulus to ACTH secretion
(Greer, Thomas et al. 1995).
1.9.6 Dopamine
A number of studies have examined the effect of dopamine agonists
and antagonists on the secretion of POMC derived peptides in the ovine fetus
in an attempt to dissect out the relative contributions of the NIL and anterior
pituitary to circulating ACTH concentrations. The evidence is conflicting.
Intravenous infusion of bromocriptine, a specific D2 receptor agonist,
decreases the expression of POMC in the NIL but not in the anterior pituitary
(Matthews, Fraser et al. 1996). Measurement of circulating hormone
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concentrations supports the contention that dopamine regulates the NIL but
not the anterior pituitary since bromocriptine decreased plasma a-MSH
concentrations, but was without effect on plasma ACTH(1-39) or Cortisol
concentrations (Hagan and Brooks 1996; Matthews, Fraser et al. 1996).
Basal secretion from the NIL is under endogenous inhibitory dopaminergic
tone as the dopamine antagonists sulpiride and metoclopramide significantly
increased plasma a-MSH concentrations (Newman, Wardlaw et al. 1987;
Hagan and Brooks 1996). Antagonism of endogenous dopaminergic
pathways also acutely increases plasma ACTH concentrations, however, in
contrast to the lack of effect of exogenous dopamine agonists (Hagan and
Brooks 1996). It seems clear that dopamine inhibits a-MSH secretion by NIL
melanotrophs through anatomically identified direct innervation (Bjorkland,
Moore et al. 1973). Dopaminergic fibres are also found in the PVN (Buijs,
Geffard et al. 1984), but the hypothalamic actions of dopamine may depend
on the background activity in other afferent inputs to CRH and AVP neurons.
The modulatory roles of adrenergic and nor-adrenergic neurons on
ACTH secretion are similarly confusing and have only been explored in adult
animals (Plotsky, Cunningham et al. 1989). Crude extraction studies find no
change in the hypothalamic content of catecholamines from 130 days
gestation onwards in the fetal sheep (Richards, Gluckman et al. 1987).
1.10 Summary
In all species that have been investigated there is an increase in the
concentration of corticosteroid in the fetal circulation shortly before parturition.
This is a consequence of increasing activity in the fetal HPA axis since the
placenta is an effective physical and metabolic barrier to the passage of
maternal corticosteroid. Increasing corticosteroid concentrations are an
endocrine 'switch" preparing the fetus for birth. In the larger domestic
species, increasing fetal HPA activity also contributes directly to the initiation
of parturition by changing the ratio of estrogen/progesterone present in the
circulation and presumably also the steroid ratio at a local tissue level.
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The development of methods to chronically cannulate the ovine fetus,
and later other species, has allowed some insight into the developmental
mechanisms involved. An increase in fetal plasma ACTH concentrations are
seen at the same time as Cortisol concentrations increase. Accompanying
increased plasma ACTH and Cortisol concentrations, the amount of POMC
message in the anterior pituitary is seen to increase from mid to late
gestation, as does the amount of CRH and AVP message in the hypothalamic
PVN. During the pre-parturient surge in HPA axis activity there may be small
decreases in CRH and AVP expression in the PVN as a consequence of
negative feedback by corticosteroids, but the expression of POMC in the
anterior pituitary seems to escape such suppression. At the same time
adrenal sensitivity to ACTH is increased, leading to increased secretion of
adrenal corticosteroids and androgenic precursors of estrogen synthesis.
The sustained increase in plasma concentrations of ACTH in the face
of elevated levels of corticosteroids in late gestation presents a paradox,
since normally corticosteroid negative feedback would be expected to limit the
activity of the hypothalamo-pituitary-adrenal axis. The paradox can be
explained in terms of "increasing hypothalamic drive" or of "reduced
glucocorticoid feedback". Both processes can be seen as part of a
programmed pattern of maturation of the fetal HPA. Little is known about the
central pathways regulating the fetal HPA axis. Limited evidence suggests
that there is a gestation related increase in the responsiveness of the HPA
axis to NMDA receptor agonists. The importance of endogenous excitatory
amino acid neurotransmitters in the regulation of ACTH secretion is, however,
unknown. Other studies have identified an increase in message expression
for NPY, one of the neurotransmitters mediating metabolic regulation of
ACTH secretion, again consistent with increasing hypothalamic drive.
Studies on pituitary glucocorticoid receptors and negative feedback have
been confusing, with the number of binding sites decreasing with gestation,
whilst message is unchanging or even increasing. Reductions in
corticosteroid negative feedback may also occur through modulation of
11 (3HSD activity, or through interactions with other transcription factors.
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The fetal HPA axis can be influenced by placental hormones and by
metabolic cues, however, it is not clear what role, if any, these factors play in
determining the fine timing of birth. In the primate fetus, it has been
suggested that estrogen induces placental 1 ipHSD activity, which inactivates
Cortisol in the fetal circulation, thereby overcoming negative feedback and
allowing continued ACTH secretion from the pituitary. Other placental
hormones may also participate in the drive to parturition: in response to
maternal starvation or hypoxia the placenta secretes hormones capable of
stimulating the fetal HPA axis.
Teleologically it could be argued that the fetus continues to grow in
utero to the point where the placenta (and maternal metabolism) are
struggling to provide adequate substrate for continuing growth. If at this point
the central pathways regulating ACTH secretion are sufficiently mature then
fetal HPA activity increases and parturition is initiated. There is an "intrinsic
clock" controlling the timing of increasing adrenal activity in the sense that
maturation of the HPA follows a preordained sequence of events that are
probably genetically determined, allowing it to respond to peripheral hormonal
and metabolic cues.
1.11 Experimental aims
The work presented in this thesis is concerned with the neural
pathways regulating ACTH secretion in the fetus. In the studies that follow
the role of endogenous excitatory amino acids acting at the NMDA receptor in
regulating basal and stimulated ACTH and Cortisol secretion in the late
gestation ovine fetus is examined using a specific competitive antagonist to
the NMDA receptor. The potential action of estrogen to mediate the late
gestation increase in fetal HPA axis activity, and especially the increase in
responsiveness to NMDA agonists, is also examined. An in vivo microdialysis
model has been developed to assess the release of AVP and CRH at the
median eminence in an attempt to define how NMDA receptor coupled
pathways regulate ACTH secretion. Finally, the potential for metabolic
feedback to influence fetal HPA axis activity in late gestation is investigated
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by examining the ability of centrally administered NPY to stimulate ACTH
secretion.
Four specific hypotheses are tested in each of the experimental chapters:
1 Endogenous excitatory amino acid neurotransmitters acting at the
NMDA receptor are important regulators of basal and stimulated ACTH and
Cortisol secretion in the ovine fetus.
2 Endogenous excitatory amino acids acting at the NMDA receptor
stimulate ACTH secretion through CRH neurons.
3 The gestation dependent increase in ACTH response to NMDA is due
to an effect of estradiol to increase HPA axis sensitivity to NMDA.
4 Central NPY pathways stimulate ACTH secretion.
The diagram below sets out schematically the four areas that are investigated
in the experimental chapters.
Role of excitatory amino acids?
2
Materials and methods
2.1 Chronically cannulated fetal sheep preparation
2.1.1 Ethical considerations
Necessarily, invasive experiments on the fetus require an animal
model and the sheep is a well characterised large animal species suitable for
these studies. All experiments were approved by the local Home Office
inspectorate and detailed on appropriate project and personal licences.
Attempts were made where at all possible to minimize the number of animals
utilised and to reduce potential suffering.
2.1.2 Animal husbandry
All animal experiments were conducted at the University of Edinburgh
Marshall Buildings, near Roslin, Midlothian, Scotland between October 1992
and August 1995. Scottish blackface and Scottish greyface sheep used in
these experiments were housed in a ventilated barn and allowed ad libetum
access to hay and water. Dietary intake was supplemented with concentrate
twice daily.
2.1.3 Timed matings
Animals with known single insemination dates were used in all
experiments. Estrous cycles were synchronised with 60 mg vaginal
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medroxyprogesterone sponges (Upjohn Ltd., Crawley,UK) for 13 days. Forty
eight hours later ewes were placed with the ram. This was deemed to be day
1 of pregnancy. During seasonal anestrous, ewes additionally received 300
IU pregnant mares serum gonadotropin (Intervet UK, Cambridge,UK) at the
time of sponge withdrawal.
2.1.4 Anaesthesia
Anaesthesia was induced with alphaxolone (0.9%) plus alphadolone
(0.3%) intravenously at a dose of 0.5 ml/kg (Glaxovet, Uxbridge, UK) and
maintained with 3-4% halothane (ICI Pharmaceuticals, Macclesfield, UK) in a
nitrous oxide/oxygen mix.
2.1.5 Intravenous cannulation
Under aseptic conditions the uterus was exposed and the fetus
partially delivered through a small incision. Care was taken not to disrupt the
fetal membranes, except where incised to allow access to the fetus, nor to
spill amniotic fluid. A cut down was performed to expose the fetal carotid
artery and jugular vein on one side of the neck and polyvinyl catheters (Bolab
Inc, Lake Havasu City, USA) were advanced approximately 10 cm so that
their tips lay in the aorta and superior vena cava respectively. The skin
incision was closed and the catheters further anchored to the skin of the neck.
An additional catheter was attached to the neck of the fetus and left free
floating in the amniotic fluid. Catheters were exteriorised through a small
incision on the maternal flank. Any additional procedures detailed below were
than carried out on the fetus. Afterwards the uterus was closed in a single
layer incorporating fetal membranes and myometrium, and then a second
suture was used to bury the incision.
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2.1.6 Lateral ventricle cannulation
For placement of lateral ventricle cannulae and microdialysis probes a
stereotaxic approach was adopted. A purpose build frame securing the head
and allowing use of a micromanipulator was commissioned from the
Department of Veterinary Medicine Workshop, University of Edinburgh. The
frame itself could be anchored to the operating table. The fetal head was
steadied in the frame by means of two "ear-bars" inserted into a small fossa
just inferior and posterior to the external auditory meatus, and by two bars
placed over the infra-orbital ridges which served to clamp the skeleton of the
face down onto a bar placed under the hard palate. All fitments were
adjustable to accommodate fetuses of differing sizes. The accompanying
series of line drawings (figures 2.1, 2.2 and 2.3 show details of the stereotaxic
frame and tracings from a series of X-rays taken during the placement of a
microdialysis probe into the median eminence).
With the head fixed so that external auditory meatus and infra-orbital
ridge were on the same plane, a midline incision was made over the scalp to
expose the sagittal suture and bregma, the point at which the two parietal and
frontal bones meet. For placement of lateral ventricular cannulae, a burr hole
approximately 1 mm in diameter was trephined 2 mm anterior and lateral to
bregma. A 15 mm long guide cannula constructed from an 18 g syringe
needle (Beckton-Dickinson, Wembley, UK) was lowered vertically into place
and cemented by means of dental cement ("Formatray", Kerr Europe, Basel,
Switzerland) to four anchoring screws which had been sunk into the skull on
either side of the midline. The lateral ventricle cannula was made from a 30
mm length of 21 g tubing (Coopers Needle Works, Birmingham,UK.). This
was lowered with the aid of a micromanipulator until gravity flow of saline into
the lateral ventricle was achieved. The lateral ventricle cannula was then
bent so that the length protruding from the top of the guide cannula came to
lie flush with the skull, and attached to a 150 cm length of polyethylene tubing
(PE20, Clay Adams, NJ, USA) exteriorised through the maternal flank. The
whole was then anchored with dental cement and the catheter secured to the
skin over the nape of the fetal neck.
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2.1.7 Median eminence dialysis
Where a microdialysis probe was to be inserted the lateral ventricle
was first cannulated and used as a route for the injection of radio-opaque
contrast ("ultravist 300"; Schering Health Care, Burges Hill, UK) into the
ventricular system. A lateral skull X-ray allowed for an accurate approach to
the median eminence. The radiological landmarks used were based on adult
ventriculography (Lignereux, Regodon et al. 1991). A second burr hole to
expose the dura was made in the midline in the same vertical plane as the
median eminence. A 25 mm guide tube constructed from a 15 g syringe
needle (Beckton-Dickinson, Wembley, UK) was then lowered and cemented
in place. The guide cannula was supported on a concentric length of 19 g
tubing, the sharpened end of which protruded just beyond the tip of the guide
and which served to pierce the dura. Once the guide was cemented in
position the supporting tubing was removed and the microdialysis probe
lowered down the guide by hand until it was felt to come to rest with its tip on
the dura overlying the pituitary fossa. The probe tip was approximately 45
mm from the top end of the guide cannula. Once in position the dialysis
probe was anchored by dental cement which also served to protect the
delicate exposed portion of the probe at the point were it was attached to a




Superior, lateral and posterior projections of the stereotaxic frame. Top panel
shows the view from above looking down on the fetal head. Two ear bars
and two eye bars fix the skull and prevent lateral movement. A mouthbar
under the hard palate serves to prevent rotation of the skull around the axis
provided by the earbars. The middle panel shows the frame from the side.
The ear, eye and mouth bars are so arranged to allow an uninterrupted view
of the base of the skull and pituitary fossa on a lateral skull X-ray.
To place the fetal head in the frame both ear bars are first positioned on the
skull and then slipped into the retaining slot on the frame. The ear bars are
secured in the frame by a screw. Next the eye bars are positioned resting on
the zygomatic arch and finally the mouth bar bought up under the hard palate.
Both the eye bar and mouth bar can be moved on their supporting platform,
and the whole platform can be moved up and down on the base plate. The
eye and mouth bars and supporting frame are locked in position by retaining
nuts. The bottom panel shows the frame from the posterior aspect (looking in
the same direction as the fetus when the head is in the frame). For clarity the
ear bars are shown separate from the frame. In cross section the two main
arms of the frame are square and rotated at 45 degrees to the vertical plane.
The micromanipulator (not shown) is attached to one or other of these arms
to allow guide cannulae and probes to be moved parallel and perpendicular to










Figure 2.2 and 2.3
Series of line drawings adapted from lateral skull X-rays taken during
placement of a microdialysis probe into the median eminence. The upper
panel in figure 2.2 shows the fetal head with ear, eye and mouth bars in
position. The middle panel shows a lateral skull X-ray of the same fetus.
Most of the bones in the fetal skull have not yet fully calcified and only limited
detail can be made out. It is possible to identify the optic foramen (allowing
the optic nerve to pass). The pituitary fossa is, however, poorly defined on
lateral skull X-ray at this gestation. In the lower panel a metal guide cannula,
directed at one lateral ventricle, has been implanted and secured to the skull
with anchoring screws and dental cement. The top panel in figure 2.3 shows
the same animal after a second cannula has been lowered down the guide
into the lateral ventricle and contrast material injected. The lateral ventricle
and third ventricle are clearly delineated by this procedure, and it is usually
possible (with the appropriate amount of contrast) to identify the supra- and
infra-optic recess, as well as the infundibular recess of the third ventricle. The
infundibular recess is that part of the third ventricle which occupies the
median eminence. In the middle panel a second guide cannula aimed at the
median eminence has been implanted and secured with dental cement. In
the lower panel a microdialysis probe has been lowered down the guide
cannula so that the tip of the microdialysis probe lies in the median eminence











After surgery the vascular and amniotic catheters were filled with
sterile saline containing 20 lU/ml of unfractionated heparin and flushed daily
with the same solution (Heparin: Leo Laboratories, Aylesbury, UK, Saline:
Travenol Laboratories, Thetford, UK). Catheters were kept in a clean plastic
bag tied to the wool over the maternal back and further held in place by a roll
of surgical dressing pulled over the maternal abdomen ("netelast", Seton
Healthcare, Oldham, UK). The fetus received a once daily injection of 106
units benzyl penicillin (Glaxovet, Uxbridge, UK) intravenously and intra-
amniotically for three days beginning on the day of surgery. The mother
received daily intramuscular injections of streptopen (Pitman Moore,
Harefield, UK) for two days. Post-operative analgesia with intramuscular
Finadyne (Schering-Plough Animal Health, Mildenhall, UK) was administered
upon recovery and then as necessary, usually for the first postoperative day.
Sheep were placed in metabolism crates following recovery. These allowed
forward and backward movement but not the freedom to turn around. All
experiments were conducted at least 5 days after surgery.
2.1.9 Blood sampling and intravenous drug administration
Fetal blood samples were withdrawn via a three-way tap (Viggo
Products, Helsingborg, Sweden) connected to the catheter, allowing for the
dead space (approximately 0.8 ml) in the tubing, and collected into
heparinised polystyrene tubes on ice (Sarstedt, Leicester, UK). Blood volume
was replaced with an equal volume of sterile heparinised saline (20units/ml).
Samples were centrifuged (2500 rpm, 15 min, 4C) within 20 min of collection
and the plasma frozen until assay in 2 ml sample tubes (Teklab Medical
Laboratories, Durham, UK). Samples spiked with 200 pg/ml ACTH at the
time of collection did not lose appreciable ACTH immunoactivity when stored
on ice for upto 2 h before centrifugation.
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Drugs for intravenous administration were introduced through the
three-way tap attached to the catheter and flushed through the dead space in
the cannulae with heparinised saline.
2.2 Hormone assays
The concentrations of ACTH, FSH, PRL, GH, and Cortisol in
unextracted plasma samples were determined by radioimmunoassay (RIA) or
by immunoradiometric assay (IRMA) as described below. Median eminence
dialysate samples were assayed for AVP and CRH by RIA and these are also
described. For convenience, the sources of standard reagents are given in
appendix 1. All assays were conducted in polystyrene tubes (Sarstedt,
Leicester, UK). Two standard curves in triplicate, prepared by serial dilution
of stock peptide, and appropriate quality controls, were included in each
assay. The standard curve included an estimate of total binding of radiolabel
to primary antibody (Bo) and non-specific binding of radiolabel to the
polystyrene tube (NSB). The upper and lower limits of sensitivity of the assay
are calculated as the hormone concentration displacing 90% and 10%
respectively of radiolabel from the primary antibody. Assay precision (intra-
and inter-assay coefficients of variation) is calculated from the quality control
samples included in each assay and is given as the standard deviation in the
measurement of a particular quality control expressed as a percentage of the
mean (Chard 1978). Since all of these assays have been previously
validated, cross-reactivities are quoted as available in the literature.
2.2.1 Adrenocorticotrophin
The concentrations of ACTH in fetal plasma samples were measured
with a specific 2-site immunoradiometric assay according to a previously
described protocol (Brooks, Howe et al. 1994; Brooks and Howe 1996).
Intact ACTH (1.39) is detected by virtue of a rabbit polyclonal capture antibody
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directed at one end of the molecule, and a 125l labelled guinea pig detection
antibody targeted to the other end of the molecule.
Assay buffer: 0.1 M phosphate buffer containing 0.5% (w/v) bovine serum
albumin, 0.001% (v/v) Triton X-100 and 0.0001% (w/v) Sodium azide.
Antibody: The antibodies are commercially available (Euro-path Ltd., Bude,
UK) and are supplied as a lyophilised powder for reconstitution in distilled
water.
Standards/Quality controls: Synthetic ACTH (1.39) (Cambridge Research
Biochemicals, Northwich, UK) was dissolved in 0.05M phoshate buffer
containing 0.5% (w/v) bovine serum albumin and 0.0001% (w/v) sodium azide
to a concentration of 100 ng/ml. This stock was stored frozen until use when
serial dilutions from 5000 to 5 pg/ml were prepared in assay buffer. Quality
controls were made by spiking dexamethasone-suppressed plasma with
synthetic ACTH to final concentrations of 25, 100, and 500 pg/ml.
Assay procedure: Samples were assayed in duplicate 100 pil aliquots. To
ensure that the same ratio of plasma to assay buffer was present in standards
and samples, 100 jxl of dexamethasone-suppressed plasma was added to
each standard, and 100 pi of assay buffer to each sample or quality control.
A100 jil aliquot of mixed capture and detection antibody was then added to all
tubes which were incubated overnight at 4C.
Separation: The capture antibody was precipitated by magnetic separation
after further overnight incubation at 4C with 200 ^il polyclonal donkey anti-
rabbit immunoglobulin. The magnetically tagged polyclonal donkey anti-rabbit
immunoglobulin was prepared in house by Dr Rodney Kelly and used at 1:2
dilution in 0.05M phosphate buffer with 0.01% (v/v) Triton-X. After overnight
incubation the tubes were clipped to a magnetic separation rack (Amerlex-M
assay rack, Amersham, Little chalfont, UK) and allowed to stand for 15 min
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before the supernatant was poured off. The tubes were then removed from
the magnet and washed with 300 pi "wash buffer" (0.075M phosphate
buffered saline containing 0.15% (w/v) sodium azide and 0.015% 9v/v) Triton-
X 100) at which point they were once more clipped to the magnet, left for 15
min and finally inverted and left to dry.
Sensitivity and cross reactivity: The assay performed with a lower limit of
detection of 11 pg/ml. The assay does not detect ACTH (18_39) or ACTH (1_24),
a-MSH or non-amidated a-MSH (White, Smith et al. 1987).
Precision: The intra-assay coefficients of variation were 12% at 25 pg/ml,
10% at 100 pg/ml and 6% at 500 pg/ml. The inter-assay coefficients of
variation were 14%, 11% and 10% respectively.
2.2.2 Cortisol
The concentration of Cortisol in plasma samples was determined by
radioimmunoassay after extraction with diethyl ether as previously described
(Brooks and White 1990).
Assay buffer: 0.01 M phosphate buffer containing 0.1% (w/v) gelatin, 0.9%
(w/v) sodium chloride, and 0.01% (w/v) thiomersal at pH 7.4
Antibody: Sheep polyclonal anti-cortisol (Code S004-201) obtained from
Scottish antibody production Unit (SAPU), Carluke, Scotland.
Radiolabel: Cortisol-3-(0-carboxymethyl)oximino-(2-(125l)iodohistamine) was
purchased from Amersham, Little Chalfont, UK.
Cortisol extraction: Aliquots of 50 pi of sample were agitated with 2.5 ml
diethyl ether in borosilicate tubes for 15 min and then placed in an ethanol/dry
ice bath to freeze the aqueous phase. The supernatant diethyl ether was
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collected into a fresh borosilicate tube and evaporated to dryness under
nitrogen. Extraction efficiency was calculated from the recovery of
radioactivity in a sample of dexamethasone-suppressed plasma spiked with
tritiated Cortisol (Amersham, Little Chalfont, UK). Samples for
radioimmunoassay were stored frozen until use and then resuspended in 500
pil assay buffer, vortexed thoroughly and left for at least 30 min at room
temperature.
Standards/Quality controls: Standards ranging between 0.15 and 80 ng/ml in
assay buffer were prepared and stored at 4C. These standards were used for
all subsequent assays. Quality controls were made by spiking
dexamethasone suppressed plasma with 0, 3.9 and 19 ng/ml Cortisol and
were stored frozen in aliquots until use.
Assay procedure: Samples and quality controls were extracted in parallel and
stored frozen at -20C. The Cortisol concentration was determined in duplicate
100 pi aliquots following resuspension in 500 pi assay buffer. Aliquots of
standard, quality control and sample were incubated overnight at 4C with 100
pi of S004-201 anti-cortisol antibody (at 1:8000 dilution) and 100 pi of
radiolabeled tracer (at 15,000 cpm/100 pi), both diluted in assay buffer.
Separation: The primary antibody was precipitated by overnight incubation at
4C with polyclonal donkey anti-goat second antibody (SAPU, Carluke,
Scotland) at a dilution of 1:1200 in 200 pi assay buffer containing 1.6%
normal sheep serum. The donkey anti-goat antibody and normal sheep
serum were combined shortly before addition to avoid precipitation of
immunoglobulin present in the sheep serum by the second antibody. The
following day 1 ml of 0.9% saline with 0.2% (v/v) Triton X-100 was added to
all samples, standards and quality controls. The tubes were centrifuged at
3000 rpm for 30 min and then inverted and left to dry.
Sensitivity and cross reactivity: The assay performed with a lower limit of
0.27 ng/ml. Cross reactivity for various steroids is reported as: corticosterone
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0.18%, cortisone 0.07%, 21-deoxycortisone 0.3%, 11-deoxycorticosterone
0.03%, 11-deoxycortisol 0.58%, 17 alpha-hydroxyprogesterone 2.1%
(Abraham 1969).
Precision: The intra-assay coefficients of variation were 5% at 0 ng/ml, 7% at
3.9 ng/ml, and 9% at 19 ng/ml. The inter-assay coefficients of variation were
all less than 10%.
2.2.3 Growth Hormone
The concentration of growth hormone (GH) in plasma samples was
determined by radioimmunoassay after a dilution step to bring the
concentrations to lie within the working range of the assay. The assay is a
modification of a previously described procedure miniaturised for fetal
samples (Thomas, Mercer et al. 1990).
Assay buffer: 0.05M phosphate buffer containing 0.5% (w/v) bovine serum
albumin, 0.8% (w/v) sodium chloride, and 0.01% (w/v) thiomersal at pH 7.4.
Antibody: Polyclonal rabbit-anti-oGH-2 (AFP-C0123080) obtained from the
National Institute of Diabetes, Digestive and Kidney Diseases, USA.
Radiolabel: Ovine GH (1.4) (Ref AFP-8758C) obtained from the National
Institute of Diabetes, Digestive and Kidney Diseases, USA was iodinated by
the lactoperoxidase method as follows. A reaction mixture of 5 pg of oGH
dissolved in 50 pi of 0.1 M sodium hydrogen carbonate, 10 pi of Sodium iodide
(125l) (1 mCi/ml; Amersham, Little Chalfont, UK), 10 pi dilute hydrogen
peroxide (1: 15000 in water) and 10 pi of lactoperoxidase (Sigma, Poole, UK)
was incubated for 20 seconds at room temperature. The reaction was
terminated by the addition of 1 ml of 0.1 M phoshate buffered saline containing
0.1% (w/v) bovine serum albumin which provides a large number of sites for
non-specific iodination. Labelled GH (1_4) was separated from free radioactive
iodine on a 45 cm Sephadex G100 column eluted with 1% bovine serum
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albumin in 0.1 M phosphate buffered saline. The column was prepared by
swelling approximately 4g Sephadex G100 beads (Pharmacia, Uppsala,
Sweden) in 100 ml 0.05M phosphate buffer. The G100 was then poured into
a 50 cm by 1 cm glass column (Amicon, Stonehouse, UK) until the packed
bed line was at 45 cm, at which point the column was covered with
approximately 50 ml of 0.05M phosphate buffer and clamped off until use.
The fractions exhibiting greatest binding to the primary were pooled, divided
into aliquots and stored frozen at -20C until use.
Standards/Quality controls: Ovine GH (1_4) from the National Institute of
Diabetes, Digestive and Kidney Diseases, USA was dissolved in assay buffer
to a final concentration of 100 pg/ml and stored frozen in aliquots. Standards
ranging between 125 and 0.49 ng/ml of GH (1_4) were prepared by double
dilution in assay buffer. Quality controls of 0.49, 7.8 and 125 ng/ml of GH ^.4)
in assay buffer were stored frozen in aliquots until use.
Assay procedure: Plasma samples were diluted 1:10 with assay buffer to lie
within the working range of the assay. Thus 20 ml fetal plasma was diluted
with 180 pi assay buffer, vortexed and from this two 50 pi aliquots assayed in
duplicate. Samples, standards and quality controls were incubated overnight
at 4C with antibody at a dilution of 1:30,000 in 100 pi assay buffer. The
following day 50 pi radiolabeled GH (1_4) (diluted to roughly 15,000 cpm/100
pi) in assay buffer was added and a further overnight incubation at 4C
allowed.
Separation: The primary antibody was incubated for 24 h at 4C with 100 pi
polyclonal donkey anti-rabbit immunoglobulin at a dilution of 1:32 (SAPU,
Carluke, Scotland) and 100 pi normal rabbit serum at a dilution of 1:400
(SAPU, Carluke, Scotland) in assay buffer. The next day, following the
addition of 1 ml of 0.9% saline with 4% (w/v) polyethylene glycol and 0.2%
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(v/v) Triton X100, the samples were centrifuged at 3000 rpm for 30 min and
then inverted and left to dry.
Sensitivity: The lower limit of detection was 1.9 ng/ml.
PrecisionThe intra-assay coefficients of variation were 12% at 0.49 ng/ml,
7% at 7.8 ng/ml, and 12% at 125 ng/ml. The inter-assay coefficients of
variation were 14%, 10% and 15% respectively.
2.2.4 Follicle stimulating hormone
The concentration of follicle stimulating hormone (FSH) in plasma
samples was determined using a modification of an established assay for
ovine FSH (McNeilly, McNeilly et al. 1976; McNeilly, Jonassen et al. 1986).
Assay buffer: 0.075M phosphate buffer with 1% (w/v) bovine serum albumin ,
0.875% (w/v) sodium chloride and 0.01% (w/v) thiomersal at pH7.4.
Antibody: polyclonal rabbit anti ovine FSH. (NIDDK-NIH anti-oFSH-1, Ref
AFP-C5288113) obtained from NIH.
Radiolabel: Radiolabeled purified ovine FSH (NIAMMD-oFSH-19) obtained
from NIH was prepared by the lactoperoxidase method. The technique is
identical to that used to prepare radiolabeled GH tracer except that
separation was achieved on a 20 cm Sephadex G100 column eluted with
0.1 M phosphate buffered saline containing 1% (w/v) bovine serum albumin.
The fractions exhibiting the strongest binding to primary antiserum were
pooled and stored at -20C until use.
Standards/Quality controls: Standards ranging between 0.1 and 25ng/ml in
assay buffer were prepared by dilution of stock NIDDK-oFSH-RP-2 (Ref AFP-
4117A from NIDDK). Standards were aliquoted and stored frozen until use.
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Quality controls were made by spiking buffer with 0.4, 0.84, and 2.64 ng/ml
oFSH-RP-2.
Procedure: Duplicate 150 [xl aliquots of sample were diluted to a final volume
of 300 ^il with assay buffer and incubated overnight at 4C with 50 pil of primary
antibody diluted 1:12000 in assay buffer. The following day 50 ^il
radiolabeled FSH tracer (roughly 15000 cpm/50 fd) was added to all tubes
and a further 24 h incubation allowed.
Separation: The primary antibody was precipitated with a donkey anti-rabbit
second antibody exactly as described for the separation of GH radiolabel.
Sensitivity and cross reactivity: The lower limit of detection was 0.29 ng/ml
and reported cross reactivities are less than 0.1% for ovine LH, thyroid
stimulating hormone (TSH), GH and prolactin (PRL) (McNeilly, McNeilly et al.
1976).
Precision: The mean intra-assay coefficient of variation was 4.8% (single
assay).
2.2.5 Prolactin
The concentration of prolactin (PRL) in samples was determined with
an established radioimmunoassay for ovine PRL (McNeilly and Andrews
1974).
Assay buffer: 0.075M phosphate buffer with 1% (w/v) bovine serum albumin,
0.875% (w/v) sodium chloride, and 0.01% (w/v) thiomersal at pH7.4.
Antibody: The primary antibody utilised was a polyclonal rabbit anti PRL
immunoglobulin gifted by Professor A. McNeilly, MRC Reproductive Biology,
Edinburgh, UK.
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Radiolabel: Purified ovine PRL (oPRL-17 from NIAMDD) was iodinated by
the lactoperoxidase method as described for the preparation of GH tracer.
Labelled oPRL-17 was separated on a 45 cm Sepadex G100 column eluted
with 1% bovine serum albumin in 0.1 M phosphate buffered saline. Aliquots of
radiolabeled tracer were stored at -20C until use.
Standards/Quality controls: Standards ranging between 0.4 and 200 ng/ml of
NIH PRL-S15 were prepared by double dilution in assay buffer and stored at -
20C until use. Quality controls of 3.2, 25 and 100 ng/ml of NIH PRL-S15
were prepared in assay buffer and stored frozen in aliquots until use.
Procedure: Plasma samples were assayed in 30 pi duplicate aliquots diluted
with 100 pi assay buffer. After the addition of 100 pi primary antibody
(1:128,000 in assay buffer) and 100 pi radiolabeled PRL-17 (at roughly
15,000 cpm/100 pi in assay buffer) to each tube an overnight incubation at 4C
carried out.
Separation: The primary antibody was precipitated with a donkey anti-rabbit
second antibody exactly as described for the separation of GH radiolabel.
Sensitivity and cross reactivity: The lower limit of sensitivity was 0.54 ng/ml.
The antibody does not detect ovine GH, LH, FSH, TSH or ACTH (McNeilly
and Andrews 1974).
Precision: The intra-assay coefficients of variation were 14% at 3.2 ng/ml,
11% at 25 ng/ml, and 12% at 100 ng/ml. The inter-assay coefficients of
variation were 14%, 14% and 15% respectively.
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2.2.6 Vasopressin
The concentration of AVP in median eminence dialysate was
measured using a previously described radioimmunoassay (Currie, Gillies et
al. 1994).
Assay buffer: 0.05M phosphate buffer containing 0.1% (w/v) bovine serum
albumin, 0.58% (w/v) sodium chloride, 0.0372% (w/v) EDTA and 0.01% (w/v)
thiomersal at pH7.4.
Antibody: Polyclonal rabbit anti-AVP (NK-2) gifted by Dr N Kasting,
Department of Physiology, University of British Columbia, Vancouver,
Canada.
Radiolabel: 125l-Arg8-AVP was prepared by the chloramine-T method as
8
follows: A reaction mixture of 5 pig of Arg -AVP (Cambridge Research
Biochemicals, Northwich, UK) dissolved in 10 pil of 0.1 M acetic acid, 15 pil of
0.5M phosphate buffer, 10pl of sodium iodide (125l) (1 mCi/ml; Amersham,
Little Chalfont, UK) and 10 pil of 0.5% (w/v) chloramine-T in 0.05M phosphate
buffer was incubated for 10 seconds at room temperature. The reaction was
terminated by the addition of 600 pi of 0.5% (w/v) bovine serum albumin
(fraction V, RIA grade) in 0.05M phoshate buffer. Labelled AVP was
separated from free radioactive iodine on a "Sep-pak" column (Millipore,
Herts, UK) prewetted sequentially with 2 ml 1% (v/v) trifluoroacetic acid in
water (1%TFA), 5ml of 80% methanol/20% of 1%TFA, 3 ml of 1%TFA and
finally, 1 ml of 0.01% (w/v) polypep in 1%TFA. Free iodine was eluted with
700 pi of 1%TFA. lodinated AVP was then eluted from the column by a
stepwise increase in methanol/1 %TFA eluant. The fraction exhibiting the
greatest binding to AVP antiserum was usually 44% methanol which was
stored at -20C until use.
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Standards/Quality controls: Arg8-AVP was dissolved in 0.1 M acetic acid to a
stock concentration of 1mg/ml and aliquots stored at-20C until use. Fresh
standards ranging between 500 to 0.5 pg/ml were prepared by serial dilution
in assay buffer for each assay. Quality controls of 2, 10, and 50 pg/ml in
assay buffer were prepared and stored frozen until use.
Procedure: Samples were assayed in singlicate 100 pi aliquots (though in
some cases samples required to be diluted to lie within the range of the
assay). Aliquots of standard, quality control and sample were diluted with 200
pi assay buffer and incubated overnight at 4C with 100 pi of antibody at a
dilution of 1: 50,000 in assay buffer. The following day 100 pi of radiolabeled
tracer at a concentration of 15000 cpm/100 pi was added to all tubes and a
further 24 h incubation at 4C allowed.
Separation: The primary antibody was precipitated by magnetic separation
after incubation with polyclonal donkey anti-rabbit antibody bound to magnetic
particles (gift of Dr. R. Kelly, MRC Reproductive Biology Unit). Briefly, 500 pi
of antibody diluted 1:80 in 0.05M phosphate buffer was added to each tube
and incubated for 30 min at room temperature. Tubes were clipped into a
commercially available magnetic separation rack (Amerlex-M assay rack,
Amersham, UK) and the supernatant poured off after allowing the tubes to
stand for 15 min. The precipitate was then resuspended in 300 pi wash buffer
by gentle agitation after the tubes had been separated from the magnetic
rack. The tubes were again clipped to the magnetic rack and after a further
15 min were inverted and left to dry.
Sensitivity and cross reactivity: The antibody to AVP is reported to have <2%
cross reactivity with oxytocin and a number of other neuropeptides (Currie,
Gillies et al. 1994). The lower limit of sensitivity was 1.75pg/ml.
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Precision: The intra-assay coefficients of variation were 15% at 2 pg/ml, 10%
at 10 pg/ml, and 12% at 50 pg/ml. The inter-assay coefficients of variation
were 18%, 10% and 16% respectively.
2.2.7 Corticotrophin Releasing Hormone
The concentrations of CRH in median eminence dialysate were
determined by established radioimmunoassay (Brooks, Power et al. 1989).
Assay buffer: 0.05M phosphate buffer containing 0.5% (w/v) bovine serum
albumin, 0.58% (w/v) sodium chloride, 0.95% (w/v) EDTA, 0.1% (v/v) Triton
X-100, and 0.01% (w/v) thiomersal at pH 7.4.
Antibody: Polyclonal rabbit anti oCRH (CRF-2G) immunoglobulin raised by
Dr. A.N. Brooks
Radiolabel: 125l-Tyr-oCRH was prepared by the chloramine-T method
described below. A reaction mixture of 4 pg of Tyr-oCRF (Cambridge
Research Biochemicals, Northwich, UK) dissolved in 10 pi of 0.1 M acetic
acid, 10 pi of 0.05M phosphate buffer, 10 pi of sodium (125l) iodide (1mCi/ml;
Amersham) and 10 pi of 1% (w/v) chloramine-T in 0.05M phosphate buffer
was incubated for 15 seconds at room temperature. The reaction was
terminated by the addition of 25 pi of 1% (w/v) sodium metabisulphite in
0.05M phoshate buffer. Labelled Tyr-oCRH was separated on a "Sep-pak"
cartridge (Millipore, Herts, UK) prewetted sequentially with 5 ml methanol, 10
ml water, and 5 ml of 0.1% (v/v) TFA in 0.05M phosphate buffer. Free iodine
was eluted with 6 ml of 0.1%TFA in 0.05M phosphate buffer, and then
radiolabeled TYR-oCRH was eluted with 3 ml of a mixture of 4 parts
acetonitrile to 1 part 0.1% TFA in 0.05M phosphate buffer. The pooled
radiolabeled TYR-oCRH was checked for binding to the primary antiserum
and then stored frozen at -20C until use.
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Standards/Quality controls: stock oCRH purchased from Cambridge
Research Biochemicals (Northwich, UK) was dissolved to a final
concentration of 10 pg/ml in assay buffer and stored frozen until use. Fresh
standards between 39 and 5000 pg/ml were prepared by double dilution in
assay buffer.
Procedure: Samples were assayed in duplicate 100 pi aliquots diluted with
100 pi assay buffer and incubated overnight at 4C with 100 pi of antibody at
1: 100,000 dilution in assay buffer. The following day 100 pi radiolabeled tyr-
CRH (15,000 cpm/100 pi) was added to all tubes and a further 24 h
incubation carried out at 4C.
Separation: Primary antibody was precipitated by magnetic separation as
described for AVP.
Sensitivity and cross reactivity: The lower limit of detection was 120 pg/ml.
The antibody is reported to have <0.001% cross reactivity with ACTH (i_39),
ACTH (i_24), beta-endorphin, alpha-melanocyte stimulating hormone, met
enkephalin, leu-enkephalin, AVP, oxytocin, thyroid releasing hormone, and
luteinizing hormone releasing hormone (Brooks, Power et al. 1989).
Precision: The intra-assay coefficient of variation was 16% (single assay).
2.2.8 Determination of hormone concentration
The gamma radiation emitting isotope of iodine (125l) was used for all
radioimmunoassays.. The activity remaining in each assay tube after
separation of free and bound radiolabeled tracer was counted over 60
seconds (Multigamma 1261, LKB, Turku, Finland) and the data were
collected online ("Datagrabber, Mutek,Box, Wiltshire,UK) onto an Apple
Macintosh computer. Assay results were computed using the program
"AssayZap" (Biosoft, Cambridge, UK) on an apple Macintosh computer.
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2.3 Statistical analysis
All statistical computations were performed using the Abacus Concepts
Statview package (version 4.1) (Abacus Concepts Inc, Berkeley, California,
USA) on an Apple Macintosh G3 powerbook. The statistical analyses for
each experiment are described more fully in each chapter. In some cases
serial blood samples have been taken and hormone concentrations analysed
with a pulse detection program (Munro, Zaristow Software, Haddington,
Scotland). Data is displayed as mean+standard error of the mean (SEM) and
the significance level is set at p<0.05.
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3
The role of endogenous central excitatory
amino acid pathways in the control of
adrenocortical activity in the fetal sheep in late
gestation
3.1 Abstract
The role of endogenous excitatory amino acids acting at the NMDA
receptor in the regulation of ACTH secretion in the late gestation ovine fetus
is investigated. Time-mated chronically catheterised fetal sheep at day 130
gestation were challenged with insulin (10 IU iv bolus) or sodium nitroprusside
(iv infusion 100 jxg/min for 10 min). Pretreatment with CGP 37849 (1 mg/kg,
iv bolus), a competitive NMDA antagonist, significantly inhibited insulin
hypoglycaemia, but not nitroprusside stimulated ACTH secretion. The effects
of CGP 37849 on pulsatile ACTH, Cortisol and GH secretion were examined
in a separate group of animals at 138 days gestation. Blood samples
withdrawn every 10 min were analysed for intact ACTH(1.39), Cortisol, and GH.
After a 3 h baseline sampling period CGP 37849 given as a loading bolus (1
mg/kg iv), followed by a 3 h infusion (1 mg/kg/h) resulted in a rapid decrease
in mean plasma levels of ACTH and Cortisol but not GH. This was a
consequence of decreased basal secretion, as pulse amplitude and interpulse
interval remained unchanged. These results demonstrate that endogenous
excitatory amino acid neurotransmitters acting at the NMDA receptor regulate
basal ACTH secretion in the late gestation ovine fetus.
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3.2 Introduction
Adrenocorticotrophin secretion in the late gestation fetus is highly
pulsatile (Brooks and Challis 1991; Apostolakis, Longo et al. 1992) and
presumably reflects secretion of the hypophysiotrophic releasing factors AVP
and CRH in to portal plasma, just as it does in the adult (Caraty, Griro et al.
1988; Engler, Pham et al. 1989). Several neurotransmitters are thought to be
involved in the control of CRH and AVP secretion (Assenmader, Szafarczyx
et al. 1987; Palkovitz 1987; Jacobowitz 1988; Plotsky 1991; Antoni 1993;
Whitnall 1993). The excitatory amino acids as a class have attracted interest
because of their widespread distribution and protean interactions with other
neurotransmitter systems (Ruzika and Jhamander 1993). There is
neuroanatomical evidence to support a role in neuroendocrine regulation:
NMDA receptors have been localised to the hypothalamic PVN and arcuate
nuclei (Monyer, Sprengel et al. 1992; Meeker, Greenwood et al. 1994) and
these same areas also contain glutamate immunoreactive fibres (Van den
Pol, Waurin et al. 1990; Van den Pol 1991; Goldsmith, Thind et al. 1994). In
other neuroendocrine situations excitatory amino acid transmitters have a role
in controlling pulsatile secretion, notably of LH. Agonist at the NMDA class of
excitatory amino acid receptor stimulate the secretion of LH (Estienne, Schillo
et al. 1990; Lincoln and Wu 1991; Kumar, Lincoln et al. 1993). Conversely,
antagonists inhibit pulsatile LH secretion (Arslan, Pohl et al. 1988; Ping,
Mahesh et al. 1994). Other pituitary hormones that are secreted in a
predominantly pulsatile manner may also be regulated by NMDA sensitive
pathways (Brann and Mahesh 1997). In adult animals NMDA stimulates
ACTH (Farah, Rao et al. 1991; Downing, Joss et al. 1996) and growth
hormone (GH) secretion (Estienne, Schillo et al. 1989; Acs, Lonart et al.
1990; Downing, Joss et al. 1996), but the effect of antagonising the actions of
the endogenous ligand(s) on pulsatile ACTH or GH secretion has not been
examined.
Administration of NMDA to the ovine fetus stimulates ACTH secretion,
and the response increases with advancing gestational age; At the same
time the pituitary sensitivity to AVP and CRH is unchanged or may even
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decrease (Brooks and Howe 1996). An appealing possibility is that
increasing glutaminergic drive to PVN neurons is the central event preceding
parturition. Accordingly, in this study the role of endogenous excitatory amino
acids acting at the NMDA receptor in mediating pulsatile ACTH secretion in
the late gestation ovine fetus is examined.
3.3 Materials and methods
Animals and surgical preparation
Mixed breed sheep with known single insemination dates were used in
these experiments. Between day 120-125 gestation (term approximately 145
days) fetal sheep were prepared with chronic indwelling jugular, carotid and
amniotic cannulae as previously described in section 2.1. Where there were
multiple fetuses only one fetus in each sheep was cannulated. Within 24 h of
surgery animals were individually housed in metabolism crates and
maintained for the duration of the experiment under a constant 12:12 h light
dark cycle. The cannulae were flushed daily with heparinised saline (5000
lU/ml) and a small arterial sample withdrawn for blood gas analysis (IL1306;
Instrumentation Laboratories, Warrington, Cheshire, UK). Only fetuses with
maintained healthy acid-base status (measurements in close agreement with
normal ranges of: pH 7.352+0.01; p02 20.28±0.49 mmHg; pC02 49.39+0.59
mmHg) were included in the experiment. Antibiotics were given to the fetus
(10 units penicillin, Glaxovet, Uxbridge, UK) and mother (Streptopen,
Glaxovet, Uxbridge, UK) for 3 days after surgery. All experiments were
conducted at least 5 days after surgery.
Blood sampling regime
Samples (1 ml) were withdrawn from the arterial cannula and replaced
with heparinised saline. All samples were collected onto ice and centrifuged




To examine the role of endogenous excitatory amino acids acting at
the NMDA receptor we examined the effect of a specific competitive NMDA
antagonist (CGP 37849, Ciba-Geigy, Basel, Switzerland) on stimulated and
basal hormone secretion in fetal sheep during late gestation. Insulin-induced
hypoglycaemia, sodium nitroprusside and NMDA were used to stimulate
hormone secretion on consecutive days from 130-132 gestation at a time
when circulating concentrations of ACTH and Cortisol are low. Effects of CGP
37849 on basal secretion were studied during the preparturient surge of
ACTH and Cortisol secretion at around day 138. Some fetuses were used for
both experiments.
Experiment 1: Effect of NMDA receptor antagonism on stimulated hormone
secretion
On day 130 gestation beginning at 0800 h, fetuses received an
intravenous bolus of either CGP 37849 (treatment, n=5) or saline vehicle
(control, n=5). CGP 37849 was given at a dose of 1 mg/kg in a solution of 2
mg/ml in saline (estimated fetal weight of 4 kg). Fetuses were then
challenged 5 min later with insulin (10 IU iv bolus; Actrapid, Novonordisk,
Crawley, UK). Blood samples (1 ml) were withdrawn at -60, -30, -15, 0, 5,
10, 15, 20, 30, 60, 90, and 120 min relative to the time of administration of
antagonist. On the following day animals underwent an identical treatment
and sampling protocol except that the insulin challenge was replaced with an
infusion of sodium nitroprusside (100 pg/0.5ml saline/min iv) for 10 min. On
the subsequent day NMDA (4 mg iv bolus; Sigma, Poole, UK) was
administered as an intravenous bolus and blood samples collected as for the
previous challenge tests.
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Experiment 2: Effect of NMDA receptor antagonism on endogenous hormone
secretion.
On day 138 gestation beginning at 0800 h blood samples were
withdrawn from fetuses at 10 min intervals for 6 h. After a baseline period of
3 h, fetuses received either an intravenous infusion of CGP 37849 (5 treated
animals) or saline vehicle (6 control animals). The CGP 37849 was prepared
as a solution of 2 mg/ml and given as a loading bolus of 1 mg/kg followed by
an infusion at 1 mg/kg/h for a further 3 h treatment period (estimated fetal
weight 5 kg). At the end of this time all fetuses received an intra-arterial bolus
injection of NMDA (4 mg/kg) whilst the antagonist or vehicle infusion was
continued intravenously. Further blood samples were withdrawn at 5, 10, 15,
20, 30, 60, 90, and 120 min after the injection of NMDA. Additional fetal
blood samples were withdrawn for blood gas analysis and determination of
haematocrit at the start of the baseline period, the treatment period, before
the NMDA challenge and at the end of the experiment. Fetuses with
significant hypoxia or acidosis or with a drop of more than 10% haematocrit
were excluded from analysis.
Hormone determination.
Samples were assayed in duplicate for immunoreactive ACTH(1.39) by
a specific 2-site immunoradiometric assay (Brooks and Howe 1996) and
described in detail in section 2.2.1. The assay limit of detection was 11.0
pg/ml. Inter- and intra-assay coefficients of variation were 12% and 9%
respectively. Cortisol concentrations were determined by radio-immunoassay
following extraction with diethyl-ether using established methods (Brooks and
White 1990) covered in section 2.2.2. The lower limit of detection was 0.27
ng/ml. Inter- and intra-assay coefficients of variation were less than 10% and
7%, respectively. Samples were assayed in duplicate 50 pi aliquots for ovine
GH (oGH) by radioimmunoassay as described in section 2.2.3. The lower
limit of detection was 1.9 ng/ml. Inter- and intra-assay coefficients of variation
were less than 12% and 10%, respectively.
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Statistical analysis
Experiment 1: The effects of CGP 37849 on hormone responses to
the insulin and nitroprusside challenge tests were assessed by two way
ANOVA for repeated measures with post hoc Scheffe's test using the Abacus
Concepts, Statview package (version 4.1) for the Apple Macintosh (Abacus
Concepts, Inc., Berkeley, CA, USA).
Experiment 2: Individual hormone profiles during the baseline and
treatment periods were analysed using a computer pulse detection program
(Munro, Zaristow software, Haddington, Scotland) as previously described
(Brooks and Challis 1991). Briefly, the program generates a baseline by
examining local nadirs, and then detects pulses as deviations from this
baseline using preset parameters. A moving average of 100 min was used to
determine baseline hormone concentrations, and values of two standard
deviations or more from the previous nadir were considered to be significant
pulses. The interpulse interval and pulse amplitude during baseline and
treatment periods in control and treated animals were compared by ANOVA.
Because absolute ACTH and Cortisol concentrations varied between
animals in later gestation (reflecting earlier activation of the HPA axis in some
animals) it was necessary to normalise the data for comparison of mean
levels between groups. The same analysis was applied for GH
concentrations. For each individual animal ACTH, Cortisol and GH
concentrations were expressed as a percentage of the mean concentration
during the 3 h basal sampling period. The group means were then calculated
and treatment and control groups compared by two factor ANOVA with post
hoc Scheffe's test. The response to NMDA challenge at the end of the serial
sampling period was similarly assessed by normalising hormone
concentrations to the average concentration in the preceding 30 min.
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3.4 Results
Gestation changes in basal hormone concentrations
All animals had measurable quantities of ACTH at 130 and 138 days of
gestation. As was expected there was a significant increase in mean basal
ACTH concentration between day 130 and day 138. The mean basal ACTH
(all animals) at day 130 was 16.60+7.37 pg/ml and at day 138 was
107.47+43.68 pg/ml (t-test; p<0.01). Similarly, GH could be detected at both
130 and 138 days gestation and increased significantly with gestation. Mean
basal levels were 12.8±3.43 ng/ml at 130 days and 55.96+14.82 ng/ml at 138
days (t-test; p<0.01).
Effect of NMDA receptor antagonism on insulin, sodium nitroprusside and
NMDA stimulated ACTH and GH secretion
Insulin administration on day 130 gestation stimulated a significant
increase in ACTH concentration, which was attenuated by CGP 37849
pretreatment (ANOVA; Change with time p<0.0001, Treatment by time
interaction p<0.02). In contrast, sodium nitroprusside infusion resulted in a
profound increase in circulating ACTH concentrations, peaking at 15 min, that
was not significantly affected by pretreatment with CGP 37849. The ACTH
responses to insulin and sodium nitroprusside are shown in figure 3.1. Insulin
induced hypoglycaemia resulted in a modest but significant decline in GH
levels that was unaffected by CGP 37849 (ANOVA; Change with time
p<0.0001, Treatment by time interaction p>0.05). Sodium nitroprusside was
without effect on GH release. The GH responses to insulin and sodium
nitroprusside are shown in figure 3.2. The ACTH response to NMDA
administration was rapid and completely abolished by pretreatment with CGP
37849 at the dose used (ANOVA; Change with time p<0.0001, Treatment by
time interaction p<0.0001). The ACTH response to NMDA is shown in figure
3.3.
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Effect of NMDA receptor antagonism on pre-parturient ACTH, Cortisol and GH
secretion
On day 138 all animals displayed pulsatile ACTH, Cortisol and GH
secretion during the baseline period. The ACTH and Cortisol concentrations
varied between animals reflecting the fact that they were sampled at different
time points during the endogenous prepartum increase in ACTH and Cortisol
secretion. For this reason ACTH and Cortisol levels were expressed as a
percentage of the mean concentration during the baseline period. After
normalisation mean ACTH and Cortisol concentrations in control animals
increased with time over the duration of the sampling period. This may reflect
a diurnal rhythm or a mild stress response to the sampling regime. There
was a clear and highly significant suppression of ACTH and Cortisol following
the start of treatment with CGP 37849 (ANOVA; Treatment by time interaction
p<0.0001 for ACTH and p<0.0003 for Cortisol). The concentration of ACTH
was depressed to a greater degree then that of Cortisol. The changes in
ACTH, Cortisol and GH concentrations with CGP 37849 treatment are shown
in figure 3.4. When ACTH pulse amplitude and interpulse interval were
compared there were no differences between groups or with treatment (Table
1). Similarly, there were no differences in Cortisol pulse amplitude or
interpulse interval between groups or with treatment (Table 1). At the end of
the 6 h baseline and treatment period, intravenous administration of NMDA
evoked a robust and significant elevation of ACTH and Cortisol concentration
in control animals. This increase was not observed in animals receiving CGP
37849 (ANOVA; Treatment by time interaction p<0.01 for ACTH and p<0.01
for Cortisol). The ACTH, Cortisol and GH responses to NMDA challenge at
the end of the infusion period are shown in figure 3.5.
In contrast, CGP 37849 had no effect on GH concentrations, and there
were no differences in GH pulse amplitude or interpulse interval between
groups or with treatment (Table 1). There was, however, a significant
increase in GH concentration in response to the NMDA challenge in the
control group, which was abolished in the animals receiving CGP 37849




Effect of CGP 37849 on the ACTH response to challenge with insulin (10 III iv
bolus) (upper panel) or sodium nitroprusside (100 pg/min iv infusion for 10
min) (lower panel). Fetuses were pretreated with CGP37849 (1 mg/kg iv
bolus) (n=5, filled circles) or saline vehicle (n=5, open circles) and the
challenge administered 5 min later. Values are mean+SEM. Pretreatment
with CGP 37849 significantly attenuated the ACTH response to insulin
induced hypoglycaemia (ANOVA; Effect of time p<0.0001, Treatment by time
interaction p<0.02) but not to sodium nitroprusside (ANOVA; Effect of time
p<0.0001, Treatment by time interaction p>0.05).
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Effect of CGP 37849 on the GH response to challenge with insulin (10 III iv
bolus) (upper panel) or sodium nitroprusside (100 pg/min iv infusion for 10
min) (lower panel). Fetuses were pretreated with CGP37849 (1 mg/kg iv
bolus) (n=5, filled circles) or saline vehicle (n=5, open circles) 5 min before
the challenge was administered. Values are mean+SEM. Insulin induced
hypoglycaemia caused a significant decline in GH concentration that was
unaffected by pretreatment with CGP 37849 (ANOVA; Change with time
p<0.0001, Treatment by time interaction p>0.05). Sodium nitroprusside








Effect of CGP 37849 on the ACTH response to challenge with NMDA (4
mg/kg iv bolus). Fetuses were pretreated with CGP 37849 (1 mg/kg iv bolus)
(n=5, filled circles) or saline vehicle (n=5, open circles) 5 min before the
challenge was administered. Values are mean+SEM. The ACTH response
to NMDA was significantly inhibited by CGP 37849 (ANOVA; Effect of time
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Effect of CGP 37849 on plasma ACTH (upper panel), Cortisol (middle panel)
and GH (bottom panel) concentrations (expressed as percentage change
from mean baseline concentrations) at day 138 gestation. After 3 h baseline
sampling fetuses received a bolus of CGP37849 (1 mg/kg iv) followed by an
infusion of CGP37849 (1 mg/kg/h) for a further 3 h (n=5, filled circles) or
saline vehicle (n=6, open circles). Values are mean±SEM. Infusion of CGP
37849 significantly reduced ACTH and Cortisol concentrations (ANOVA;
Treatment by time interaction p<0.0001 for ACTH and p<0.0003 for Cortisol),
but not GH concentrations (Treatment by time interaction p>0.05).
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Inhibition of ACTH (upper panel), Cortisol (middle panel) and GH (bottom
panel) responses to NMDA by CGP 37849 infusion. After 3 h of infusion of
CGP 37849 (n=5, filled circles) or saline (n=6, open circles), fetuses were
challenged with NMDA (4 mg/kg iv bolus) and the infusion of CGP 37849 (1
mg/kg/h) continued. Hormone concentrations are expressed as a percentage
of mean over the preceding 30 min baseline. Values are mean +SEM.
Challenge with NMDA produced an elevation of plasma ACTH, Cortisol and
GH concentrations that was significantly inhibited by CGP 37849 infusion
(ANOVA; Treatment by time interaction p<0.01 for ACTH, p<0.01 for Cortisol






Montage showing plasma ACTH concentrations in individual animals
receiving CGP 37849. The NMDA antagonist was given as a bolus of 1
mg/kg after 180 min and continued as an infusion (1 mg/kg/h) for the
remainder of the sampling period.
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Montage showing plasma ACTH concentrations in individual animals
receiving saline vehicle. The saline was given as a bolus of 2.5 ml after 180
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Montage showing plasma Cortisol concentrations in individual animals
receiving CGP 37849. The NMDA antagonist was given as a bolus of 1
mg/kg after 180 min and continued as an infusion (1 mg/kg/h) for the
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Montage showing plasma Cortisol concentrations in individual animals
receiving saline vehicle. The saline was given as a bolus of 2.5 ml after 180
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Montage showing plasma GH concentrations in individual animals receiving
CGP 37849. The NMDA antagonist was given as a bolus of 1 mg/kg after
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Montage showing plasma GH concentrations in individual animals receiving
saline vehicle. The saline was given as a bolus of 2.5 ml after 180 min and
continued as an infusion of 2.5 ml/h for the remainder of the sampling period
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Table 1: Effects of NMDA receptor antagonism with CGP 37849 on pulsatile
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A significant role for endogenous excitatory amino acid
neurotransmitters acting at the NMDA receptor to mediate basal activity of the
fetal HPA axis, and its response to certain stresses, is demonstrated in these
experiments. At day 130 gestation pretreatment with CGP 37849 inhibited
the rise in ACTH concentration seen in response to insulin-induced
hypoglycaemia indicating a role for NMDA receptors in this stress responsive
pathway. Later in gestation, at a time when basal (unstimulated) ACTH
concentrations are increased in preparation for parturition, treatment with
CGP 37849 resulted in a decline in mean ACTH and Cortisol concentrations.
In contrast GH secretion was unchanged by NMDA antagonism.
At 130 days gestation ACTH secretion is readily stimulated by NMDA
as previously reported (Brooks and Howe 1996). The compound CGP 37849
has been shown to be a competitive NMDA receptor antagonist in the rat
(Schmutz, Portet et al. 1990), and the demonstration that pretreatment with
CGP 37849 completely abolishes the ACTH response to NMDA confirms that
CGP 378494 is an NMDA antagonist in the ovine fetus. Using CGP 37849
the role of endogenous excitatory amino acids acting at the NMDA receptor in
the regulation of ACTH secretion has been examined.
Insulin-induced hypoglycaemia stimulated ACTH secretion in the ovine
fetus, and this is in agreement with earlier work (Ozolins, Young et al. 1992).
There is good evidence in adult animals that both AVP and CRH are involved
in this response. Direct sampling of portal plasma in conscious adult sheep
during insulin induced hypoglycaemia revealed that AVP and CRH are
secreted in increased amounts (Engler, Pham et al. 1989; Caraty, Grino et al.
1990), and chronic active immunisation against AVP or CRH diminished the
ACTH response in adult sheep (Guillaume, Conte-Devolx et al. 1992;
Guillaume, Conte-Devolx et al. 1992). The involvement of the NMDA
receptor pathways in this response has not been investigated, but is indicated
by the attenuated ACTH response in the fetuses that were pretreated with
CGP 37849.
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A nitroprusside infusion was originally included in this study to examine
the effects of NMDA receptor antagonism on the ACTH response to
nitroprusside induced hypotension. Subsequently it has become apparent
that nitroprusside, by acting as a nitric oxide donor, is able to bypass
blockade of the NMDA receptor. Nitric oxide is a component of the signalling
pathway generated after activation of the NMDA receptor in the luteinising
hormone (LH) response to NMDA (Mahachoklertwattana, Black et al. 1994;
Pu, Xu et al. 1996). Evidence from in vitro studies also supports a role for
nitric oxide in the modulation of ACTH secretion (Costa, Poma et al. 1996)
and neurons of the PVN and SON are immunoreactive for both NMDAR1 and
nitric oxide synthase (Bhat, Mahesh et al. 1995).
In the late gestation ovine fetus two studies have identified pulsatile
secretion of ACTH but were unable to demonstrate any change in pulse
amplitude or frequency in the few days before labour (Brooks and Challis
1991; Apostolakis, Longo et al. 1992). Our data on pulse frequency and
amplitude are in broad agreement with this earlier work. We find that pulses
are variable in amplitude and duration and that the mean ACTH
concentrations vary considerably between animals. This presumably reflects
the fact that fetuses were sampled at different time points during the pre-
parturient ACTH surge. The administration of CGP 37849 resulted in a rapid
decline in mean ACTH concentrations but was without significant effect on
pulse frequency and amplitude. This suggests that ACTH secretion
comprises two components: basal secretion and superimposed pulsatile
secretion, and that NMDA receptors are important for basal secretion.
A recent study reports the persistence of pulsatile ACTH secretion in
the hypothalamo-pituitary disconnected ovine fetus (Canny, Young et al.
1998). This suggests that pulsatile secretion of ACTH is an intrinsic property
of the pituitary and not dependent upon hypothalamic releasing factors. In
adult animals, however, simultaneous sampling of portal blood and the
systemic circulation reveals a high degree of synchrony between pulses of
CRH and AVP and ACTH (Caraty, Griro et al. 1988; Engler, Pham et al.
1989). It is notable that both NMDA antagonism in this study and opioid
receptor antagonism with naloxone (Brooks and Challis 1991) reduced mean
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ACTH levels seemingly without affecting pulse characteristics. One
explanation may be that hypothalamic releasing factors determine overall
basal release and help synchronise secretion by the corticotrophs, but that
pulses of releasing factor are not obligatory for secretion of ACTH. In support
of this it is found that a significant number of corticotrophs in culture secrete
ACTH in the absence of CRH or AVP, but exposure to the releasing
hormones changes the electrical activity of the corticotroph and increases
release of ACTH (Kwiecieu and Hammond 1998). An alternative explanation
is that ACTH pulses are intrinsically variable in amplitude and frequency, and
that the limitations of the ACTH assay and pulse detection analysis conspire
to hide subtle changes in pulse characteristics. Interestingly, LH pulses,
which generally have more consistent secretory characteristics, are inhibited
by NMDA antagonism which has an effect to reduce pulse amplitude without
affecting pulse frequency (Ping, Mahesh et al. 1995).
The decline in ACTH concentration during infusion of CGP 37849 also
results in a decrease in circulating Cortisol concentrations. The magnitude of
the decrease, however, is less than that of ACTH. Inspection of hormone
profiles shows a remarkable concordance between ACTH and Cortisol in
some animals, implying very acute modulation of Cortisol secretion by ACTH.
In other animals, however, Cortisol pulses seem to continue despite a marked
drop in circulating ACTH concentration. Others report a dissociation between
ACTH and Cortisol pulses in the ovine fetus (Apostolakis, Longo et al. 1992).
It may be that the adrenal is actually responding to small changes in ACTH
concentration, rather than absolute levels, and that the techniques used in the
present study have not been sufficiently sensitive to detect small fluctuations
in ACTH concentration. The fetal adrenal gland certainly does not need
pulsatile ACTH for there to be an increase in Cortisol secretion since infusions
of low doses of ACTH into hypophysectomised fetuses result in increased
Cortisol secretion (Jacobs, Young et al. 1994).
The secretion of GH in late gestation ovine fetuses is also pulsatile
(Bassett and Gluckman 1986; Bauer, Breier et al. 1995). Reported pulse
frequencies are somewhat lower than ours (0.74+0.46 pulses/h (Bassett and
Gluckman 1986)), but this may be a consequence of different sampling
109
frequencies and pulse detection programmes. Our data on pulse amplitude
and basal (nadir) levels are within the range previously documented (Bassett
and Gluckman 1986; Bauer, Breier et al. 1995). In contrast to the situation
with ACTH, antagonism of NMDA receptors is without effect on mean GH
concentrations or pulse amplitude or frequency, though GH is raised in
response to NMDA challenge in the control animals. The difference in the
responses of ACTH and GH to NMDA and CGP 37849 may be explained by
differences in the control of their secretion from the anterior pituitary.
Hypothalamic control of GH secretion is mediated by the stimulatory action of
growth hormone releasing hormone (GHRH) and the inhibitory action of
somatostatin. Pulses of GH secretion in the adult animal are generated by a
simultaneous decline in somatostatin secretion and an increase in GHRH
secretion (Plotsky and Vale 1985; Frohman, Downs et al. 1990). It is possible
that NMDA antagonism reduces both GHRH and somatostatin secretion so
that the overall drive to the somatotroph is unchanged. Several studies have
confirmed that exogenous NMDA stimulates GH secretion (Estienne, Schillo
et al. 1989; Acs, Lonart et al. 1990; Downing, Joss et al. 1996). This action of
NMDA is thought to be via increased GHRH secretion (Brann and Mahesh
1997). For instance, NMDA stimulated GH secretion is prevented by
destruction of GHRH neurons in the arcuate nucleus and by pretreatment with
GHRH antibody (Acs, Lonart et al. 1990). Chronic NMDA antagonism
reduces hypothalamic GHRH mRNA but not somatostatin mRNA (Cocilovo,
Colonna et al. 1992). At the same time, release of somatostatin from
hypothalamic explants in response to hypoglycaemia is NMDA dependent
(Issa, Lewis et al. 1998) and direct measurement of somatostatin secretion at
the median eminence demonstrates a role for NMDA sensitive pathways in
stimulating somatostatin release (Estupina, Abarca et al. 1996).
An important role for endogenous neurotransmitters acting at the
NMDA receptor in the late gestation activation of the fetal HPA axis is
indicated by the acute decline in mean ACTH concentrations following
administration of NMDA antagonist. This suggests that NMDA sensitive
pathways are involved in initiating the endocrine events that lead to labour in
the sheep. Most evidence indicates that NMDA receptor agonists influence
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anterior pituitary hormone secretion via an action within the hypothalamus.
NMDA receptors have been demonstrated by autoradiography, in-situ
hybridization and by immunocytochemistry in the central nervous system and
also in lower abundance in the pituitary gland in rodents (Bhat, Mahesh et al.
1995).
The secretion of ACTH from the anterior pituitary is controlled
principally by AVP and CRH secreted by parvocellular neurons located in the
PVN. NMDA receptors are located within the PVN and administration of
glutamate directly into the PVN stimulates ACTH release (Darlington,
Miyamoto et al. 1989). Several studies have documented the involvement of
CRH in the response to NMDA. Administration of glutamate into the
amygdala stimulates release of CRH at the median eminence in a dose
responsive manner (Gabr, Birkle et al. 1995). In the immature rat NMDA
stimulates the release of ACTH and this action can be blocked by anti-CRH
antibodies (Chautard, Boudouresque et al. 1993). In adult rat hypothalami,
however, NMDA stimulates the release of AVP but not CRH (Costa, Yasin et
al. 1992; Patchev, Karalis et al. 1994) though others report an effect on CRH
secretion (Joanny, Steinberg et al. 1997). The principal anatomical site at
which endogenous excitatory amino acids act on the NMDA receptor to
regulate ACTH secretion in the ovine fetus is unclear. Recently it has been
suggested that exogenous NMDA stimulates ACTH secretion through a direct
action at the pituitary in the ovine fetus (Szeto, Soong et al. 1999) since the
ACTH response to NMDA could not be inhibited by pretreatment with an AVP
or CRH antagonist.
The unique properties of the NMDA receptor enable it to play
important roles in synaptic plasticity and the organisation of the developing
brain. Activation of the NMDA receptor is thought to stabilise developing
synaptic connections and inhibit neuronal apoptosis (Wu, Malinow et al.
1996; Zhang, Rubin et al. 1998). In the developing cerebellum and
hippocampus the NMDA receptor subtype expressed is developmentally
regulated and correlates to the appearance of a mature pattern of nerve
activity (Farrant, Feldmeyer et al. 1994; Gottmann, Mehrle et al. 1997).
Blockade of the NMDA receptor disrupts the normal elimination of excess
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synapses in the cerebellum (Rabacchi, Bailly et al. 1992). Similar events
probably occur during development of the neuroendocrine hypothalamus.
For example, at puberty there is a reduction in the number of synapses onto
LHRH neurons (Perera and Plant 1997). In the female rat there is a critical
period for the action of NMDA to advance puberty which may relate to
development of the neuronal circuitry controlling LHRH release (Smyth and
Wilkinson 1994). There is conflicting evidence about the level of expression
of NMDA receptors in the hypothalamus over this time period (Nyberg,
Srivastava et al. 1995; Eyigor and Jennes 1997). The NMDA receptor may
have a comparable influence on the functional maturation of the HPA axis
during critical periods in fetal development and as such would offer a
molecular locus determining the timing of parturition in the sheep.
In summary, these studies have demonstrated that excitatory amino
acid neurotransmitters acting through the NMDA receptor mediate basal
activity of the HPA axis in the immediate period leading to parturition, and
also the response to certain stresses. It is tempting to speculate that
increasing fetal HPA activity in late gestation is associated with an increase in
the number of NMDA receptors or a change in the pattern of subunit




Arginine vasopressin and corticotrophin
releasing hormone regulation by central N-
methyl-D-aspartate pathways : a
microdialysis study
4.1 Abstract
Endogenous excitatory amino acid neurotransmitters acting through
the NMDA receptor provide drive to basal ACTH secretion in the fetal sheep
in late gestation, since the NMDA antagonist CGP 37849 reduces plasma
ACTH concentrations. The principal site of action of CGP 37849, however, is
unkown. A microdialysis technique was developed in the chronically
cannulated unanaesthetised ovine fetus to investigate the effect of CGP
37849 on secretion of AVP and CRH at the median eminence. Insulin-
induced hypoglycaemic stress was used to elevate AVP and CRH secretion.
Fetal sheep between 125 and 130 days gestation were pretreated with CGP
37849 (1 mg/kg) or saline vehicle before iv challenge with 10 IU insulin.
Plasma concentrations of ACTH and Cortisol increased significantly following
insulin challenge in control animals, and this increase was attenuated in
animals that had been pretreated with CGP 37849. Insulin-induced
hypoglycaemia stimulated an increase in the concentration of AVP recovered
in median eminence dialysate that was unaffected by pretreatment with CGP
37849. These results demonstrate that AVP secretion at the median
eminence is not regulated by NMDA receptor coupled pathways.
Unfortunately, no CRH could be detected in any of the dialysis samples.
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Median eminence dialysate also contained measurable, but low quantities of
glutamate, but concentrations were unaffected by insulin-induced
hypoglycaemia.
4.2 Introduction
An important role for endogenous excitatory amino acid
neurotransmitters acting through the NMDA receptor to drive ACTH secretion
in late gestation was demonstrated in chapter 3. The pathways through which
NMDA stimulates ACTH secretion are not known. In situ hybridisation studies
have colocalised CRH and the NMDA receptor in the PVN in the rat (Aubry,
Bartanusz et al. 1996). Magnocellular AVP neurons also express the NMDA
receptor (Decavel and Curras 1997). In the immature rat NMDA stimulated
ACTH release is blocked by anti-CRH antibodies (Chautard, Boudouresque et
al. 1993). Studies in vitro with adult rat hypothalami or slices are conflicting,
with some reporting that NMDA stimulates the release of AVP but not CRH
(Costa, Yasin et al. 1992), while others find that NMDA does stimulate CRH
secretion (Joanny, Steinberg et al. 1997). The stimulation of ACTH by NMDA
in the sheep fetus may even involve a direct action on the pituitary (Szeto,
Soong et al. 1999). In an attempt to characterise the pathways through which
the NMDA receptor controls ACTH secretion in the fetus a microdialysis
technique is developed to sample the secretion of releasing factors at the
median eminence in the chronically catheterised fetus.
Microdialysis was developed to allow the estimation of local
neurotransmitter release in brain tissue (Benveniste and Huttemeier 1990;
Stamford 1992; Westerink 1995). A length of tubing made from a semi¬
permeable membrane is implanted in the region of interest and perfused with
a physiological solution. Neurotransmitters in the vicinity diffuse across the
membrane in proportion to their local tissue concentration and membrane
permeability and can then be measured in the collected dialysate if an assay
of sufficient sensitivity is available. The technique has been used to measure
glutamate release in the parietal cortex in the fetus during asphyxia (Tan,
Williams et al. 1996), but has not been applied to the measurement of median
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eminence peptide secretion. One of the difficulties is the accurate placement
of the tip of the microdialysis probe in to the median eminence and this has
necessitated a contrast guided stereotaxic approach.
4.3 Materials and Methods
Animals and surgical preparation
Mixed breed sheep with known single insemination dates were used in
these experiments. Between day 125-130 gestation (term in our flock is 145
days) fetal sheep were prepared with chronic indwelling jugular, carotid and
amniotic cannulae . A microdialysis probe was then positioned in the median
eminence under X-ray guidance as described in section 2.1. Construction of
the microdialysis probe is detailed below. To aid probe placement contrast
medium was injected into the lateral ventricle via a lateral ventricle.
Satisfactory placement of the microdialysis probe in the medium eminence
was later confirmed by the recovery of AVP in the dialysate, and by visual
inspection of the brain and pituitary at the completion of the experiment.
Finally, emg electrodes (AS 632, Cooner Wire Co, Chatsworth, CA, USA)
were sutured to the serosal surface of the myometrium.
On the afternoon of surgery animals were placed into metabolism
crates and the microdialysis probe continuously perfused at 2 jil/min overnight
with artificial cerebrospinal fluid (140 mM NaCI, 3 mM KCI, 2.4 mM CaCI2, 1
mM MgCI2, 1.2 mM Na2HP04, 0.27 mM Nah^P04, 7.2 mM glucose pH7.4).
Antibiotics were given to the fetus (106 units penicillin, Glaxovet, Uxbridge,
UK) and mother (Streptopen, Glaxovet, Uxbridge, UK) for 3 days after
surgery. Animals were fed twice daily and allowed free access to water. The
cannulae were flushed daily with heparinised saline (20 lU/ml) and a small
arterial sample withdrawn for blood gas analysis (IL1306; Instrumentation
Laboratories, Warrington, Cheshire, UK). Only fetuses with maintained
healthy acid-base status (measurements in close agreement with normal
ranges of: pH 7.352+0.01; p02 20.28+0.49 mmHg; pC02 49.39+0.59 mmHg)
were challenged with insulin-induced hypoglycaemia.
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Microdialysis probes
Microdialysis probes were constructed from a length of 36g tubing
(Coopers needle works, Birmingham, UK) placed concentrically inside a
length of thin walled 24g tubing (Coopers Needle Works, Birmingham, UK).
The tip of the 36g tubing protruded approximately 4 mm past the end of the
outer tubing. A 10-15 mm length of dialysis membrane (Althin Medical Inc,
Florida, USA) sealed at one end with epoxy resin was then pushed over the
end of the 36g tubing, advanced inside the outer tubing and secured in
position with more epoxy resin. At the other end of the assembly a short
piece of polyvinyl tubing (Bolab V4, Bolab Inc., Lake Havasu City, USA) was
cemented over the outer 24g tube and bent over to one side. The inner 36g
tubing pierced the side wall of this polyvinyl tubing and protruded
approximately 3 mm. A 100 cm length of polyvinyl tubing (Bolab V1, Bolab
Inc., Lake Havasu City, USA) was attached to the end of the 36g tubing and
served as the inflow channel. The outflow channel was created by cementing
a 100cm length of polyvinyl tubing (FEP tubing, Carnegie Medicine,
Stockholm, Sweden) into the Bolab V4 polyvinyl tubing. Both inflow and
outflow channels were about 100cm long and were threaded through a larger
diameter polyvinyl tube (Bolab V11, Bolab Inc., Lake Havasu City, USA) to
prevent kinking. A diagrammatic representation of a microdialysis probe is
given on the following page.
Recovery of neurotransmitters in vitro
The in vitro performance of the probe before implantation was
assessed by dialysing a solution containing known amounts of AVP, CRH,
glutamate and GABA overnight. The probe was perfused at 2 pl/minute as in
the in vivo experiments with artificial csf. Mean (±SEM) in vitro recoveries
were: AVP 7.2.4+2.1%, CRH 1.2+0.6%, glutamate 8.6+3% and GABA
5.2+4%.
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Details of microdialysis system
Dialysis membrane
The microdialysis probe is made up of two concentric steel tubes with
a piece of dialysis tubing, sealed at one end with epoxy resin, cemented
inside the outer tubing. Dialysis fluid forced down the inner tubing circulates
past the dialysis membrane before passing back through the outer steel
tubing to be collected.
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Experimental design
To determine the role of endogenous excitatory amino acids acting at
the NMDA receptor in the regulation of the hypothalamic releasing factors
AVP and CRH, the secretion of these factors at the median eminence was
examined by a microdialysis technique. Insulin induced hypoglycaemia was
used as a challenge to elevate excitatory amino acid neurotransmitter activity
after animals have been pretreated with CGP 37849 or saline vehicle.
Differences in AVP or CRH release can then be attributed specifically to
activation of the NMDA receptor. Because the performance of the
microdialysis probe over time was not known these experiments were carried
out 24 h after the probes were inserted. A second group of animals were also
implanted with microdialysis probes and were dialysed continuously until they
were adjudged to be in labour on the basis of myometrial emg activity. At this
point an insulin challenge was administered.
Insulin-induced hypoglycaemia challenge
On the morning following surgery fetuses received an insulin challenge
(10 IU iv bolus; Actrapid,Novo Nordisk, Crawley, UK) 5 minutes after
pretreatment with either CGP37849 (4 mg iv bolus; Ceiba-Geigy, Basel,
Switzerland) in 2 ml saline (n=5) or saline vehicle (n=5). Blood samples (1 ml
sample, replaced with heparinised saline) were collected at -60, -30, 0, 10,
20, 30, 60, 90, and 120 min around the insulin injection. Microdialysis
samples were collected over 30 min periods starting 60 min before insulin
administration, allowing for the time delay in fluid reaching the collection tube.
Samples were collected into 500 pi plastic tubes (Eppendorf, Hamburg,
Germany), snap frozen on dry ice and stored at-20C until assay.
Long term performance of microdialysis system
A second group of 7 animals were prepared with microdialysis probes
and dialysis fractions collected continuously every 2 h by automated fraction
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collector until the sheep laboured. In addition, animals from the group
challenged with insulin on the day after surgery were also followed into
labour. Animals were inspected twice daily and blood samples withdrawn for
hormone estimation. A blood gas analysis was also performed on each
sample. Batches of accumulated dialysis samples were frozen every 12 h. A
three way tap allowed replenishment of the csf reservoir without the
incorporation of air bubbles into the dialysis probe. When the sheep were
judged to be in labour by the appearance of an emg pattern characteristic of
labour (Nathanielsz, Bailey et al. 1980; Farber, Guissani et al. 1997), a further
insulin challenge (10 IU iv bolus) was administered. Samples were collected
at -30, 0, 10, 20, 30, 60, 90, and 120 min around the sample where possible
(in many animals in labour it was no longer possible to withdraw blood
samples)
Radioimmunoassay
Samples were assayed in duplicate for immunoreactive ACTH (1.39) by a
specific 2 site immunoradiometric assay (Brooks and Howe 1996) which is
detailed in section 2.2.1. The assay limit of detection was 11.0 pg/ml. The
intra-assay coefficient of variation was less than 12% and the inter-assay
coefficient of variation less than 14% at 25 pg/ml. Cortisol concentrations
were determined by radio-immunoassay following extraction with diethyl-ether
(Brooks and White 1990). The method is described fully in section 2.2.2. The
lower limit of detection was 0.27 ng/ml. The intra-assay coefficient of
variation was 7% and the inter-assay coefficient of variation 10% at 3.9ng/ml.
Median eminence dialysate AVP concentrations were determined in singlicate
using an established method (Currie, Gillies et al. 1994) detailed in section
2.2.6. For fractions collected over 30 min epochs during insulin-induced
hypoglycaemia 50 pi aliquots were diluted to 100 pi for assay. Samples
collected over 2 h longitudinally throughout gestation were assayed undiluted.
Intra- and inter-assay coefficients of variation were less than 15% and 16%
respectively and the lower limit of detection 1.8 pg/ml. The concentration of
CRH in the dialysate was determined in duplicate 100 pi aliquots from
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fractions collected overnight prior to insulin challenge using an established
assay (Brooks, Power et al. 1989) which is described in section 2.2.7. All of
these samples contained measurable quantities of AVP. A single assay run
was carried out with intra-assay coefficient of variation of 16% and lower limit
of detection of 120 pg/ml.
HPLC separation and fluorimetric assay of amnio acids
The concentration of amino acid neurotransmitters in the dialysate was
determined by fluorimetric analysis after separation on a reversed-phase
HPLC column. Samples were prederivatised using a modification of a
commercially available chemistry package (AccQ.Tag, Millipore, Milford, MA,
USA). Briefly, 20 pil sample or standard were mixed with 1 pil 0.5M borax
solution in a borosilicate glass tube and 5 \x\ AccQ.Tag reagent added and
vortexed immediately. A 10 pil aliquot of derivatised sample or standard was
then loaded onto column. Standards consisted of the amino acid hydrolysate
stock supplied with the addition of GABA, homocysteic acid, tryptophan,
taurine, histamine, adrenaline, Nor-adrenaline, serotonin, dopamine and L-
DOPA. A range of standards were prepared by serial dilution to load 50, 20,
10 and 5 pmol derivatised amino acid onto the column. Since the fluorescent
product is then stable, samples and standards could be derivatised some time
before loading onto the column and stored at 4C until analysis.
The HPLC system consisted of Waters 625 LC pump and Waters 470
scanning fluorescence detector with excitation and emission wavelengths set
at 250 nm and 395 nm respectively. Samples (10 ^il) were manually injected.
Separation of the derivatised amino acids was achieved at 37C on a reverse
phase C18, 4 [xm column (Millipore, Milford, MA, USA) with a mobile phase of
0-17% acetonitrile and 100-83% Eluant A at a flow rate of 1 ml/min.
Each assay run included 50, 20, 10, and 5 pmol standards along with
the samples collected during the insulin challenge for each individual animal.
In some cases the identity of the glutamate or GABA peak was confirmed by
spiking a further aliquot of the sample with additional amino acid and
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demonstrating co-elution of the peak of interest with the additional amino
acid. The area under the peak of the fluorescence signal for each amino acid
of interest was plotted against concentration and found to be linear over the
range 1 pmol to 50 pmol loaded onto the column. The intraassay coefficients
of variation at the 10 pmol level for various neurotransmitters were: aspartate
10%, glutamate 8.9%, GABA 9.6%, nor-adrenaline 22.9%, adrenaline 25.9%,
and dopamine 12.6%. The interassay coefficients of variation were: aspartate
12.4%, glutamate 10.1%, GABA 11%, nor-adrenaline 25%, adrenaline 28.2%,
and dopamine 14.6%.
Statistical analysis
Dialysate and plasma hormone concentrations during the insulin challenge
were analysed by analysis of the variance (ANOVA) with repeated measures
using the Abacus Concepts, Statview package (version 4.1) for the Apple
Macintosh (Abacus Concepts, Inc., Berkley, CA, USA).
4.4 Results
Detection of AVP, CRF and glutamate in microdialysis samples
Satisfactory probe placement was judged by two means: firstly the
detection of AVP in dialysate obtained in the samples collected immediately
after surgery, and secondly by inspection of the median eminence and
pituitary at euthanasia. The concentration of AVP in dialysate was very
variable, presumably reflecting small differences in probe placement, and
declined rapidly with time so that by 36 to 48 h after surgery levels were
below the assay limit of sensitivity in most animals. We were unable to detect
CRH in any samples (even those with high concentrations of AVP). All
animals had measurable quantities of AVP at the time of insulin challenge.
Several amino acid neurotransmitters were detected in the dialysate
(glutamate, GABA, aspartate) but levels were generally low.
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Effect of insulin induced hypoglycaemia on release of AVP at the median
eminence and plasma ACTH and Cortisol concentrations
Because levels of AVP in dialysate varied between animals the data
was normalised by expressing AVP concentrations as a percentage of the
mean concentration in the two samples prior to insulin challenge. Insulin
induced hypoglycaemia produced a significant increase in AVP recovered in
the dialysate which was not inhibited by pretreatment with CGP 37849
(ANOVA, Change with time p<0.02, Treatment by time interaction p=0.99).
The AVP response to insulin induced hypoglycaemia is shown in figure 4.1.
Plasma ACTH and Cortisol concentrations were also normalised for
comparison. Insulin challenge elevated plasma ACTH concentrations and
this was significantly reduced by pretreatment with CGP 37849 (ANOVA,
Change with time p<0.001, Treatment by time interaction p<0.05). Plasma
Cortisol concentrations increased significantly with insulin induced
hypoglycaemia, but there was no effect of CGP 37849 to blunt the rise in
Cortisol (ANOVA, Change with time p<0.01, Treatment by time interaction
p=0.17). Levels of glutamate detected in median eminence dialysate samples
were low and did not rise following insulin challenge. The plasma ACTH and
Cortisol responses to insulin induced hypoglycaemia are shown in figure 4.2.
Longitudinal recovery of AVP in dialysate
The time interval from surgery to delivery or fetal demise (in two cases)
was quite variable. In total 19 animals were prepared with median eminence
dialysis probes and cannulae. Two fetuses died in utero. The time from
surgery to labour in the remainder ranged from 2-14 days, with an average
duration of 7.1+0.9 days (mean+SEM). Fetal Cortisol concentrations were
generally high in the days immediately post surgery. There was a tendency
for lower levels in those destined to continue for longer until labour. When
daily Cortisol concentrations are centred around day of labour there was a
significant rise in Cortisol levels over the last 2-3 days prior to labour as shown
in figure 4.3 (ANOVA; Effect of time p<0.0001). Concentrations of AVP in
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dialysate fell rapidly over the first 24-48 h after surgery to undetectable levels
in most animals and remained undetectable even during labour. The AVP
recovery in dialysate (as a percentage of initial recovery) with time is shown in
figure 4.4. In four fetuses it was possible to sample blood during labour
(ANOVA; Effect of time p>0.05). In these animals insulin challenge failed to
elevate dialysate AVP. The insulin challenge in labour, however, was also
without effect on ACTH or Cortisol levels. In two fetuses that became
significantly hypoxic detectable quantities of AVP were recovered in the




Effect of insulin-induced hypoglycaemia on AVP concentrations in median
eminence dialysate (expressed as a percentage of basal levels). After two
basal samples fetuses were pretreated with the NMDA antagonist CGP
37849 (1 mg/kg, iv) (n=5, open bars) or saline vehicle (n=5, filled bars) and
were challenged five minutes later with an iv bolus of 10 IU insulin. Values
are mean+SEM. Insulin induced hypoglycaemia produced a significant
increase in AVP recovered in the dialysate which was not inhibited by
pretreatment with CGP 37849 (ANOVA, Change with time p<0.02, Treatment
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Effect of insulin-induced hypoglycaemia on ACTH (upper panel) and Cortisol
(lower panel). Fetuses were pretreated with the NMDA antagonist CGP
37849 (n=5, filled circles) or saline vehicle (n=5, open circles) five minutes
before challenge with an iv bolus of 10 IU insulin. Values are mean+SEM.
Insulin challenge elevated plasma ACTH concentrations and this was
significantly reduced by pretreatment with CGP 37849 (ANOVA, Change with
time p<0.001, Treatment by time interaction p<0.05). Plasma Cortisol
concentrations increased significantly with insulin-induced hypoglycaemia, but
there was no effect of CGP 37849 to blunt the rise in Cortisol (ANOVA,






Plasma Cortisol concentrations centred around the day of delivery. Values
are mean+SEM. Plasma concentrations of Cortisol rise significantly prior to







AVP concentrations in median eminence dialysate (expressed as a






AVP concentrations in median eminence dialysate (expressed as a
percentage of initial recovery) in two fetuses which died in utero. Note



























These results demonstrate that it is possible to use the microdialysis
technique in the chronically cannulated ovine fetus to examine
neuroendocrine regulation of pituitary hormone secretion. Insulin-induced
hypoglycaemia provoked the secretion of AVP at the median eminence and
levels increased in parallel with plasma ACTH and Cortisol concentrations.
Furthermore, pretreatment with CGP 37849 attenuated the ACTH response to
insulin induced hypoglycaemia without affecting AVP secretion.
The studies reported in chapter 3 have identified a role for NMDA
receptor coupled pathways in the ACTH response to hypoglycaemia and in
basal ACTH secretion in late gestation, but were unable to identify if NMDA
receptor coupled pathways regulate AVP or CRH secretion. The finding by
others that AVP or CRH antagonism does not prevent exogenous NMDA from
stimulating ACTH secretion suggests a pituitary site of action (Szeto, Soong
et al. 1999). It should be remembered that the distribution of NMDA and CGP
37849 in the brain after intravenous injection may not be the same, and that
the finding that exogenous NMDA acts at the pituitary does not necessarily
indicate that endogenous excitatory amino acids act principally at the same
locus. The role of endogenous transmitters in regulating AVP and CRH
secretion are best addressed by studies measuring release at the median
eminence
Direct measurement of secretion of releasing factors at the median
eminence in the conscious fetus is problematic. The use of a microdialysis
system is appealing since, once implanted, the fetus can be replaced in utero
and no further access is needed. A number of studies have reported the
recovery of AVP and CRH from the brain and median eminence in rodents
and larger species using microdialysis (Gabr, Gladfelter et al. 1994; Gabr,
Birkle et al. 1995; Levy, Kendrick et al. 1995). When tested in vitro the
concentration of AVP recovered in the dialysate using our microdialysis
system was about 7% at a flow rate of 2 pl/min. Even with
ventriculographically aided placement of the microdialysis probes, however,
levels of AVP recovered in vivo were quite variable, presumably reflecting
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small differences in probe position within the median eminence. Initial levels
of AVP recovered in dialysate were high but fell fairly rapidly over 24 to 48 h.
Several phenomena may account for this: Firstly, insertion of the probe
causes local disruption of nerve fibres and terminals in the median eminence;
Secondly, the stress response to the surgery itself; And thirdly, the
development of gliosis around the probe tip limits recovery of
neurotransmitters from the extracellular fluid space. These considerations
limit microdialysis techniques to short term studies unless it is possible to
demonstrate similar recovery of neurotransmitter in response to identical
challenges over a prolonged period of time (Benveniste and Huttemeier 1990;
Stamford 1992; Westerink 1995).
Insulin-induced hypoglycaemia stimulated an increase in plasma
concentrations of ACTH and Cortisol in the ovine fetus. The same insulin-
hypoglycaemia paradigm increases ACTH and Cortisol secretion in a number
of other species (Redekopp, Irvine et al. 1986; Guillaume, Grino et al. 1989;
Ellis, Schmidli et al. 1990; Raff, Papanek et al. 1991; Carnes, Brownfield et al.
1992; Heisler, Tumber et al. 1994). There is good evidence in adult animals
that both AVP and CRH are involved in this response. Direct sampling of
portal plasma in conscious adult sheep, horses and rats during insulin-
induced hypoglycaemia reveals that AVP and CRH are secreted in increased
amounts (Redekopp, Irvine et al. 1986; Engler, Pham et al. 1989; Guillaume,
Grino et al. 1989; Caraty, Grino et al. 1990), and chronic active immunisation
against AVP or CRH diminishes the ACTH response in adult sheep
(Guillaume, Conte-Devolx et al. 1992; Guillaume, Conte-Devolx et al. 1992).
Insulin induced hypoglycaemia also increases expression of message for
AVP and CRH in the rat hypothalamus (Paulmyer-Lacroix, Anglade et al.
1994). In accordance with these observations, we find concentrations of AVP
in median eminence dialysate are increased after insulin challenge in the
ovine fetus. Unfortunately, CRH was not detectable in any of our samples,
but given the low sensitivity of the assay and low recovery of CRH in vitro this
is not surprising.
The NMDA receptor antagonist CGP 37849 attenuated the ACTH
response to insulin-induced hypoglycaemia in the ovine fetus but did not
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affect the release of AVP at the median eminence in response to
hypoglycaemia. This strongly suggests that suprapituitary NMDA receptor
coupled pathways regulate ACTH secretion through CRH and not AVP. In
fact several studies suggest that CRH mediates the action of NMDA to
stimulate ACTH secretion. In vitro NMDA stimulates release of CRH from
hypothalamic slices (Joanny, Steinberg et al. 1997), and passive
immunisation against CRH prevents the ACTH response to NMDA in vivo in
the immature rat (Chautard, Boudouresque et al. 1993). Microinjection of
glutamate into the amygdala stimulates the secretion of CRH at the median
eminence in adult rats (Gabr, Birkle et al. 1995).
The precise site at which intravenously administered NMDA acts to
stimulate CRH secretion is not clear. The NMDA receptor is widely
distributed throughout the neuroaxis and in theory agonists could act on
NMDA receptors found in the pituitary and median eminence (Monyer,
Sprengel et al. 1992; Meeker, Greenwood et al. 1994; Bhat, Mahesh et al.
1995), on CRH neuron cell bodies (Aubry, Bartanusz et al. 1996), or at extra-
hypothalamic sites (Monyer, Sprengel et al. 1992; Brann and Mahesh 1997).
Despite good in vitro recovery of glutamate median eminence dialysate
contained little glutamate and concentrations did not change in response to
insulin challenge. Our results argue against the median eminence being a
major site at which endogenous excitatory amino acids mediate the ACTH
response to stress in the ovine fetus. Others, however, have measured
changes in median eminence glutamate release in response to restraint
stress in rats (Estupina, Abarca et al. 1996).
To assess chronic functioning of the microdialysis system the insulin-
induced hypoglycaemia challenge was repeated once the ewe was in labour.
Unfortunately, the dose of insulin used did not stimulate ACTH or Cortisol
secretion in the fetuses of these labouring ewes, perhaps because the high
endogenous Cortisol concentrations in these fetuses made them relatively
insulin resistant. An inhibition of ACTH and Cortisol responses to
hypoglycaemia has been reported after prior stress (Keller-Wood, Shinsako et
al. 1983) or dexamethasone treatment (Carnes, Brownfield et al. 1992).
Tantalisingly, in two fetuses very high levels of AVP were recovered in the
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dialysate after several days at around the time of fetal demise in utero. This
observation indicates that the probes were still capable of recovering AVP
after several days.
In summary this study has demonstrated that it is possible to sample
AVP secreted at the median eminence in the conscious ovine fetus using a
microdialysis technique. Furthermore, it is also shown that AVP secretion in
response to insulin induced hypoglycaemia is not regulated by the NMDA
receptor. Over the longer term the concentrations of AVP recovered in
median eminence dialysate fell to undetectable levels and remained
undetectable even in labour. It is not clear if this was a consequence of a
decline in the in vivo performance of the probe, perhaps associated with
gliosis, or if endogenous secretion of AVP is low in this situation. In two
fetuses that died in utero, concentrations of AVP in the dialysate rose to very
high levels around the time of death.
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The role of estrogen in regulating the
hypothalamo-pituitary-adrenal axis sensitivity to
N-methyl-D-aspartate in the fetal sheep in late
gestation
5.1 Abstract
Excitatory amino acid neurotransmitters acting at the NMDA receptor
are an important regulator of basal ACTH secretion in late gestation. The
ACTH response to NMDA increases with gestation, but the factors
responsible for increasing activity of NMDA pathways are unknown. These
studies investigate the effect of infusion of 17-(3 estradiol (100 ng/kg/24 h) or
saline vehicle starting on day 120 gestation (term=145) on basal and NMDA
stimulated plasma ACTH and Cortisol concentrations in the chronically
cannulated ovine fetus. Basal plasma ACTH and Cortisol concentrations were
unchanged over 96 h infusion of 17-(3 estradiol (n=5) or saline vehicle (n=5).
Over this same time period plasma concentrations of PRL were significantly
elevated and plasma concentrations of FSH were significantly suppressed by
estradiol infusion. After 72 h infusion challenge with AVP (80 ng/kg), CRH
(400 (ig/kg) and LHRH (125 ng/kg) stimulated an increase in plasma ACTH
and Cortisol concentrations in both groups, but there was no significant
difference between groups. When FSH concentrations were normalised to
the preceding baseline, LHRH stimulated a modest increase in plasma FSH
concentrations that did not differ between groups. Similarly, after 96 h
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infusion intravenous challenge with NMDA (4 mg/kg) stimulated an increase
in plasma ACTH and Cortisol concentrations, but there was no significant
difference between groups. These results indicate that the late gestation
increase in HPA axis activity is not dependent upon estrogen.
5.2 Introduction
Excitatory amino acid pathways acting through the NMDA receptor
stimulate the ovine fetal HPA axis in late gestation and the ACTH response to
exogenous NMDA increases with gestation (Brooks and Howe 1996). The
work reported in chapter 3 demonstrated that near term endogenous
excitatory amino acids are required for a significant proportion of basal ACTH
secretion. Critical to an understanding of the mechanisms that initiate labour
is a knowledge of the factors responsible for the increase in the ACTH
response to exogenous NMDA are unknown.
In the reproductive axis the effects of agonists at the NMDA receptor
on LH secretion are dependent upon the steroid environment (Estienne,
Schillo et al. 1990; Pu, Xu et al. 1996). Gonadal steroids modulate both
release of transmitter (Carbone, Szwarcfarb et al. 1992; Carbone, Szwarcfarb
et al. 1995) and expression of the NMDA receptor (Weiland 1992; Gazzaley,
Weiland et al. 1996; Woolley, Weiland et al. 1997), though this has not been
substantiated by all researchers (Brann, Zamorano et al. 1993). In the sheep
fetus there is some evidence for increasing estrogen concentrations prior to
the surge at parturition that could potentially regulate NMDA receptor
expression (Findlay and Cox 1970; Nathanielsz, Eisner et al. 1982; Yu,
Cabalum et al. 1983). Further support for an increase in biologically active
estrogen is drawn from the observation that the levels of gonadotropin in fetal
circulation decline over late gestation at around the same time that estrogen
negative feedback is developing (Gluckman, Marti-Henneberg et al. 1983).
Reports of the actions of estrogen on the fetal HPA axis have been
conflicting. It has demonstration that implants of estradiol increase basal and
stimulated ACTH concentrations in the late gestation ovine fetus (Saoud and
Wood 1997; Wood and Saoud 1997). In contrast others find direct infusion of
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estradiol is without effect (Wang, Matthews et al. 1997). These investigators
have not examined HPA axis sensitivity to NMDA.
In the primate fetus it has been proposed that estrogen activates the
fetal HPA axis by inducing placental 11 (3HSD activity (Baggia, Albrecht et al.
1990; Pepe, Waddell et al. 1990). Placental 11 (3HSD prevents maternal
Cortisol from reaching the fetal circulation and so releases the fetal pituitary
and hypothalamus from inhibition (Pepe, Davies et al. 1994). There are other
sites in the HPA axis where feedback can be altered by 11 (3HSD activity: in
adult rats 11 (3HSD in the brain appears to modulate glucocorticoid negative
feedback (Seckl, Dow et al. 1993). It is not clear, however, if brain 11|3HSD is
estrogen inducible. The ovine placenta, fetal pituitary and hypothalamus also
express 1ipHSD (Yang 1992).
These experiments test the hypothesis that small increases in fetal
estrogen activate the fetal HPA axis by increasing the sensitivity to NMDA.
5.3 Materials and methods
Animals and surgical preparation
Mixed breed sheep with known single insemination dates were used in
these experiments. Animals were housed indoors at the MRC field station in
mid-Lothian, Scotland. At day 115 gestation (term in our flock is 145 days)
fetal sheep were prepared with chronic indwelling jugular, carotid and
amniotic cannulae as described in section 2.1. Where there were multiple
fetuses only one fetus in each ewe was instrumented. Electrodes (AS 632,
Cooner Wire Co, Chatsworth, CA, USA) for recording uterine
electromyographic activity were also sutured to the serosal surface of the
uterus close to the hysterotomy site. Antibiotics were given to the fetus (106
units penicillin, Glaxovet, Uxbridge, UK) and mother (Streptopen, Glaxovet,
Uxbridge, UK) for 3 days after surgery. Post-operatively, animals were
individually housed in metabolism crates. At least two animals were always
housed in the same room to lessen isolation stress on the mother. Animals
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were fed twice daily and allowed free access to water. The cannulae were
flushed daily with heparinised saline (20 lU/ml) and a small arterial sample
withdrawn for blood gas analysis (IL1306; Instrumentation Laboratories,
Warrington, Cheshire, UK). Only fetuses with maintained healthy acid-base
status (measurements in close agreement with normal ranges of: pH
7.352+0.01; p02 20.28+0.49 mmHg; pC02 49.39+0.59 mmHg) were included
in the experiment. All experiments were conducted at least 5 days after
surgery.
Blood sampling regime
Samples (1 ml unless otherwise stated) were withdrawn from the
arterial cannula and replaced with heparinised saline. All samples were
collected onto ice and centrifuged within 15 min (3000 rpm, 15 min, 4C),
separated and stored frozen at -20C until analysis.
Experimental design
To test the effects of estradiol on the HPA axis fetuses received a
continuous infusion of either estradiol or saline vehicle for a period of four
days. On the morning of the third day a pituitary challenge of LHRH, AVP
and CRH was administered. The estradiol or control infusion was continued
and on the morning of the fourth day serial blood samples were withdrawn for
a period of four hours to assess pulsatile ACTH and Cortisol secretion. At this
point animals were challenged with NMDA to estimate the sensitivity of
central NMDA receptor coupled pathways.
Infusion and sampling procedure
Blood samples (2 ml) were withdrawn twice daily from fetuses at 0800
h and 2000 h starting on day 119 of gestation. On the morning of day 120
gestation, after the 0800 h blood sample, fetuses commenced an infusion of
either 17-(3 estradiol (Sigma, Poole, UK, iv infusion, 0.5 ml/h) (n=5) or saline
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vehicle (n=5). The total dose of estradiol was 100 pg/kg/24 h which has
previously been demonstrated to suppress fetal gonadotropin levels at day
110 gestation (Gluckman, Marti-Henneberg et al. 1983). A fetal weight of 3
kg was assumed. After 3 days continuous infusion animals were challenged
with a cocktail of AVP (80 ng/kg), CRH (400 pg/kg) and LHRH (125 ng/kg) in
2 ml saline to estimate pituitary sensitivity. Blood samples were taken at -30,
-20, -10, 0, 10, 20, 30, 60, 90, and 120 min around the challenge. Fetal
haematocrit and blood gases on initial and final blood samples were also
analysed. After a further 24 h of estradiol infusion animals underwent a 4 h
serial sampling regime with blood samples withdrawn every 10 min. At the
end of this time they were challenged intra-arterially with a bolus of NMDA (12
mg/0.6 ml saline) and further blood samples taken at 10, 20, 30, 60, 90, and
120 min after this challenge.
Radioimmunoassay
Immunoreactive ACTH^^gj was measured in duplicate 100 pi aliquots
with a specific 2-site immunoradiometric assay (Brooks and Howe 1996) as
described in section 2.2.1, with lower limit of sensitivity of 11 pg/ml and inter
and intra-assay coefficients of variation of less than 14% and 12%
respectively. Cortisol was determined in duplicate 100 pi aliquots after
extraction with diethyl-ether (Brooks and White 1990) as described in section
2.2.2. The inter and intra-assay coefficients of variation were less than 10%
and 9% respectively and the lower limit of detection 0.27 ng/ml. The plasma
concentrations of FSH and PRL were determined by radioimmunoassay
previously validated for sheep (McNeilly and Andrews 1974; McNeilly,
Jonassen et al. 1986) and these are detailed fully in sections 2.2.4 and 2.2.5
respectively. The lower limit of detection of the FSH assay was 0.24 ng NIH
FSH S14/ml, and the intra-assay coefficient of variation 4.9%. The
corresponding values for the prolactin assay were 0.54 ng NIH PRL S15/ml,
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inter and intra-assay coefficients of variation were less than 15% and 14%
respectively.
Statistical analysis
Hormone concentrations (ACTH, Cortisol, PRL and FSH) in the twice
daily samples from control and treated fetuses were compared by two factor
analysis of the variance with post hoc analysis of individual means by
Scheffe's F test (Statview 4.1, Abacus Concepts, Berkeley, on Apple
Macintosh computer system). Plasma ACTH and Cortisol concentrations in
control and treated fetuses in response to pituitary challenge on day 3 of the
estradiol infusion were similarly compared by two factor analysis of the
variance. Since estradiol was found to significantly suppress basal FSH
secretion, the pituitary FSH responses to LHRH were analysed after
normalising the amplitude of the FSH response to the basal FSH. Individual
plasma ACTH, Cortisol and FSH profiles during the 4 h serial sampling period
on the fourth day were analysed using a computer pulse detection program
(Munro, Zaristow software, Haddington, Scotland). Briefly, the program
generates a baseline by examining local nadirs, and then detects pulses as
increments of two standard deviations or more from this baseline. Plasma
ACTH, Cortisol and FSH levels in control and treated fetuses during the 4 h
sampling period and after NMDA challenge were then compared by two factor
AN OVA.
5.4 Results
Effect of estradiol infusion on basal and NMDA stimulated ACTH and Cortisol
concentrations, and on pituitary sensitivity to AVP and CRH.
The plasma concentrations of ACTH and Cortisol in the daily samples
over the course of the experiment are shown in figure 5.1. Basal ACTH and
Cortisol concentrations were similar in the two groups prior to and during
estradiol infusion (ANOVA, Main effect for treatment for ACTH p=0.67 and for
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Cortisol p=0.49). Plasma ACTH and Cortisol concentrations were elevated on
the evening after the morning pituitary challenge on day 4, but there was no
significant difference between groups (ANOVA, treatment by time interaction
for ACTH, p=0.98; and for Cortisol, p=0.98).
Pituitary and adrenal responses to AVP and CRH challenge on day 4
(after 72 h infusion) are shown in figure 5.2. Plasma ACTH concentrations
peaked 10 min after challenge with AVP and CRH and declined thereafter,
but were still elevated above basal at 120 min (ANOVA, Effect of time
p<0.001). There were no significant differences between estradiol and saline
infused groups (ANOVA, Treatment by time interaction p=0.97). Similarly,
plasma Cortisol concentrations peaked at 20 min, but remained elevated
through to 120 min (ANOVA, Effect of time p<0.001). There were no
significant differences between the groups (ANOVA, Treatment by time
interaction, p=0.92).
The basal plasma ACTH and Cortisol concentrations and the changes
in response to NMDA challenge on day 5 (after 96 h infusion) are shown in
figure 5.3. There were no significant differences in ACTH or Cortisol
concentrations between control and estrogen treated animals. Plasma ACTH
concentrations peaked at 30 min after NMDA challenge and remained
elevated at 120 min, but there were no significant differences between
estradiol and saline infused animals (ANOVA, Treatment by time interaction,
p=0.99). Cortisol concentrations also rose rapidly after NMDA challenge and
remained elevated, and were unaffected by estradiol infusion (ANOVA,
Treatment by time interaction, p=0.95). When individual hormone profiles
were subjected to pulse analysis no pulses were detected.
Effect of estradiol infusion on basal and NMDA stimulated FSH
concentrations, and on pituitary sensitivity to LHRH
The plasma concentrations of FSH in the daily samples over the
course of the experiment are shown in figure 5.4. Basal FSH concentrations
declined significantly in the estradiol infused animals, and were below the
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assay limit of sensitivity after 48 h (ANOVA, Treatment by time interaction
p<0.01).
The pituitary response to LHRH challenge on day 4 (after 72 h
infusion) is shown in figure 5.5. Plasma FSH concentrations were
significantly higher in the saline infused group (ANOVA, Main effect for
treatment p<0.05). When plasma FSH concentrations are normalised by
expressing them as a percentage of baseline values, there are no significant
differences in the pituitary FSH response to LHRH (ANOVA, Treatment by
time interaction, p=0.45).
The basal plasma FSH concentrations and the changes in response to
NMDA challenge on day 5 (after 96 h infusion) are shown in figure 5.6.
Plasma FSH concentrations were lower in the estradiol infused group and
there was an increase in FSH concentrations over the duration of the
sampling period (ANOVA, Effect of time p<0.01, Treatment by time interaction
p=0.3). When FSH concentrations after NMDA challenge are normalised to
the 30 min preceding challenge, then neither group is seen to respond to
NMDA challenge (ANOVA, Treatment by time interaction p=0.6).
Effect of estradiol on PRL concentrations
Daily plasma PRL concentrations during the infusion are shown in
figure 5.4. Estradiol infusion resulted in a significant increase in PRL
concentrations over the duration of the experiment when expressed as a
percentage increase over basal (pre-infusion) levels wheras PRL
concentrations in the saline infused group were unchanged (ANOVA, Effect of
time p<0.001, Treatment by time interaction p,0.001).
Uterine activity
Throughout the experiment all animals demonstrated a pattern of uterine
activity consistent with contractures (Nathanielsz, Bailey et al. 1980; Farber,





Plasma ACTH (upper panel) and Cortisol (lower panel) concentrations for the
day before and during four days intravenous infusion (indicated by the open
bar) of estradiol (n=5, filled circles) or saline vehicle (n=5, open circles).
Values are mean+SEM. Estradiol infusion had no effect on basal plasma
ACTH or Cortisol concentrations (ANOVA, Treatment by time interaction for
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Plasma ACTH (upper panel) and Cortisol (lower panel) concentrations
following intravenous challenge with CRH (400 pg/kg) and AVP (80 ng/kg) in
estradiol (n=5, filled circles) or saline vehicle (n=5, open circles) infused
fetuses. Values are mean+SEM. The pituitary responses did not differ
between groups (ANOVA, Treatment by time interaction for ACTH p=0.97,
and for Cortisol p=0.92).
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Plasma ACTH (upper panel) and Cortisol (lower panel) concentrations in ten
min serial samples collected over four hours after four days of estradiol
infusion (n=5, filled circles) or saline vehicle (n=5, open circles). A bolus of
NMDA (4 mg/kg intra-arterial) was given after four hours and samples
collected over a further two hours. Values are mean+SEM. Estradiol had no
significant effect on either basal or NMDA stimulated ACTH or Cortisol







Plasma FSH (upper panel) and PRL (lower panel) concentrations for the day
before and during four days intravenous infusion (shown by the open bar) of
estradiol (n=5, filled circles) or saline vehicle (n=5, open circles). Values are
mean+SEM. Estradiol infusion resulted in a significant fall in plasma FSH
concentrations and an increase in plasma PRL concentrations over the
course of the infusion (ANOVA, Treatment by time interaction for FSH p<0.01



































Plasma FSH concentrations following intravenous challenge with LHRH
(125ng/kg) in estradiol (n=5, filled circles) or saline vehicle (n=5, open circles)
infused fetuses. Values are mean+SEM. FSH concentrations were
significantly higher in the saline infused group (ANOVA, Effect of treatment
p<0.05). After normalisation of FSH concentrations to the preceding baseline,
there were no significant differences between groups in response to LHRH





Plasma FSH concentrations in ten minute serial samples collected over four
hours after four days of estradiol infusion (n=5, filled circles) or saline vehicle
(n=5, open circles). A bolus of NMDA (4 mg/kg intra-arterial) was given after
four h and samples collected over a further two h. Values are mean+SEM.
FSH concentrations were significantly higher in the saline infused group
(ANOVA, Main effect of treatment p<0/05). When FSH values were
normalised to the preceding baseline, NMDA challenge did not stimulate an
increase in FSH (ANOVA, Treatment by time interaction p=0.6).
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These results demonstrate physiological levels of estradiol are without
effect on the ovine fetal HPA axis at day 120 gestation. Four days continuous
estradiol infusion had no effect on basal ACTH or Cortisol concentrations, and
did not alter pituitary sensitivity to AVP and CRH. Furthermore, the sensitivity
of the HPA axis to challenge with NMDA was unchanged. In contrast, there
was a significant suppression of the already low FSH levels over the four
days of the infusion indicating the hypothalamo-pituitary-gonadal (HPG) axis
to be sensitive to estradiol. This action of estradiol appears to occur at a
supra-pituitary level since the amplitude of the pituitary FSH response to
LHRH challenge was unchanged by estradiol infusion. Estradiol also had an
action to elevate daily PRL concentrations.
Estradiol infusion from day 120 gestation in the ovine fetus is seen to
affect the HPG axis and PRL secretion, but not the HPA axis, suggesting that
estradiol is not responsible for the preparturient increase in HPA activity in
this species. Similar findings are reported using an infusion of 100 pg/24 h,
but with different stress tests of HPA activity (Wang, Matthews et al. 1997).
Others, however, report that in fetal sheep at a similar gestation
subcutaneous implants releasing 0.24 mg estradiol per day result in
increased basal ACTH concentrations after 5 days (Saoud and Wood 1997;
Wood and Saoud 1997). In this study a total dose of 1.2 mg was
administered over a 96 h period without effect. This dose and route of
estradiol administration has previously been demonstrated to produce
biological effects despite there being only a modest elevation of conjugated
estradiol with no increase in levels of free estradiol (Gluckman, Marti-
Henneberg et al. 1983). The concentrations of estradiol achieved by this
infusion are comparable to the endogenous concentrations seen in later
gestation. At day 120 gestation endogenous unconjugated estradiol levels
are low (Nathanielsz, Eisner et al. 1982; Yu, Cabalum et al. 1983). Estradiol
production does, however, increase from mid to late gestation as evidenced
by the rise in circulating conjugated estradiol (Findlay and Cox 1970;
Carnegie and Robertson 1978) and by the decline in FSH concentrations
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(Gluckman, Marti-Henneberg et al. 1983). The current study indicates that
modest elevations of estradiol, within the physiological range, at a gestation
shortly before the concentrations of ACTH and Cortisol in the fetal circulation
start to rise, are without effect on the ovine fetal HPA axis.
This study has also examined the effects of estradiol on basal activity
in the HPG axis and on the response to challenge with NMDA. Levels of
gonadotropins in the fetal ovine circulation are highest at mid-gestation and
decline with advancing gestation (Foster, Roach et al. 1972; Sklar, Mueller et
al. 1981). Negative feedback actions of estradiol develop somewhere
between 90 and 105 days gestation and at least in part cause the decline in
gonadotropins (Gluckman, Marti-Henneberg et al. 1983). In accordance with
this we find that estradiol infusion suppresses basal FSH concentrations but
not the pituitary FSH response to LHRH challenge. Stimulation of the HPG
axis with NMDA did not elevate FSH secretion in control animals. In contrast,
the same dose of NMDA is known to stimulate LH secretion at this gestation
(Brooks and Howe 1996). The lack of FSH response to NMDA may be
related to low pituitary FSH responsiveness to LHRH. Challenge with LHRH
produced an approximate doubling of FSH concentrations in our control
animals, wheras, at the same gestation, the same dose of LHRH is reported
to increase LH by 10 to 20 fold (Brooks and Howe 1996).
During late gestation the fetal HPA axis becomes more sensitive to
NMDA challenge (Brooks and Howe 1996) and the hypothesis was advanced
that increasing responsiveness to NMDA was estrogen dependent. The
absence of effect of estradiol on the HPA axis despite suppression of FSH
and stimulation of PRL suggests that the mechanisms allowing sustained
activation of the HPA axis in the late gestation fetal sheep do not depend
upon estrogen. It is possible, however, that at day 120 the fetal sheep is
developmentally too immature to show estradiol enhancement of the ACTH
response to NMDA: in ovariectomised rats, the stimulatory effect of estrogen
on the LH response to NMDA is linked to development events at puberty,
since before this time treatment with estrogen and progesterone suppresses
LH (Carbone, Szwarcfarb et al. 1995).
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In summary, this study does not support the concept that estradiol
increases NMDA receptor stimulated ACTH release in the maturing ovine
fetus. There may, though be a role for other steroids in the increase in HPA
axis responsiveness to NMDA. Infusion of Cortisol in late gestation has a
positive action on the ovine fetal HPA axis (Apostolakis, Longo et al. 1994)
and chronic corticosterone treatment in adult rats has been shown to increase




Evidence that central Neuropeptide-Y pathways
regulate hypothalamo-pituitary-adrenal axis
activity in the late gestation fetal sheep
6.1 Abstract
The HPA axis in adult animals has a role in regulating metabolism.
Central NPY containing neurons in the arcuate nucleus are important in
signalling the metabolic state to the HPA axis. The potential role of NPY in
the regulation of pituitary-adrenal function was examined in fetal sheep at day
125 gestation. Fetuses were prepared with lateral cerebral ventricle cannulae
and NPY(6.5 pg, or 30 pg in 50 pi saline) or saline vehicle administered on
consecutive days as a bolus over 5 min. A significant increase in plasma
concentrations of ACTH but not Cortisol occurred in response to the highest
dose of NPY.
6.2 Introduction
In adult animals the HPA axis participates in the endocrine responses
during the transition from the fed to the fasted state, and during refeeding
(Dallman, Strack et al. 1993). Similar functions can be envisaged during fetal
life, and it is even possible that the late gestation increase in ACTH and
Cortisol secretion reflects a kind of intra-uterine starvation from which the
fetus escapes by initiating labour. The hypothalamic pathways regulating
energy balance include an NPY projection from the arcuate nucleus to the
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PVN that appears to be present in the late gestation fetus (Warnes, Morris et
al. 1998), though it has not been established that this pathway is functional.
Neuropeptide-Y is stimulatory action on the HPA axis. Administration
of NPY either directly into the PVN or into the cerebral ventricles results in
elevated plasma concentrations of ACTH or Cortisol in the rat and dog
(Harfstrand, Eneroth et al. 1987; Wahlestedt, Skagerberg et al. 1987; Inoue,
Inui et al. 1989). Furthermore, administration of specific antibodies to NPY
via the third cerebral ventricle significantly inhibits the ACTH and Cortisol
response to insulin-induced hypoglycaemia (Inui, Inoue et al. 1990). Thus,
endogenous NPY appears to be involved in the regulation of pituitary adrenal
function. Further evidence for a functional role for NPY in the control of
pituitary adrenal function is provided by studies which demonstrate a
decrease in the expression of NPY mRNA in the arcuate nucleus (from where
afferent fibres project to the PVN) after adrenalectomy (Bai, Yamano et al.
1985). The effect of adrenalectomy on NPY expression is reversed by
glucocorticoid treatment (White, Dean et al. 1990). In addition, a diurnal
rhythm of NPY immunoreactivity has been detected in the suprachiasmatic
and arcuate nuclei as well as the parvocellular region of the PVN (Jhanwar-
Uniyal, Beck et al. 1990).
To date there is no information concerning the role of central NPY
pathways in the control of pituitary-adrenal function during fetal life. It is
known that the NPY gene is expressed in the fetal sheep mediobasal
hypothalamus from at least day 110 gestation, and expression increases with
gestation and in response to maternal undernutrition (Warnes, Morris et al.
1998). In this study the response of the ovine fetal HPA axis to
intracerebroventricularly administered NPY is examined.
6.3 Materials and methods
Animals and surgical preparation
Mixed breed sheep with known single insemination dates were used in
these experiments. Between day 115-120 gestation (term approximately 145
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days) four fetal sheep were prepared with chronic indwelling jugular, carotid
and amniotic cannulae as previously described in section 2.1. The lateral
cerebral ventricle was catheterised using previously described methods
(Brooks 1992). Briefly, a 2 mm burr hole was made in the parietal bone 4-5
mm lateral to the sagittal suture and 5 mm rostral to the coronal suture. A
holding plate manufactured from a Vacutainer needle holder (Beckton-
Dickinson Vacutainer Systems) was anchored over the hole using stainless
steel screws and dental acrylic. A 5 mm guide cannula (modified 20 G
Vacutainer needle) was then screwed into the holding plate. A 26 G needle
attached to a 20 cm length of polyethylene tubing (PE20, Clay Adams, NJ,
USA) filled with sterile saline, was then lowered until the saline entered the
lateral ventricle by gravity flow. The needle was then secured at the correct
depth with dental acrylic and a 150 cm polyethylene cannula (PE20) was
attached and exteriorised through the ewes flank along with the vascular
catheters. The dead volume of the lateral ventricle cannula was 100 pi.
Where there were multiple fetuses only one fetus in each sheep was
cannulated.
Within 24 h of surgery animals were individually housed in metabolism
crates and maintained for the duration of the experiment under a constant
12:12 h light dark cycle. The cannulae were flushed daily with heparinised
saline (20 lU/ml) and a small arterial sample withdrawn for blood gas analysis
(IL1306; Instrumentation Laboratories, Warrington, Cheshire, UK). Only
fetuses with maintained healthy acid-base status (measurements in close
agreement with normal ranges of: pH 7.352+0.01; p02 20.28±0.49 mmHg;
pC02 49.39±0.59 mmHg) were included in the experiment. Antibiotics were
given to the fetus (106 units penicillin; Crystapen, Glaxovet) and mother
(Streptopen, Glaxovet) for 3 days after surgery. All experiments were
conducted at least 5 days after surgery.
Blood sampling regime
Samples (1 ml) were withdrawn from the arterial cannula and replaced
with heparinised saline. All samples were collected onto ice and centrifuged
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within 15 min (3000 rpm, 15 min, 4C), separated and stored frozen at -20C
until analysis.
Experiment: Effect of intracerebroventricular NPY on ACTH secretion
Between day 120-122 gestation beginning at 0800 h, fetuses received
an intracerebroventricular (icv) injection over 5 min of saline, 6.5 pg and 30 pg
human NPY in a volume of 50 pi on each of three consecutive days.
Peptides were purchased from Cambridge Research Biochemicals
(Northwich, Cheshire, UK) and dissolved freshly each day in sterile saline
without heparin. Blood samples (1 ml) were withdrawn at -30, -15, and 0 min
before and 15, 30, 60, 90, 120, 150 and 180 min after the injection.
Hormone determination.
Samples were assayed in duplicate for immunoreactive ACTH ^.ggj by
a specific 2-site immunoradiometric assay (Brooks and Howe 1996) which is
described in section 2.2.1. The assay limit of detection was 11.0 pg/ml. Inter-
and intra-assay coefficients of variation were less than 14% and 12%
respectively. Cortisol concentrations were determined by radio-immunoassay
following extraction with diethyl-ether (Brooks and White 1990) described in
section 2.2.2. The lower limit of detection was 0.27 ng/ml. Inter- and intra-
assay coefficients of variation were less than 10% and 9%, respectively.
Statistical analysis.
Basal ACTH concentrations in the blood samples taken before the
administration of NPY were averaged and subtracted from all subsequent
samples. The influence of saline or NPY on plasma ACTH concentrations
was then compared by two factor analysis of the variance (ANOVA) with
repeated measures using the Abacus Concepts, Statview package (version
4.1) for the Apple Macintosh (Abacus Concepts, Inc., Berkley, CA, USA).
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6.4 Results
Intracerebroventricular injection of a bolus of NPY stimulated a
modest increase in plasma ACTH which peaked at 60 min post injection.
There was a significant treatment by time interaction (p<0.03). The difference
between the high dose (30 pig) and saline groups with respect to time was
significant (p<0.03), but there were no significant difference between either
saline and low dose (6.5 ^g) groups or between low and high dose groups.




Plasma ACTH (upper panel) and Cortisol (lower panel) concentrations in
response to icv NPY. On consecutive days starting at day 120 gestation,
saline vehicle (open circles), 6.5 ^g NPY (triangles) and 30 pg NPY (filled
circles) were administered into the lateral cerebral ventricles of fetal sheep
(n=4). Values are mean+SEM. Treatment with 30 pg NPY stimulated a
significant increase in plasma ACTH concentrations (ANOVA; Treatment by
time interaction p<0.03). The ACTH response to the lower dose of NPY failed
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This study demonstrates that central administration of NPY in fetal
sheep at around day 120 gestation increases plasma concentrations of
ACTH, confirming a role for central NPY pathways in regulating ACTH
secretion. We were unable, however, to detect any changes in plasma
Cortisol concentrations.
Central NPY pathways have been implicated in the regulation of ACTH
secretion in other species. For instance, intracerebroventricular injection of
NPY in the rat and dog results in increased plasma ACTH concentrations as
does direct injection of NPY into the PVN of anaesthetized rats (Harfstrand,
Eneroth et al. 1987; Wahlestedt, Skagerberg et al. 1987; Inoue, Inui et al.
1989). Furthermore, recent studies have demonstrated that in adult sheep,
intracerebroventricular administration of NPY stimulates an increase in
plasma ACTH and Cortisol concentrations (Porter, Naylor et al. 1993; Brooks,
Howe et al. 1994). Part of the effect of NPY on HPA activity is likely to be
mediated via the secretion of CRH from the hypothalamus since NPY has
been shown to increase the concentrations of CRH in the median eminence
in association with increased plasma concentrations of ACTH (Haas and
george 1987). Additionally, NPY stimulates the secretion of CRH from rat
hypothalami incubated in vitro in a dose dependent manner (Tsagarakis,
Rees et al. 1989). The most convincing evidence that endogenous NPY
contributes to the physiological regulation of ACTH secretion is provided by a
report which shows that central immunoneutralization of NPY using a specific
antibody to NPY substantially blocks the increase in ACTH following insulin-
induced hypoglycaemia (Inui, Inoue et al. 1990). In adult sheep
administration of a bolus of 6.5 pg NPY into the third cerebral ventricle
stimulates an increase in plasma ACTH concentrations (Brooks, Howe et al.
1994). It is not clear if the difference in sensitivity between adult and fetal
sheep reflects a maturational change, or simply differences in route of
administration (third versus lateral cerebral ventricle). None-the-less, these
results do demonstrate that central NPY pathways are coupled to ACTH
secretion in the ovine fetus by at least day 125 gestation.
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The lack of significant Cortisol response to elevated plasma ACTH
secretions may be due to the relatively low adrenal sensitivity at this time
(Rose, Meis et al. 1982). An alternative explanation is that much of the
measured increase in ACTH activity is in fact larger molecular weight
precursor with low biological activity. Others have demonstrated a
developmental change in the ratio of low to high molecular weight ACTH
species, with increasing amounts of bioactive ACTH secreted with advancing
gestation (Brieu and Durand 1987; Saphier, Glynn et al. 1993; Carr, Jacobs et
al. 1995).
In adult animals central NPY pathways are part of a complex system
regulating behavioural and metabolic responses to nutritional state (Schwartz
and Seeley 1997; Schwartz 1998; Woldbye and Larsen 1998). Chronic
administration of NPY into the hypothalamus leads to obesity (Stanley,
Kyrkouli et al. 1986; Zarjevski, Cusin et al. 1993). There is considerable
redundancy in the system, though, as body mass and daily food intake are
not significantly disturbed in mice lacking NPY and are actually increased in
mice lacking the NPY Y1 or Y5 receptors (Erickson, Clegg et al. 1996; Marsh,
Hollopeter et al. 1998; Palmiter, Erickson et al. 1998; Pedrazzini, Seydoux et
al. 1998). The role of NPY pathways in the fetus is even less clear since the
fetus cannot increase energy intake in response to NPY, though other
components of the effector systems regulating body adipose stores are likely
to be functional. An increase in plasma ACTH and Cortisol concentrations in
response to NPY leads to peripheral insulin resistance and helps mobilise
metabolic substrate at times of energy restriction. Potentially, activation of
the fetal HPA axis in late gestation can be interpreted as a metabolic
response to failing energy supply, but without NPY antagonist studies it is
impossible to assess the contribution of NPY pathways to the preparturient




7.1 Summary of findings
The studies reported in this thesis have examined aspects of the
central regulation of the adrenal gland during fetal life. Excitatory amino acid
neurotransmitters acting through the NMDA receptor are shown to be
important for basal ACTH secretion in late gestation. The NMDA receptor
probably regulates ACTH secretion through CRH neurons since antagonism
of the NMDA receptor attenuated the ACTH response to insulin induced
hypoglycaemia without affecting the release of AVP at the median eminence,
though it remains possible that endogenous excitatory amino acids act
directly at the pituitary. The contribution of peripheral signals to HPA axis
activity has also been investigated. Estrogen infusion was without effect on
basal ACTH or Cortisol concentrations, pituitary sensitivity to AVP and CRH,
and the ACTH response to NMDA demonstrating that the late gestation
increase in HPA axis activity and response to NMDA is not due to placental
estrogen. Peripheral metabolic signals, however, can potentially drive the
late gestation increase in HPA axis activity through arcuate nucleus NPY
pathways as the HPA axis is able to respond to central NPY from at least day
125 gestation.
7.2 The NMDA receptor and ACTH secretion in the fetus
The marked decline in basal plasma ACTH concentrations with NMDA
receptor antagonism in the final few days before parturition confirms a
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prominent role for endogenous excitatory amino acid neurotransmitters in the
preparturient surge in HPA axis activity. Coupled with the earlier observation
that the ACTH response to bolus administration of NMDA increases with
gestation (Brooks and Howe 1996), these findings identify the NMDA receptor
as an important molecular locus determining the timing of parturition in the
sheep fetus.
Exactly what role the NMDA receptor has in the modulation of
neuroendocrine secretion is unclear at a cellular level. Glutamate receptors
mediate most of the fast excitatory synaptic transmission in the adult central
nervous system (Seeburg, Burnashev et al. 1995; Ozawa, Kamiya et al.
1998). Based on pharmacological and molecular analysis, ion-channel
coupled excitatory amino acid receptors are subdivided into two broad
classes: NMDA and non-NMDA receptors, and both types of receptor are
clustered in the post-synaptic membrane at central synapses (Seeburg,
Burnashev et al. 1995; Ozawa, Kamiya et al. 1998; Paas 1998).
Uniquely, the ion channel of the NMDA receptor at normal resting
membrane potential is blocked by a magnesium ion, and so is prevented from
acting as a calcium channel. If, however, the post-synaptic cell is depolarised
the magnesium ion is expelled from the ion channel, and the NMDA receptor
is free to conduct calcium ions once it has been activated by glutamate. That
is, the NMDA receptor can only function as an ion channel if the postsynaptic
neuron has already been depolarised (Seeburg, Burnashev et al. 1995;
Ozawa, Kamiya et al. 1998). In this way the NMDA receptor functions as a
molecular co-incidence detector that recognises when the presynaptic neuron
(which releases glutamate) is active at the same time as the post-synaptic
neuron has been depolarised by another synaptic input. The entry of calcium
into the post-synaptic cell through the NMDA receptor is able, through
calcium dependent kinases, to effect longer lasting changes in the function of
the synapse and this modulation of synapse function is termed synaptic
plasticity.
Secretion of releasing factor at the hypothalamus occurs in short
bursts of neurosectory activity, at least for LHRH neurons and for
magnocellular AVP and oxytocin neurons (Lincoln, Fraser et al. 1985). It is
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difficult to comprehend a role for the NMDA receptor in the acute modulation
of neurosecretory activity during the generation say of an LHRH pulse, but
certainly changes in synaptic efficiency could underlie the more sustained
secretion in particular physiological circumstances such as the LHRH surge at
ovulation, or of AVP secretion during dehydration. Interestingly, however, the
NMDA receptor may have rather different functions in the fetal brain, and
indeed may not be so readily blocked by the magnesium ion. It seems that
during development NMDA receptors are expressed before non-NMDA
receptors, so at particular points in development the NMDA receptor must
mediate much of the excitatory neurotransmission (Wu, Malinow et al. 1996;
Golshani, Warren et al. 1998). Additionally, the subunits of the NMDA
receptor expressed in the developing brain are such that magnesium provides
little block to ion conductance (Ozawa, Kamiya et al. 1998). Such factors
could account for the major role of the NMDA receptor in regulating ACTH
secretion in the fetus.
Earlier work has shown that the ACTH response to NMDA increases
with gestation (Brooks and Howe 1996). There are a number of potential
explanations. Firstly, there may be a maturational increase in the number or
affinity of NMDA receptors. In other brain regions there is a well
characterised developmental change in the subunits of the NMDA receptor
that are expressed (Farrant, Feldmeyer et al. 1994; Gottmann, Mehrle et al.
1997). Different subunit compositions of the receptor are known to produce
different ion channel kinetics (Ozawa, Kamiya et al. 1998; Paas 1998). An
alternative explanation is that the number or peptide content of the CRH and
AVP neurons stimulated by NMDA increases. In other words, that there is a
greater releasable pool of CRH and AVP in late gestation. The reported
changes in total hypothalamic CRH and AVP content, however, do not
parallel the gestational increases in NMDA responsiveness, suggesting that
this is not the correct explanation. Hypothalamic immunoreactive CRH and
AVP content reaches a plateau around day 135 and declines somewhat to
term (Brieu, Tonon et al. 1989; Watabe, Levidiotis et al. 1991; Currie and
Brooks 1992; Keiger, O'Steen et al. 1994). Increased pituitary sensitivity to
AVP and or CRH could account for the increase in ACTH release, but here
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too the evidence is that sensitivity declines in late gestation (Norman, Lye et
al. 1985; Norman and Challis 1987). Finally, exogenous NMDA acting
directly on the pituitary could account for the progressive increase in ACTH
release with gestation. Certainly pituitary POMC message concentrations
increase with gestation, suggesting there is a greater releasable pool, though
message does not always equate with peptide content. Ultimately, the basis
for the increasing response to NMDA with gestation cannot be resolved
without studies specifically examining the ontogeny of the NMDA receptor in
the PVN and associated pathways.
Equally since the drive provided by endogenous excitatory amino acid
neurotransmitters has not been probed at different gestations (by measuring
the decline in basal ACTH secretion in response to antagonist) it is not
possible to comment upon the idea that increasing ACTH secretion reflects
increasing release of transmitter. When originally envisaged, the
microdialysis studies were intended to look at glutamate release in the PVN
and other hypothalamic nuclei. Lack of suitable stereotaxic co-ordinates in
our fetal sheep would have necessitated long preliminary studies to define the
location of the PVN, and instead it was decided to concentrate upon median
eminence AVP and CRH secretion. The low and unchanging concentrations
of glutamate at the median eminence indicate that this is not the principal site
at which endogenous excitatory amino acids regulate AVP or CRH
neurosecretion. Clearly, further studies are required to assess the possibility
of increasing glutaminergic transmission in the PVN providing the drive to
ACTH secretion in late gestation.
7.3 The NMDA receptor and neuroendocrine development
Following largely genetically programmed early events establishing
synaptic connections between neurons, often over considerable distances,
functional activity of the neurons becomes important for the maintenance of
appropriate connections. It is thought that initially incoming axons establish
multiple synapses on nearby neurons and subsequently inappropriate
connections are withdrawn while correct synapses persist (Goodman and
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Shatz 1993). The persistence of synapses depends upon trophic factors
released by the post-synaptic cell in response to neural activity (Patterson
and Hiroyuki 1993; Davies 1994; Lindsay, Wiegrand et al. 1994).
Long term changes in synaptic function bought about through the
NMDA receptor seem tailor made for the formation and stabilisation of
appropriate synaptic connections during development. Activation of the
NMDA receptor is thought to stabilise developing synaptic connections and
inhibit neuronal apoptosis (Wu, Malinow et al. 1996; Zhang, Rubin et al.
1998). The NMDA receptor is expressed at excitatory synapses before non-
NMDA receptors in the central nervous system of the tadpole and rat (Wu,
Malinow et al. 1996; Golshani, Warren et al. 1998) whilst in the developing
mammalian cerebellum and hippocampus the NMDA receptor subtype
expressed is developmental^ regulated and correlates to the appearance of a
mature pattern of nerve activity (Farrant, Feldmeyer et al. 1994; Gottmann,
Mehrle et al. 1997). Blockade of the NMDA receptor disrupts the normal
elimination of excess synapses in the cerebellum (Rabacchi, Bailly et al.
1992). Similar events probably occur during development of the
neuroendocrine hypothalamus.
Interesting parallels can be drawn between the fetal HPA axis and the
hypothalamo-pituitary gonadal axis at puberty. Pubertal activation of the HPG
axis is associated with increasing LH responsiveness to NMDA (Cicero,
Meyer et al. 1988; Carbone, Szwarcfarb et al. 1992). Pulses of NMDA
advance puberty (Urbanski and Ojeda 1987; Plant, Gray et al. 1989) while
NMDA receptor blockade delays puberty (Urbanski and Ojeda 1990; Wu,
Howe et al. 1990). During pubertal maturation there is increasing release of
excitatory amino acid transmitters within the preoptic area as measured by
push-pull perfusion and by release from in vitro explants (Goroll, Arias et al.
1993; Carbone, Szwarcfarb et al. 1995). The onset of LHRH pulse generator
activity at puberty is thought to be dependent upon maturation of the neuronal
systems controlling LHRH release (Carbone, Szwarcfarb et al. 1995; Perera
and Plant 1997) and it is thought that exogenous pulses of NMDA may
promote the maturation of these pathways (Smyth and Wilkinson 1994). The
NMDA receptor may have a comparable influence on the functional
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maturation of the HPA axis during critical periods in fetal development. There
are, however, no studies on the maturation of synaptic connections onto AVP
and CRH neurons in late gestation.
7.4 Metabolic signals and parturition
If the NMDA receptor is involved in the establishment of the correct
innervation of the CRH and AVP neurons in the PVN and in longer term
regulation of basal hormone secretion, then the role of endogenous excitatory
amino acid neurotransmitters in the fetal hypothalamus might be seen as
permissive. In other words, the activation of the HPA axis in late gestation is
dependent upon the maturation of the neuronal circuitry regulating the PVN
and upon the enhancement of synaptic inputs to PVN neurons. What inputs,
then, may ultimately determine activation of the HPA axis? A metabolic
signal is an attractive candidate for matching the timing of birth to the growth
of the fetus and the ability of the placenta to sustain intrauterine growth.
Crucial to this hypothesis is evidence for a decline in oxygen, or metabolic
substrate in later gestation. In fact, there is a surprising paucity of information
about longitudinal changes in metabolite concentrations in fetal plasma during
pregnancy. In cross sectional studies of small and appropriately grown
human fetuses, no change in glucose concentration was demonstrated with
gestation, though the fetal glucose/insulin ratio increased exponentially
(Economides and Nicolaides 1989; Economides, Proudler et al. 1989). At the
same time there was a decline in the concentration of amino acids in fetal
plasma implying increasing consumption by the fetus or placenta
(Economides, Nicolaides et al. 1989). There is also a gestation related fall in
the partial pressure of oxygen and an increase in the partial pressure of
carbon dioxide in the fetal circulation (Nicolaides, Economides et al. 1989). In
other words, the in utero environment probably does become more hostile
near the end of pregnancy and could provide the drive leading to parturition.
This hypothesis can only really be tested by restoring the late gestation in
utero environment to a state found earlier in gestation. Circumstantial
evidence can be garnered by examining the changes in the central pathways
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likely to be involved in responding to metabolic and hypoxic stress, and
attempting to manipulate these pathways.
The arcuate nucleus NPY system is likely to be part of the central
pathway mediating metabolic feedback. Others have shown an increase in
the expression of message for NPY in the arcuate nucleus in the sheep fetus
with gestation, and further, that NPY message expression is increased by
maternal undernutrition (Warnes, Morris et al. 1998). The demonstration that
central administration of NPY stimulates ACTH secretion in late gestation
confirms the potential for this pathway to drive the HPA axis. Studies with
NPY antisera or antagonists, however, are needed to establish the
contribution of endogenous NPY pathways to parturition.
7.5 Steroid regulation of the NMDA receptor
The factors regulating the pattern of NMDA receptor subunit
expression during development are unknown. Evidence from the adult
hypothalamus suggests that gonadal steroids modulate both release of
transmitter (Carbone, Szwarcfarb et al. 1992; Carbone, Szwarcfarb et al.
1995) and expression of the NMDA receptor (Weiland 1992; Gazzaley,
Weiland et al. 1996; Woolley, Weiland et al. 1997), though not all studies
have found the NMDA receptor to be estradiol sensitive. A lack of estradiol
sensitivity is reported in studies of glutamate receptors in adult hippocampus
and temporal cortex (Kohama, Garyfallou et al. 1998) and hypothalamus
(Brann, Zamorano et al. 1993). No previous studies have specifically
examined the effects of estrogen on the sensitivity of the fetal HPA axis to
NMDA, though it has been demonstrated that in primates (Baggia, Albrecht et
al. 1990; Pepe, Waddell et al. 1990; Pepe, Davies et al. 1994) and sheep
(Saoud and Wood 1997; Wood and Saoud 1997) that estrogen will increase
basal HPA axis activity.
The studies described in chapter 5 indicate that estradiol at biologically
active concentrations does not increase HPA axis sensitivity to NMDA in the
sheep fetus. In addition, the estradiol infusion failed to elevate basal HPA
axis activity in contradiction to the previous results. The failure of estradiol to
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activate the fetal HPA axis is reported in one other study (Wang, Matthews et
al. 1997). The reasons for the differences between the fetal sheep studies
are unclear but relate to route of administration, since dosages and gestation
are otherwise similar. The two studies from Woods laboratory utilise an
estradiol implant that is presumed to release at a constant rate over several
days, wheras the work in chapter 5, and that of Wang are based on measured
infusion of estradiol. The results reported in chapter 5 and those of Wang
suggest that at physiological levels found prior to the onset of labour it is
unlikely that estradiol significantly increases either basal ACTH secretion or
the response to NMDA.
Another candidate for increasing expression of the NMDA receptor is
Cortisol (Weiland, Orchinik et al. 1997). And in this regard, recent
experiments have demonstrated the potential for sustained Cortisol infusion to
lead to increased ACTH secretion (Apostolakis, Longo et al. 1994) but further
studies are required to examine the role of the NMDA receptor in this
phenomenon. Steroids almost certainly modulate NMDA receptor subunit
expression indirectly through regulation of other transcription factors capable
of binding the upstream promoter of the various NMDA receptor subunits (Bai
and Kusiak 1997; Bai, Norton et al. 1998; Klein, Pieri et al. 1998; Kranic, Bai
et al. 1998) but this is a complex and poorly understood area beyond the
remit of this discussion.
7.6 Conclusions
The NMDA receptor offers a defined locus important for determining
basal ACTH secretion in late gestation. The NMDA receptor is probably
coupled to ACTH secretion through CRH neurons, but this conclusion
requires more direct confirmation. The factors regulating the expression of
the NMDA receptor and the development of the neural pathways controlling
HPA axis activity in the fetus remain unknown. In other situations the NMDA
receptor is implicated in the development of nerve pathways, and it is
tempting to speculate that the increased sensitivity of the fetal HPA axis to
NMDA in late gestation reflects maturation of the nerve pathways regulating
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ACTH secretion. The timing of parturition is then dependent both upon
maturation of the nerve pathways and increasing activity in these pathways.
Potentially metabolic cues may drive increased ACTH secretion, and in this
regard central NPY containing pathways are capable of stimulating ACTH
secretion in late gestation. Further experiments are needed, however, to
substantiate the hypothesis that parturition is triggered by failing metabolite
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